
<html lang="en"     class="pb-page"  data-request-id="2d257c4f-1e3a-4008-b2da-b0e8c249539a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm300771j;issue:issue:10.1021/jmcmar.2012.55.issue-20;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Identification of High-Affinity P2Y12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone" /></meta><meta name="dc.Creator" content="Gernot  Zech" /></meta><meta name="dc.Creator" content="Gerhard  Hessler" /></meta><meta name="dc.Creator" content="Andreas  Evers" /></meta><meta name="dc.Creator" content="Tilo  Weiss" /></meta><meta name="dc.Creator" content="Peter  Florian" /></meta><meta name="dc.Creator" content="Melitta  Just" /></meta><meta name="dc.Creator" content="Jörg  Czech" /></meta><meta name="dc.Creator" content="Werngard  Czechtizky" /></meta><meta name="dc.Creator" content="Jochen  Görlitzer" /></meta><meta name="dc.Creator" content="Sven  Ruf" /></meta><meta name="dc.Creator" content="Markus  Kohlmann" /></meta><meta name="dc.Creator" content="Marc  Nazaré" /></meta><meta name="dc.Description" content="A series of novel, highly potent P2Y12 antagonists as inhibitors of platelet aggregation based on a phenylpyrazole glutamic acid piperazine backbone is described. Exploration of the structural requ..." /></meta><meta name="Description" content="A series of novel, highly potent P2Y12 antagonists as inhibitors of platelet aggregation based on a phenylpyrazole glutamic acid piperazine backbone is described. Exploration of the structural requ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 4, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300771j" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300771j" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300771j" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300771j" /></link>
        
    
    

<title>Identification of High-Affinity P2Y12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300771j" /></meta><meta property="og:title" content="Identification of High-Affinity P2Y12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0016.jpeg" /></meta><meta property="og:description" content="A series of novel, highly potent P2Y12 antagonists as inhibitors of platelet aggregation based on a phenylpyrazole glutamic acid piperazine backbone is described. Exploration of the structural requirements of the substituents by probing the structure–activity relationship along this backbone led to the discovery of the N-acetyl-(S)-proline cyclobutyl amide moiety as a highly privileged motif. Combining the most favorable substituents led to remarkably potent P2Y12 antagonists displaying not only low nanomolar binding affinity to the P2Y12 receptor but also a low nanomolar inhibition of platelet aggregation in the human platelet rich plasma assay with IC50 values below 50 nM. Using a homology and a three-dimensional quantitative structure–activity relationship model, a binding hypothesis elucidating the impact of several structural features was developed." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300771j"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300771j">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300771j&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300771j&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300771j&amp;href=/doi/10.1021/jm300771j" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8615-8629</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm300801u" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm300789g" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of High-Affinity P2Y<sub>12</sub> Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gernot++Zech">Gernot Zech</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gerhard++Hessler">Gerhard Hessler</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Evers">Andreas Evers</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tilo++Weiss">Tilo Weiss</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Florian">Peter Florian</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melitta++Just">Melitta Just</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%B6rg++Czech">Jörg Czech</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Werngard++Czechtizky">Werngard Czechtizky</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jochen++G%C3%B6rlitzer">Jochen Görlitzer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sven++Ruf">Sven Ruf</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Markus++Kohlmann">Markus Kohlmann</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marc++Nazar%C3%A9">Marc Nazaré</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Building G878, D-65926 Frankfurt am Main, Germany</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#8ec3effceda0c0eff4effcebcefdefe0e1e8e7a0ede1e3"><span class="__cf_email__" data-cfemail="95d8f4e7f6bbdbf4eff4e7f0d5e6f4fbfaf3fcbbf6faf8">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300771j&amp;href=/doi/10.1021%2Fjm300771j" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8615–8629</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 17, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 June 2012</li><li><span class="item_label"><b>Published</b> online</span>4 October 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 October 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300771j" title="DOI URL">https://doi.org/10.1021/jm300771j</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8615%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGernot%2BZech%252C%2BGerhard%2BHessler%252C%2BAndreas%2BEvers%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D20%26contentID%3Djm300771j%26title%3DIdentification%2Bof%2BHigh-Affinity%2BP2Y12%2BAntagonists%2BBased%2Bon%2Ba%2BPhenylpyrazole%2BGlutamic%2BAcid%2BPiperazine%2BBackbone%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8629%26publicationDate%3DOctober%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300771j"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1423</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300771j" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of High-Affinity P2Y12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gernot&quot;,&quot;last_name&quot;:&quot;Zech&quot;},{&quot;first_name&quot;:&quot;Gerhard&quot;,&quot;last_name&quot;:&quot;Hessler&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Evers&quot;},{&quot;first_name&quot;:&quot;Tilo&quot;,&quot;last_name&quot;:&quot;Weiss&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Florian&quot;},{&quot;first_name&quot;:&quot;Melitta&quot;,&quot;last_name&quot;:&quot;Just&quot;},{&quot;first_name&quot;:&quot;Jörg&quot;,&quot;last_name&quot;:&quot;Czech&quot;},{&quot;first_name&quot;:&quot;Werngard&quot;,&quot;last_name&quot;:&quot;Czechtizky&quot;},{&quot;first_name&quot;:&quot;Jochen&quot;,&quot;last_name&quot;:&quot;Görlitzer&quot;},{&quot;first_name&quot;:&quot;Sven&quot;,&quot;last_name&quot;:&quot;Ruf&quot;},{&quot;first_name&quot;:&quot;Markus&quot;,&quot;last_name&quot;:&quot;Kohlmann&quot;},{&quot;first_name&quot;:&quot;Marc&quot;,&quot;last_name&quot;:&quot;Nazaré&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;8615-8629&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300771j&quot;},&quot;abstract&quot;:&quot;A series of novel, highly potent P2Y12 antagonists as inhibitors of platelet aggregation based on a phenylpyrazole glutamic acid piperazine backbone is described. Exploration of the structural requirements of the substituents by probing the structure–activity relationship along this backbone led to the discovery of the N-acetyl-(S)-proline cyclobutyl amide moiety as a highly privileged motif. Combining the most favorable substituents led to remarkably potent P2Y12 antagonists displaying not only low nanomolar binding affinity to the P2Y12 receptor but also a low nanomolar inhibition of platelet aggregation in the human platelet rich plasma assay with IC50 values below 50 nM. Using a homology and a three-dimensional quantitative structure–activity relationship model, a binding hypothesis elucidating the impact of several structural features was developed.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300771j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300771j" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300771j&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300771j" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300771j&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300771j" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300771j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300771j&amp;href=/doi/10.1021/jm300771j" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300771j" /></input><a href="/doi/pdf/10.1021/jm300771j" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300771j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300771j%26sid%3Dliteratum%253Aachs%26pmid%3D22984835%26genre%3Darticle%26aulast%3DZech%26date%3D2012%26atitle%3DIdentification%2Bof%2BHigh-Affinity%2BP2Y12%2BAntagonists%2BBased%2Bon%2Ba%2BPhenylpyrazole%2BGlutamic%2BAcid%2BPiperazine%2BBackbone%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D20%26spage%3D8615%26epage%3D8629%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jmcmar.2012.55.issue-20/production/jmcmar.2012.55.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of novel, highly potent P2Y<sub>12</sub> antagonists as inhibitors of platelet aggregation based on a phenylpyrazole glutamic acid piperazine backbone is described. Exploration of the structural requirements of the substituents by probing the structure–activity relationship along this backbone led to the discovery of the <i>N</i>-acetyl-(<i>S</i>)-proline cyclobutyl amide moiety as a highly privileged motif. Combining the most favorable substituents led to remarkably potent P2Y<sub>12</sub> antagonists displaying not only low nanomolar binding affinity to the P2Y<sub>12</sub> receptor but also a low nanomolar inhibition of platelet aggregation in the human platelet rich plasma assay with IC<sub>50</sub> values below 50 nM. Using a homology and a three-dimensional quantitative structure–activity relationship model, a binding hypothesis elucidating the impact of several structural features was developed.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46538" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46538" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The activation and aggregation of blood platelets are essential for normal hemostasis but are also key mechanisms for triggering acute, potentially life-threatening arterial thrombotic events like myocardial infarction or thromboembolic stroke. In this context, adenosine-5′-diphosphate (ADP) is a central signaling molecule inducing platelet activation and aggregation, thus playing a key role in the initiation and progression of arterial thrombus formation. Upon activation by various stimuli, like collagen (Col) and thrombin (Thr), ADP is released from blood platelets in the vasculature, as well as from damaged blood cells, endothelium, or tissues.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The ADP-induced platelet aggregation is triggered by its binding to two specific G-protein-coupled receptors (GPCRs), P2Y purinoceptor 1 (P2Y<sub>1</sub>) and P2Y purinoceptor 12 (P2Y<sub>12</sub>), which are expressed on the plasma membrane of human platelets. ADP binding to these receptors induces inhibition of adenylyl cyclase and modulation of intracellular signaling pathways such as influx and mobilization of intracellular Ca<sup>2+</sup>, activation of phosphoinositide-3 kinase (PI3K), shape change, platelet aggregation, and secretion of other mediators, thus amplifying the initial proaggregatory signal.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In particular the P2Y<sub>12</sub> receptor has been recognized as a highly attractive target, as its activation is required for platelet secretion and stabilization of platelet aggregates, and in contrast to the ubiquitously expressed P2Y<sub>1</sub> receptor, the P2Y<sub>12</sub> receptor is mainly expressed on platelets.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Moreover, experimental studies have shown that sole inhibition of the P2Y<sub>12</sub> receptor is sufficient to block and prevent platelet aggregation.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">The widespread successful clinical use of the irreversible P2Y<sub>12</sub> antagonist clopidogrel<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> has demonstrated the high impact and relevance of inhibiting this mechanism for the prevention of thrombotic complications of atherosclerosis. Albeit being highly selective, clopidogrel requires hepatic metabolic conversion to an active metabolite that covalently modifies the P2Y<sub>12</sub> receptor, which results in a slow onset and offset of its pharmacological action.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Consequently, extensive drug discovery efforts were made to identify potent, direct-acting, and reversible P2Y<sub>12</sub> antagonists resulting in promising compounds like Ticagrelor (AZD-6140) (<b>1</b>),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Elinogrel (PRT-128) (<b>2</b>),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and BX 667 (<b>3</b>)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>).</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Structures of <b>1</b> (Ticagrelor), <b>2</b> (Elinogrel), and <b>3</b> (BX 667) and Their Respective Affinity in the P2Y<sub>12</sub> Binding Assay and Antiaggregatory Activity in the Human Platelet-Rich Plasma (hPRP) Assay Used Throughout This Investigation (See the <a class="ref internalNav" href="#sec7" aria-label="Experimental Section">Experimental Section</a>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The activity data for the majority of reversible antagonists show that, despite high binding affinity to the P2Y<sub>12</sub> receptor, the inhibitory activity in the clinical relevant functional human platelet-rich plasma (hPRP) assay, which is a key predictor for the antithrombotic pharmacological effect,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> still leaves significant room for improvement. For example, when evaluating the antiaggregatory activity in hPRP of <b>1</b>–<b>3</b> in our standard assay system, which was used throughout this investigation, potencies in the micromolar range were determined. However, improving the P2Y<sub>12</sub>-mediated inhibitory potency in the hPRP assay setting remains a significant challenge as the observed activity is governed by the complex interplay of several parameters such as receptor binding affinity, plasma protein binding, and polarity of the antagonist.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p last">In seeking suitable P2Y<sub>12</sub> drug candidates in this area, we<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> along with others<a onclick="showRef(event, 'ref9 ref11 ref13'); return false;" href="javascript:void(0);" class="ref ref9 ref11 ref13">(9, 11, 13)</a> have explored glutamic acid piperazine derivatives as reversible P2Y<sub>12</sub> antagonists. Here, we report our findings on the identification of novel, highly potent P2Y<sub>12</sub> antagonists based on a phenylpyrazolone scaffold and the discovery of new high-affinity ligand substitution patterns resulting in a dramatic enhancement in binding affinity and functional activity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2 Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50816" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50816" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1 Identification of the Phenylpyrazolone Scaffold by Structure-Based Alignment Studies</h3><div class="NLM_p">As a result of initial alignment considerations in the context of P2Y<sub>12</sub> antagonists of the glutamic acid piperazine type, we anticipated that a phenylpyrazolone scaffold<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> as shown in compound <b>4</b> could be a suitable replacement for the initial quinoline scaffold in compound <b>3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). To further rationalize our ligand design efforts and direct our structure–activity relationship (SAR) investigation, we intended to use structure-based alignments. However, although tremendous progress has been made in revealing 3D structures of GPCRs, the investigation of 3D structures of membrane proteins remains a significant challenge, and there is currently no P2Y<sub>12</sub> X-ray crystal structure available. Therefore, we resorted to the use of homology modeling to gain structural insights into protein–ligand interactions for P2Y<sub>12</sub>. For the generation of binding hypotheses, a homology model of the P2Y<sub>12</sub> receptor was created using the crystal structure of the C-X-C chemokine receptor type 4 (CXCR4) receptor as a structural template (see the <a class="ref internalNav" href="#sec7" aria-label="Experimental Section">Experimental Section</a>), which had previously been identified as the most-suited structural template.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Two main factors limit the accuracy of the P2Y<sub>12</sub> protein model, namely, the relatively low sequence identity of 25.6% in the transmembrane region and the diverse orientations of the extracellular 2 (EC2) loop linked to transmembrane helix 3 (TM3) by a cysteine bridge. On the basis of the analysis of different GPCR crystal structures, it has been shown that residues from this loop region participate in ligand binding in different GPCRs.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Consequently, we had to take into account that the EC2 loop orientation is different from that observed in the CXCR4 template. To compensate for these factors, limiting the accuracy of the protein model, we cross-checked the docking mode with available mutagenesis and ligand SAR data. Furthermore, we used the docking modes of quinoline lead <b>3</b> and phenylpyrazolone <b>4</b> as the structural basis for the generation of multiple ligand alignments and derivation of ligand-based 3D quantitative structure–activity relationship (QSAR) models.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Binding hypothesis of quinoline <b>3</b> in the P2Y<sub>12</sub> receptor obtained from docking into a receptor homology model. (b) Three-dimensional alignment of quinoline <b>3</b> and phenylpyrazolone <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a shows the binding hypothesis for <b>3</b>, which was obtained from molecular docking into our homology model of the P2Y<sub>12</sub> receptor. The quinoline lead <b>3</b> binds into a cavity formed by residues from TM3, TM4, TM5, TM6, and TM7. The carboxy group is coordinated by the basic side chains of residues Arg6.55 and Lys7.35. Whereas the docking mode proposes a localization of the 4-hydroxy-quinoline moiety in a hydrophobic subpocket, the piperazinyl carbamate substituent points toward the extracellular region. Interestingly, a similar docking hypothesis was recently described for a related chemical series of piperazinyl glutamic acid pyrimidines.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Pyrazole <b>4</b> was docked in to the P2Y<sub>12</sub> homology model as well (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b). As shown, the large identical glutamic acid piperazinyl carbamate fragments align well. The phenylpyrazolone moiety is placed in the same hydrophobic pocket as the quinoline fragment. However, a more careful inspection of the 3D alignment of <b>3</b> with <b>4</b> reveals that the substituent at the 5-position of the pyrazole <b>4</b> does not align with the corresponding substituent at the 4-position of the quinoline <b>3</b> (see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b). Thus, the substantial topological change from the quinoline to the pyrazole scaffold obviously also required an examination of the remaining regions of the ligand.</div><div class="NLM_p">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>a gives a schematic representation of the regions that we intended to explore based on the phenylpyrazole glutamic acid piperazine backbone. Analysis of the docking mode of pyrazole <b>4</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>b) suggested that in particular the 5-position of the pyrazole should be a promising region for further variations. Consequently, we first set out to systematically probe the influence of variations at the 5-position of the phenylpyrazole. The glutamic acid side chain was kept constant throughout these initial variations serving as a strong mediator of affinity for the putative antagonists.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Schematic representation of the regions to be investigated based on the phenylpyrazolone backbone. (b) Proposed binding mode of pyrazole <b>4</b> into the P2Y<sub>12</sub> homology model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3 Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> shows the synthesis of representative building blocks, which were sequentially attached to the 3-carboxyphenylpyrazole, enabling a highly convergent and flexible synthesis of the final ligands. The glutamic piperazinyl carbamate building block <b>7</b> was prepared from the commercially available <i>Z</i>-<i>O</i>-<i>tert</i>-butyl protected <b>5</b> in two steps by standard amide coupling using <i>O</i>-((ethoxycarbonyl)cyanomethyleneamino)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate (TOTU) followed by the hydrogenolytic removal of the CbZ-protecting group (sequence a). The second key intermediate used throughout this investigation was the fully decorated phenylpyrazole building block <b>10</b> (sequence b). This fragment was synthesized by subjecting the phenylpyrazole ester <b>8</b> to an <i>O</i>-alkylation with benzyl 2-bromoacetate followed by selective hydrogenolytic cleavage of the benzylester to give <b>9</b>. This intermediate was then converted to the acid <b>10</b> by a high-yielding sequence of amide coupling and deprotection steps.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes to Key Building Blocks<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TOTU, <i>N</i>-ethylmorpholine, DMF, room temp, 16 h, 90%. (b) H<sub>2</sub> (3 bar), Pd/C (10%), ethanol, room temp, 6 h, 90%. (c) Benzyl 2-bromoacetate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 12 h, 95%. (d) H<sub>2</sub> (3 bar), Pd/C (10%), EtOAc, room temp, 6 h, 76%. (e) Benzyl (2<i>S</i>)-pyrrolidine-2-carboxylate, EDC, HOBt, EtN<i>i</i>Pr<sub>2</sub>, DMF, room temp, 16 h, 84%. (f) H<sub>2</sub> (3 bar), Pd/C (10%), EtOAc, room temp, 6 h, 98%. (g) Cyclobutyl amine, HATU, EtN<i>i</i>Pr<sub>2</sub>, DMF, room temp, 16 h, 95%. (h) NaOH, H<sub>2</sub>O/THF, room temp, 16 h, 95%.</p></p></figure><div class="NLM_p">The syntheses of the fully decorated final phenylpyrazolone ligands with different substituents attached to the 5-position of the pyrazole and all other side chain variations were carried out by two optional routes starting from commercially available 3-carboxy phenyl pyrazolones <b>8</b> and <b>11</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes Used for the Assembly of the Final P2Y<sub>12</sub> Antagonists<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EDC, HOBt, EtN<i>i</i>Pr<sub>2</sub>, <b>16</b>, DMF, room temp. (b) Benzyl 2-bromoacetate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, room temp. (c) H<sub>2</sub> (3 bar), Pd/C (10%), EtOAc, room temp. (d) EDC, HOBt, EtN<i>i</i>Pr<sub>2</sub>, DMF, room temp or HATU, EtN<i>i</i>Pr<sub>2</sub>, DMF, room temp. (e) NaOH, H<sub>2</sub>O/THF, room temp.</p></p></figure><div class="NLM_p">Phenylpyrazolone variations keeping the piperazinyl side chain constant were synthesized according to route 1. Phenylpyrazolones of type <b>14</b> were prepared by using standard amide coupling conditions with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)/1-hydroxybenzotriazole (HOBt) followed by <i>O</i>-alkylation of the phenylpyrazole with benzyl 2-bromoacetate in the presence of cesium carbonate in DMF and hydrogenolytic deprotection to the carboxylic acid <b>12</b>. The diversifying amide variation step was then conducted using EDC/HOBt or <i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HATU) in DMF as activating reagents.</div><div class="NLM_p last">Route 2 was used to explore the impact of other side chain variations retaining the 5-<i>O</i>-alkyl amide substituent. The preassembled phenylpyrazole <b>15</b> and the piperazinyl side chain <b>16</b> were prepared according to the synthetic sequences outlined for the respective building blocks (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, synthesis of <b>7</b> and <b>10</b>) and then coupled using either EDC/HOBt or HATU activation in DMF to give the final derivatives <b>14</b>. By using these synthetic routes, we were able to systematically synthesize a wide range of P2Y<sub>12</sub> antagonists and to obtain a dense set of SAR data, which revealed key features of favorable and unfavorable interactions.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">3 Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02286" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02286" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The binding affinity of the compounds was determined by a human P2Y<sub>12</sub> receptor binding assay employing [<sup>33</sup>P]2-MeS-ADP as the radioligand and human P2Y<sub>12</sub> transfected Chinese hamster ovary (CHO) cell membranes.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The inhibitory effect on the ADP-stimulated platelet aggregation was determined in vitro in hPRP using a turbidimetric method in a 96-well format. For several compounds, the antiaggregatory activity was additionally confirmed as indicated in a second hPRP assay, the clinically relevant “Born method” using single cuvettes.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> shows the SAR of an initial explorative library intended to examine the effects of various ester, ketone, and amide derivatizations obtained by route 1 transformations.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding and hPRP Activity of Explorative Variations around the Initial Hit <b>4</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">P2Y<sub>12</sub> binding assay using cell membranes from CHO cells with recombinant expression of human P2Y<sub>12</sub> receptors employing [<sup>33</sup>P]2-MeS-ADP as the radioligand.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Antiagreggatory effect on ADP-stimulated hPRP using a 96-well format.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">In parentheses: Antiagreggatory effect on ADP-stimulated hPRP according to the Born method using single cuvettes.</p></div></div><div></div></div><div class="NLM_p">This survey illustrated the fact that the receptor recognition was highly sensitive to modifications at the 5-position of the pyrazole, which—according to our docking hypothesis—points into a buried subpocket composed of several hydrophobic amino acid side chains (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>b). Consequently, lipophilic substituents were preferred, and certain steric requirements existed to fill the lipophilic environment. This observation was also captured by the steric fields of the comparative molecular similarity index analysis (CoMSIA) model used to analyze the ligand data. (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Having no substituent at the 5-position as in pyrazole <b>17a</b> (R = H) resulted in an essentially inactive compound and pinpointed the necessity for further substitution in this region. Introduction of substituted alkyl esters like <b>4</b> or <b>17b</b> or isosteric lipophilic ketones <b>17c</b>, <b>17d</b>, or <b>17e</b> were effective to obtain significant binding affinity and hPRP activity in the range of 2 μM. In contrast, the simple primary amide <b>17f</b> or the acyclic tertiary amide <b>17g</b> did not improve the activity but were significantly less active. Interestingly, when cyclic pyrrolidine amides were attached to the 5-position of the pyrazole instead (<b>17h</b>, <b>17i</b>), the most active compounds of this first survey were obtained reaching up to submicromolar potency in the hPRP assay [IC<sub>50</sub> (hPRP): 1.37 and 0.9 μM for <b>17h</b> and <b>17i</b>]. With this first evidence that cyclic amides could considerably enhance the ligand affinity and in particular the potency in the hPRP assay and with the aim to avoid the imide functionality present in <b>17i</b>, we turned our attention to proline derivatives, which appeared to be closest analogues bearing a similar functionality.</div><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> shows that even simple primary proline carboxamides like <b>18a</b> essentially retain the activity as compared to the initial pyrrolidine derivatives <b>17h</b> and <b>17i</b>. However, a remarkable increase in binding affinity and in particular hPRP activity was observed with lipophilic secondary proline amides. A stepwise extension of the lipophilic volume from methyl amide <b>18b</b> over a linear ethyl amide <b>18c</b> to a <i>n</i>-propyl amide <b>18d</b> [IC<sub>50</sub> (hPRP): 0.058 μM] strongly increased the activity. Successive branching of the terminal lipophilic amide from the isopropyl amide <b>18e</b> to the spherical <i>tert</i>-butyl amide <b>18f</b> further enhanced the activity [IC<sub>50</sub> (hPRP): 0.040 and 0.017 μM]. Notably, the cyclopropyl amide <b>18g</b> [IC<sub>50</sub> (hPRP): 0.013 μM] was even more potent as compared to the corresponding isosteric acyclic isopropyl amide <b>18e</b>. Interestingly, the (<i>R</i>)-enantiomer <b>18h</b> addressing the opposite trajectory of (<i>S</i>)-enantiomer <b>18g</b> showed a more than 10-fold drop of binding affinity as compared to <b>18g</b>, suggesting a highly specific hydrophobic interaction of <b>18g</b> with the receptor. Further extension of the ring size from a cyclopropyl amide (<b>18g</b>) to a cyclobutyl amide (<b>18i</b>) or cyclopentyl amide (<b>18j</b>) unveiled one of the most potent substitution patterns of the present study, displaying optimal binding affinity and hPRP activity in the nanomolar range [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 7.3 and 20 nM; IC<sub>50</sub> (hPRP): 0.025 and 0.013 μM]. This very subtle interaction is further illustrated by the compounds <b>18k</b>–<b>18m</b>. Small variations from the optimal presentation of the cyclobutyl moiety like a proline <i>N</i>-methyl-cyclobutyl amide <b>18k</b>, a methylene-linker extension in <b>18l</b>, or the ring-contracted proline analogue, azetidine <b>18m</b>, resulted in moderate loss of binding affinity and a moderate to significant drop of hPRP activity. Stronger deviations from the optimal trajectorial angle presenting the cyclobutyl carboxamide moiety as in compounds <b>18n</b> or <b>18o</b> turned out to be deleterious for the activity [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 238 and 613 nM; IC<sub>50</sub> (hPRP): 3.13 and 2.94 μM]. Next, we explored compounds bearing a cyclic amide variation of increasing ring size. Again, even small, incremental changes from the moderately active pyrrolidine carboxamide <b>18p</b> to the piperidine carboxamide <b>18q</b> were sufficient to obtain an acceptable binding affinity and potency in hPRP [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 219 vs 56 nM; IC<sub>50</sub> (hPRP): 0.60 vs 0.070 μM]. The attempted bioisosteric replacement of the carboxamide group with an imidazole moiety resulted in the reasonably active compound <b>18r</b>. Notably, the profound impact of the lipophilic interaction with the receptor at this region was also demonstrated when the entire alkyl carboxamide was omitted and replaced by a phenyl ring. Despite the relatively large structural change, this compound <b>18s</b> displayed an unexpectedly high binding affinity and hPRP activity as compared to several other more conservative variations of the proline cyclobutyl amide motif [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 33 nM; IC<sub>50</sub> (hPRP): 0.29 μM].</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Binding and hPRP Activity of Compounds Carrying Various Proline Variations</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0010.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0011.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">P2Y<sub>12</sub> binding assay using cell membranes from CHO cells with recombinant expression of human P2Y<sub>12</sub> receptors employing [<sup>33</sup>P]2-MeS-ADP as the radioligand.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Antiagreggatory effect on ADP-stimulated hPRP using a 96-well format.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">In parentheses: Antiagreggatory effect on ADP-stimulated hPRP according to the Born method using single cuvettes.</p></div></div><div></div></div><div class="NLM_p">These results indicate that the 5-position of the pyrazole ring directs the substituent to a lipophilic pocket, which exhibits a steric confinement, as illustrated by the significant drop of activity, if the ideal geometry is violated. A more concise structure-based rationalization of the observed SAR is provided in the section <a class="ref internalNav" href="#sec5" aria-label="Development of 3D QSAR Models">Development of 3D QSAR Models</a>.</div><div class="NLM_p">The results in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> established the structural requirements for the decoration of the 5-position of the phenylpyrazole with the <i>N</i>-acetyl-(<i>S</i>)-proline cyclobutyl amide residue as the optimal substituent. We next turned our attention toward a potential optimization of the piperazine carbamate portion of our preliminary lead compound (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Our docking hypothesis (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) proposed that this substituent points to the extracellular site of the receptor and establishes interactions with residues from the ECs. Because we considered the accuracy of our protein model in this region to be very low, a reliable structure-based rationalization of the piperazine carbamate SAR was not feasible. Nevertheless, the preference for lipophilic residues of a certain length (e.g., butyl substituents) was captured by the steric fields of the CoMSIA model (see Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Introducing a 4-amino piperidine group as a piperazine homologue resulted in the considerably less active compound <b>19a</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Interestingly, <b>19b</b> incorporating the inverse 4-amino piperidine spacer exhibited a higher binding affinity to the receptor and had a much higher activity in hPRP than <b>19a</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 22 vs >5000 nM; IC<sub>50</sub> (hPRP): 0.055 vs >5.0 μM]. The same trend was also observed for the related analogues, the corresponding 3-amino pyrrolidine compounds <b>19c</b> and <b>19d</b>, which confirmed that a C-terminal attachment of the glutamic acid to a secondary amine is crucial for high receptor affinity. Any effort to replace the alkyl carbamate unit by more rigid <i>N</i>-aryl piperazines like in <b>19e</b> or <i>N</i>-acyl piperazines like in <b>19g</b> was unsuccessful and did not lead to compounds of higher binding affinity or hPRP activity. In contrast, very conservative variations of the alkyl carbamate moiety turned out to be most effective. Simple alkyl extension from ethyl (<b>18i</b>) to <i>n</i>-propyl (<b>19j</b>) and <i>n</i>-butyl (<b>19k</b>) provided derivatives that showed the highest binding affinities and an extraordinarily good hPRP activity [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 3.1 and 0.8 nM; IC<sub>50</sub> (hPRP): 0.021 and 0.019 μM]. An equal potency was found for the cyclobutyl derivative <b>19l</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 5.0 nM; IC<sub>50</sub> (hPRP): 0.014 μM]. In an attempt to rigidify and restrict the conformational flexibility of the piperazine spacer, the corresponding 2- or 3-methyl-substituted piperazines <b>19m</b>–<b>p</b> were investigated. Interestingly, a pronounced influence of the position and absolute configuration of the methyl group was observed. Among the variations <b>19m</b> to <b>19p</b>, only the (3<i>R</i>)-configured stereoisomer <b>19m</b> was able to restore the activity of the nonsubstituted piperazine derivative <b>18i</b> in the binding and hPRP assay. All other variations were less active. This result is indicative for the considerable spatial restrictions and conformational preferences for the receptor–ligand interaction.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Binding and hPRP Activity of Variations around the Piperazine Ethyl Carbamate</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0012.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0013.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">P2Y<sub>12</sub> binding assay using cell membranes from CHO cells with recombinant expression of human P2Y<sub>12</sub> receptors employing [<sup>33</sup>P]2-MeS-ADP as the radioligand.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Antiagreggatory effect on ADP-stimulated hPRP using a 96-well format.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">In parentheses: Antiagreggatory effect on ADP-stimulated hPRP according to the Born method using single cuvettes.</p></div></div><div></div></div><div class="NLM_p">Previous studies<a onclick="showRef(event, 'cit11a cit11c ref16 ref18'); return false;" href="javascript:void(0);" class="ref cit11a cit11c ref16 ref18">(11a, 11c, 16, 18)</a> suggested an indispensable role of the γ-carboxylic acid moiety of the central glutamic acid for binding affinity by a strong putative salt bridge interaction with Lys7.35 and Arg6.55 at the ADP binding pocket (see also Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Despite these putative prerequisites, we hypothesized that the remarkably strong receptor interaction of the <i>N</i>-acetyl-(<i>S</i>)-proline cyclobutyl amide-substituted pyrazolone backbone would allow us to vary the central amino acid region without a serious loss of activity. Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> shows the set of variations made to probe the significance of the side chain of the glutamic acid linker and to evaluate the spatial and electrostatic environment. Examination of compounds bearing polar amino acid side chains like sulfonamide <b>20a</b> or <b>20b</b> did not reveal any superior motif than the glutamic acid moiety in <b>18i</b>. None of these variations showed hPRP IC<sub>50</sub> values better than 100 nM. Nonetheless, the detected binding affinities around 100 nM for those ligands indicated that there were no severe unfavorable interactions present. Consequently, when the carboxylic acid portion in compounds <b>18i</b> and <b>19k</b> was replaced by the nonclassical bioisostere tetrazole, equally potent compounds <b>20c</b> and <b>20d</b> were obtained [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 5.0 and 1.5 nM; IC<sub>50</sub> (hPRP): 0.040 and 0.050 μM]. In agreement with our docking hypothesis, introduction of a basic ethyl amine side chain <b>20e</b> led to a significant drop of activity, which could be partially recovered by acetylation (<b>20f</b>), suggesting that the amino acid side chain is accommodated in a positively charged environment of the receptor. Notably, the simple noncharged C2 serine homologue <b>20g</b> turned out to be very active [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 23 nM; IC<sub>50</sub> (hPRP): 0.210 μM]. Further chain elongation led to the corresponding C3 serine homologue <b>20h</b>, which exhibited an even higher binding affinity and a hPRP activity in the low nanomolar range [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 6.5 nM; IC<sub>50</sub> (hPRP): 0.092 μM]. However, commencing spatial restrictions became evident with the corresponding longer hydroxyl derivative <b>20i</b>, which was found to be inferior in terms of both binding affinity and hPRP activity. Deletion of any polarity by introducing linear and branched lipophilic amino acids of different length and extension (<b>20j</b>–<b>m</b>) showed in general lower binding affinities and much lower hPRP activities, supporting the hypothesis that there are no favorable hydrophobic contacts at this site of the receptor binding pocket and that competing plasma protein binding due to the increased lipophilicity is likely. Unexpectedly, replacement of alanine (<b>20m</b>) by glycine (<b>20n</b>) led to a more than 20-fold increase in hPRP activity through sole omission of a single methyl group [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 111 vs 107 nM; IC<sub>50</sub> (hPRP): 0.090 vs 2.21 μM]. The corresponding <i>n</i>-butyl carbamate <b>20o</b> was found to be even more potent in the binding assay and in the hPRP assay, closely reaching the potency of the analogues bearing the glutamic acid linker [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 7.7 nM; IC<sub>50</sub> (hPRP): 0.030 μM]. One might hypothesize that in the absence of the glutamic acid or any other side chain, the interaction with the basic residues is established via one or more water molecules. However, this result was highly unexpected as in related series described by others,<a onclick="showRef(event, 'cit11a cit11c'); return false;" href="javascript:void(0);" class="ref cit11a cit11c">(11a, 11c)</a> the corresponding glycine analogues were found to be inactive in the hPRP assay. Therefore, it has to be anticipated that the strong impact of the cyclic amides at the 5-position of the pyrazole on the hPRP activity apparently outbalances the absence of the carboxyl group of the glutamic acid moiety, which usually is required to obtain good activities in both binding and hPRP assays.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Binding and hPRP Activity of Compounds with Variations around the Central Amino Acid Moiety</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0014.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0015.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">P2Y<sub>12</sub> binding assay using cell membranes from CHO cells with recombinant expression of human P2Y<sub>12</sub> receptors employing [<sup>33</sup>P]2-MeS-ADP as the radioligand.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Antiagreggatory effect on ADP-stimulated hPRP using a 96-well format.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">In parentheses: Antiagreggatory effect on ADP-stimulated hPRP according to the Born method using single cuvettes.</p></div></div><div></div></div><div class="NLM_p">Selected compounds were further evaluated to elucidate the origin of the observed very high inhibitory activity in the hPRP assay as compared to the initial lead <b>4</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). To estimate the contribution of a reduced association of the compounds to plasma proteins, the antiaggregatory activity with isolated platelets (IPs) preparations was determined to avoid additional blood components interfering with the inhibitory effects. As expected from the binding affinity and hPRP data, lead <b>4</b> was also the least active compound on IPs. Moreover, a comparison of the respective activity in hPRP reveals that lead compound <b>4</b> exhibits the highest loss of antiaggregatory activity in hPRP with a 4-fold shift in the presence of plasma proteins [IC<sub>50</sub> (IP): 0.701 μM vs IC<sub>50</sub> (hPRP): 2.93 μM]. In contrast, the compounds <b>18i</b>, <b>20n</b>, and <b>20o</b>, bearing the <i>N</i>-acetyl-(<i>S</i>)-proline cyclobutyl amide moiety, showed only a moderate shift in activity in hPRP as compared to IP, thus indicating that the association to plasma proteins does not impair the antiaggregatory activity to a significant extent. To exclude that the observed strong antagonistic action of these compounds originates from the interference of the ligands with other activation pathways, IPs were stimulated using Col and Thr as agonists in the presence of the <b>4</b>, <b>18i</b>, <b>20n</b>, and <b>20o</b>. Neither the Col- nor the Thr-stimulated aggregation was affected at relevant concentrations by <b>4</b>, <b>18i</b>, <b>20n</b>, and <b>20o</b>.<a onclick="showRef(event, 'ref9 ref19'); return false;" href="javascript:void(0);" class="ref ref9 ref19">(9, 19)</a> In addition, these compounds were highly selective versus the P2Y<sub>1</sub> receptor, thus excluding any synergistic interaction and contribution of this receptor. These results clearly indicate that the observed strong inhibition of the ADP-mediated platelet aggregation in hPRP is due to the specific antagonistic action on the P2Y<sub>12</sub> receptor. Moreover, apart from the high functional activity shown in IP, the reduced plasma protein binding appears to contribute to the observed high antagonistic activity in hPRP.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Activity and Selectivity Data of Selected Compounds Using P2Y<sub>1</sub> Cell Membranes and IPs Stimulated with Different Agonists</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">compds</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>4</b></th><th class="colsep0 rowsep0" align="center"><b>18i</b></th><th class="colsep0 rowsep0" align="center"><b>20n</b></th><th class="colsep0 rowsep0" align="center"><b>20o</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>K</i><sub>i</sub> (P2Y<sub>12</sub>)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">139 nM</td><td class="colsep0 rowsep0" align="left">7.3 nM</td><td class="colsep0 rowsep0" align="left">107 nM</td><td class="colsep0 rowsep0" align="left">7.7 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>K</i><sub>i</sub> (P2Y<sub>1</sub>)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">>20 μM</td><td class="colsep0 rowsep0" align="left">>20 μM</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>20 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (IP, ADP)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.701 μM</td><td class="colsep0 rowsep0" align="left">0.007 μM</td><td class="colsep0 rowsep0" align="left">0.099 μM</td><td class="colsep0 rowsep0" align="left">0.022 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (hPRP, ADP)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">2.93 μM</td><td class="colsep0 rowsep0" align="left">0.009 μM</td><td class="colsep0 rowsep0" align="left">0.100 μM</td><td class="colsep0 rowsep0" align="left">0.046 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (IP, col)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>2 μM</td><td class="colsep0 rowsep0" align="left">>2 μM</td><td class="colsep0 rowsep0" align="left">>2 μM</td><td class="colsep0 rowsep0" align="left">>2 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (IP, thr)<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">>2 μM</td><td class="colsep0 rowsep0" align="left">>2 μM</td><td class="colsep0 rowsep0" align="left">>2 μM</td><td class="colsep0 rowsep0" align="left">>2 μM</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">P2Y<sub>12</sub> binding assay using cell membranes from CHO cells with recombinant expression of human P2Y<sub>12</sub> receptors employing [<sup>33</sup>P]2-MeS-ADP as the radioligand.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">P2Y<sub>1</sub> binding assay using cell membranes from CHO cells with recombinant expression of human P2Y<sub>1</sub> receptors employing [<sup>33</sup>P]2-MeS-ADP as the radioligand.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Antiagreggatory effect on ADP-stimulated human IPs according to the Born method using single cuvettes.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Antiagreggatory effect on ADP-stimulated hPRP according to the Born method using single cuvettes.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">Antiagreggatory effect on collagen (col)-stimulated human IP according to the Born method using single cuvettes.</p></div><div class="footnote" id="t5fn6"><sup>f</sup><p class="last">Antiagreggatory effect on thrombin (thr)-stimulated human IP according to the Born method using single cuvettes.</p></div></div></div><div class="NLM_p last">The potential for the further development of these compounds was underscored by the evaluation of the antiaggregatory activity in an ex-vivo dog model.<a onclick="showRef(event, 'ref9 ref20'); return false;" href="javascript:void(0);" class="ref ref9 ref20">(9, 20)</a> For example, when <b>20o</b> was orally administered with 10 mg/kg a sustained antiaggregatory effect with 73% inhibition after 24 h [whole blood platelet aggregation (impedance), 2.5 μM ADP, area under curve (AUC mean)] was observed.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">4 Development of 3D QSAR Models</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74124" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74124" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because the binding hypotheses provided in this publication were based on docking modes into homology models and not on high-resolution crystal structures, we generated multiple ligand alignments for the establishment of 3D QSAR [comparative molecular field analysis (CoMFA) and CoMSIA] models to reveal essential features for activity. Starting with the docking mode of <b>4</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) as a reference, all remaining compounds were consistently aligned with our multiple ligand alignment approach Multiple Alignments by ROCS-based Similarity (MARS).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> On the basis of this alignment, statistically good CoMFA (<i>q</i><sub>LOO</sub><sup>2</sup> = 0.60, <i>q</i><sub>LNO</sub><sup>2</sup> = 0.59 for four partial least-squares components) and CoMSIA (<i>q</i><sub>LOO</sub><sup>2</sup> = 0.63, <i>q</i><sub>LNO</sub><sup>2</sup> = 0.62 for four partial least-squares components) models were obtained. The steric and electrostatic std*coeff fields of the CoMSIA model are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> with <b>4</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 139 nM]. Green contours indicate regions where steric bulk is favorable for P2Y<sub>12</sub> activity, whereas yellow contours highlight regions where substituents are detrimental for activity.</div><div class="NLM_p">Because the reference conformation for the multiple ligand alignment was based on a docking hypothesis in the P2Y<sub>12</sub> receptor, the contour fields can be analyzed in the context of the binding site (model) environment. Indeed, the maps are consistent with steric and electrostatic requirements of the modeled P2Y<sub>12</sub> binding site. For example, the carboxy group of the central glutamic acid of the initial lead <b>4</b> is located close to a region (indicated by a red contour) where negatively charged substituents are favorable for activity due to electrostatic interactions to the cationic amino acids Arg6.55 and Lys7.35. Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> panels a–d illustrate the SAR of the substituents at the 5-position of the pyrazole moiety. The beneficial effect of lipophilic substituents at the 5-position is visualized in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>b,c by the steric fields (indicated by a green contour). For example, the propyl side chain of <b>18d</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 66 nM] is located in a green contour field, where additional steric bulk is favorable for affinity. This is in contrast to the methyl substituent of <b>18b</b>, which shows a considerably lower activity [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 536 nM]. Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>d explains the configurational dependence of the activity for the proline stereoisomers <b>18g</b> and <b>18h</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Whereas the (<i>S</i>)-configured stereoisomer <b>18g</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 105 nM] shows an optimal interaction with the modeled binding site, the (<i>R</i>)-configured stereoisomer <b>18h</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>): 958 nM] clashes with the surrounding protein residues, resulting in a less favorable overall fit of the molecule in the receptor binding site.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Shows steric and electrostatic std*coeff contour maps from the CoMSIA model with our initial lead compound <b>4</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>), 139 nM]: Green contours refer to regions where additional steric bulk is favorable for affinity, while yellow contours indicate disfavored areas. Red contours indicate regions where negatively charged substituents are favorable. (b) The same as panel a with all 63 compounds aligned. (c) The same as panel a with <b>18d</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>), 66 nM]. (d) The same as panel a with <b>18g</b> [molecule shown in green; <i>K</i><sub>i</sub> (P2Y<sub>12</sub>), 105 nM] and <b>18h</b> [yellow; <i>K</i><sub>i</sub> (P2Y<sub>12</sub>), 958 nM].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">5 Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have developed a series of highly active P2Y<sub>12</sub> antagonists based on a phenylpyrazolone scaffold. Investigation of the structural requirements at three different regions generated a set of structural diverse P2Y<sub>12</sub> antagonists. Notably, noncharged residues attached to the 5-<i>O</i>-position of the pyrazolone like the <i>N</i>-acetyl-(<i>S</i>)-proline cyclobutyl amide group accumulated strong evidence that these moieties address a distinct binding pocket of the receptor. Addressing this binding pocket resulted in not only an increase in binding affinity but also a dramatic increase of functional hPRP activity, a recognized parameter for the antithrombotic activity in the clinic, up to the low nanomolar range. Surprisingly, revisiting the structural requirements of the piperazinyl ethyl carbamate and the central glutamic acid moiety revealed that the charged glutamate residue could be replaced by a glycine. This was highly unexpected, as the glutamic residue had been previously considered to form an indispensable strong interaction with the basic residues Arg6.55 and Lys7.35 of the P2Y<sub>12</sub> receptor. Further investigations using IPs and other agonists revealed a reduced association to plasma proteins of these compounds as compared to the initial lead <b>4</b> and excluded the interference of the antagonists with other significant activation pathways. These results underscore the key role played by the high affinity <i>N</i>-acetyl-(<i>S</i>)-proline cyclobutyl amide ligand moiety, in determining not only the high binding affinity but also the strong functional hPRP activity. Exploiting this behavior may potentially allow the generation of other highly potent P2Y<sub>12</sub> antagonists by using other <i>N</i>-acetyl-(<i>S</i>)-proline cyclobutyl amide ligand–scaffold combinations.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">6 Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58284" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58284" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">6.1 Chemistry</h3><div class="NLM_p">Solvents and other reagents were used as received without further purification. Normal phase column chromatography was carried out on Merck silica gel 60 (230–400 mesh). Reversed phase high-pressure chromatography was conducted on an Agilent 1100 instrument using an Agilent Prep. C18 column (10 μm, 30 mm × 250 mm). Thin-layer chromatography (TLC) was carried out on TLC aluminum sheets with silica gel 60F254 from Merck. Varying ratios of acetonitrile and 0.1% trifluoroacetic acid in water were used as solvent systems. NMR spectra were recorded in CD<sub>3</sub>OD, CDCl<sub>3</sub>, or DMSO-<i>d</i><sub>6</sub> either on a Bruker DRX 400 or a Bruker FN-ARX 500. Chemical shifts are reported as δ values from an internal tetramethylsilane standard. All final compounds were purified by normal phase or reversed phase chromatography. Purity and characterization of compounds were established by a combination of analytical HPLC, LC-MS, and NMR analytical techniques. All tested compounds were found to be >95% pure by analytical HPLC and LC-MS analysis.</div><div class="NLM_p">LC-MS analyses were performed with an Agilent HPLC Series 1100. The following HPLC methods were used to obtain the reported retention times. Method a: YMC Jsphere column 33 mm × 2 mm; 4 μM; flow rate, 1.0 mL/min. Gradient: water + 0.05% trifluoroacetic acid:acetonitrile + 0.05% trifluoroacetic acid: 98 (1 min) to 95:5 (5.0 min) to 95:5 (6.25 min); Waters LCT-MUX, ESI+ mode. Method b: YMC Jsphere column 33 mm × 2 mm; 4 μm; flow rate, 1.0 mL/min. Gradient: water + 0.05% trifluoroacetic acid:acetonitrile + 0.05% trifluoroacetic acid 95:5 (0 min) to 5:95 (3.7 min); Waters LCT-MUX, ESI+ mode. Method c: Waters XBridge C18 column 4.6 mm × 50 mm; 2.5 μm; flow rate, 1.3 mL/min. Gradient: water + 0.1% formic acid:acetonitrile + 0.08% formic acid 97:3 (0 min) to 40:60 (3.5 min) to 2:98 (4 min) to 2:98 (5 min) to 97:3 (5.2 min) to 97:3 (6.5 min); Waters Quattro Ultima, ESI+ mode. Method d: Waters XBridge C18 column 4.6 mm × 50 mm; 2.5 μm; flow rate, 1.3 mL/min. Gradient: water + 0.05% trifluoroacetic acid:acetonitrile + 0.05% trifluoroacetic acid 95:5 (0 min) to 95:5 (0.3 min) to 5:95 (3.5 min) to 5:95 (4 min); Waters LCT, ESI+ mode. Method e: YMC Jsphere column 33 mm × 2 mm; 4 μm; flow rate, 1.3 mL/min. Gradient: water + 0.05% trifluoroacetic acid:acetonitrile + 0.05% trifluoroacetic acid 95:5 (0 min) to 5:95 (2.5 min) to 95:5 (3.2 min); Waters LCT, ESI+ mode. Method f: YMC Jsphere column 33 mm × 2 mm; 4 μm; flow rate, 1.0 mL/min. Gradient water + 0.05% trifluoroacetic acid:AcN + 0.05% trifluoroacetic acid 95:5 (0 min) to 5:95 (3.7 min); Waters LCT-MUX, ESI+ mode. Method g: YMC Jsphere column 33 mm × 2 mm; 4 μm; flow rate, 1.3 mL/min. Gradient: water + 0.05% formic acid:acetonitrile + 0.05% formic acid 95:5 (0 min) to 95:5 (0.5 min) to 5:95 (3.5 min) to 5:95 (4 min); Waters LCT, ESI+ mode. Method h: YMC Jsphere column 33 mm × 2 mm; 4 μm; flow rate, 1.3 mL/min. Gradient: water + 0.05% formic acid:acetonitrile + 0.05% formic acid 95:5 (0 min) to 5:95 (2.5 min) to 5:95 (3 min); Waters LCT, ESI+ mode. Method i: YMC Jsphere column 33 mm × 2 mm; 4 μm; flow rate, 1.3 mL/min. Gradient: water + 0.1% formic acid:acetonitrile + 0.08% formic acid 95:5 (0 min) to 5:95 (2.5 min); Waters Quattro Ultima, ESI+ mode. Method j: YMC Jsphere column 20 mm × 2 mm; 4 μm; flow rate, 1.0 mL/min. Gradient: water + 0.05% trifluoroacetic acid:acetonitrile + 0.05% trifluoroacetic acid 94:6 (0 min) to 5:95 (2.4 min) to 94:6 (2.45 min); Agilent series 1100 MSD, ESI+ mode.</div><div id="sec7_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">6.1.1 4-((<i>S</i>)-2-Amino-4-<i>tert</i>-butoxycarbonyl-butyryl)-piperazine-1-carboxylic Acid Ethyl Ester (<b>7</b>)</h4><div id="sec7_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19">6.1.1.1 4-((<i>S</i>)-2-Benzyloxycarbonylamino-4-<i>tert</i>-butoxycarbonyl-butyryl)-piperazine-1-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of (<i>S</i>)-2-benzyloxycarbonylamino-pentanedioic acid 5-<i>tert</i>-butyl ester (<b>5</b>) (15.0 g, 44.5 mmol) in DMF (75 mL) were added 1-ethoxycarbonylpiperazine (<b>6</b>) (6.9 mL, 44.5 mmol), <i>N-</i>ethylmorpholine (22.6 mL, 177.8 mmol), and TOTU (14.6 g, 44.5 mmol). After it was stirred for 12 h, the solution was diluted with ethyl acetate and subsequently washed with aqueous LiCl (4% w/w) and saturated aqueous NaHCO<sub>3</sub>. The crude product (20.9 g, 99%) obtained after evaporation of the solvent was directly subjected to the subsequent deprotection reaction without further purification. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.52 (d, <i>J</i> = 8.3 Hz, 1H), 7.34 (m, 5H), 5.04 (d, <i>J</i> = 12.6 Hz, 1H), 4.99 (d, <i>J</i> = 12.6 Hz, 1H), 4.47 (m, 1H), 4.06 (q, <i>J</i> = 7.4 Hz, 2H), 3.52 (m, 4H), 3.39 (m, 4H), 2.27 (m, 2H), 1.80 (m, 1H), 1.67 (m, 1H), 1.39 (s, 9H), 1.19 (t, <i>J</i> = 7.4 Hz, 3H). <i>t</i><sub>R</sub> (method j): 1.52 min. MS (ES) <i>m</i>/<i>z</i>: 478.3 (MH+).</div></div><div id="sec7_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20">6.1.1.2 4-((<i>S</i>)-2-Amino-4-<i>tert</i>-butoxycarbonyl-butyryl)-piperazine-1-carboxylic Acid Ethyl Ester (<b>7</b>)</h5><div class="NLM_p last">To a solution of 4-((<i>S</i>)-2-benzyloxycarbonylamino-4-<i>tert</i>-butoxycarbonyl-butyryl)-piperazine-1-carboxylic acid ethyl ester (20.9 g, 43.9 mmol) in ethanol (120 mL) was added Pd/C (2.0 g, 10% w/w), and the suspension was stirred under an atmosphere of hydrogen (3 bar) for 12 h. The reaction mixture was filtrated over a plug of Celite, washed with ethanol, and concentrated to give the pure product <b>7</b> (13.6 g, 89%) as a colorless oil, which was not further purified. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 4.06 (q, <i>J</i> = 7.4 Hz, 2H), 3.57 (m, 1H), 3.49 (m, 4H), 3.37 (m, 4H), 2.30 (m, 2H), 1.6<i>5</i> (m, 2H), 1.39 (s, 9H), 1.19 (t, <i>J</i> = 7.4 Hz, 3H). <i>t</i><sub>R</sub> (method j): 0.82 min. MS (ES) <i>m</i>/<i>z</i>: 344.3 (MH+).</div></div></div><div id="sec7_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">6.1.2 5-Carboxymethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic Acid Ethyl Ester (<b>9</b>)</h4><div id="sec7_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22">6.1.2.1 5-Benzyloxycarbonylmethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of 5-hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid ethyl ester (<b>8</b>) (10.0 g, 43.1 mmol) in DMF (100 mL) were added benzyl bromoacetate (7.1 mL, 43.1 mmol) and cesium carbonate (24.0 g, 86.1 mmol). After it was stirred for 16 h at room temperature, the suspension was filtered, washed with DMF, and concentrated. The residue was taken up with ethyl acetate and extracted with aqueous LiCl (4% w/w). Evaporation of the solvent yielded the crude product as a yellow oil (15.5 g, 95%), which was used in the subsequent debenzylation reaction. <i>t</i><sub>R</sub> (method j): 1.64 min. MS (ES) <i>m</i>/<i>z</i>: 381.2 (MH+).</div></div><div id="sec7_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23">6.1.2.2 5-Carboxymethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic Acid Ethyl Ester (<b>9</b>)</h5><div class="NLM_p last">To a solution of 5-benzyloxycarbonylmethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid ethyl ester (15.5 g, 40.8 mmol) in ethyl acetate (100 mL) was added Pd/C (1 g, 10%), and the resulting suspension stirred under an atmosphere of hydrogen (3 bar) for 5 h. The reaction mixture was filtered over a plug of Celite and washed with ethyl acetate and methanol to give the crude product <b>9</b> as colorless platelets (11.5 g, 98%) after evaporation of the solvents. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.28 (s br, 1H), 7.74 (d, <i>J</i> = 7.9 Hz, 2H), 7.54 (t, <i>J</i> = 7.9 Hz, 2H), 7.42 (t, <i>J</i> = 7.9 Hz, 1H), 6.42 (s, 1H), 4.93 (s, 2H), 4.29 (q, <i>J</i> = 7.0 Hz, 2H), 1.30 (t, <i>J</i> = 7.0 Hz, 3H). <i>t</i><sub>R</sub> (method j): 1.11 min. MS (ES) <i>m</i>/<i>z</i>: 291.2 (MH+).</div></div></div><div id="sec7_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">6.1.3 Preparation of 5-[2-((<i>S</i>)-2-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic Acid (<b>10</b>)</h4><div id="sec7_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25">6.1.3.1 5-[2-((<i>S</i>)-2-Benzyloxycarbonyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of 5-carboxymethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid ethyl ester (<b>9</b>) (9.5 g, 32.8 mmol) in DMF (100 mL) were added HOBt (5.0 g, 32.8 mmol), EDC (6.3 g, 32.8 mmol), and DIPEA (10.9 mL, 65.7 mmol). After 5 min, <span class="smallcaps smallerCapital">l</span>-proline benzyl ester hydrochloride (7.9 g, 32.8 mmol) was added, and the resulting solution was stirred for 16 h. The reaction mixture was concentrated, dissolved in dichloromethane, and extracted with aqueous LiCl (4% w/w) and saturated NaHCO<sub>3</sub>. The crude product obtained after evaporation of the solvent was purified by flash chromatography on silica using ethyl acetate/heptane 1:1 as an eluent to give the product as colorless foam (13.2 g, 84%). <i>t</i><sub>R</sub> (method j): 1.55 min. MS (ES) <i>m</i>/<i>z</i>: 478.3 (MH+).</div></div><div id="sec7_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26">6.1.3.2 5-[2-((<i>S</i>)-2-Carboxy-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of 5-[2-((<i>S</i>)-2-benzyloxycarbonyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid ethyl ester (13.2 g, 27.6 mmol) in ethyl acetate (100 mL) was added Pd/C (1 g, 10%), and the resulting suspension was stirred under an atmosphere of hydrogen (3 bar) for 6 h. The reaction mixture was filtered over a plug of Celite and washed with ethanol to give the crude product as colorless foam (8.9 g, 70%) after evaporation of the solvents. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 12.61 (s br, 1H), 7.83 (d, <i>J</i> = 8.4 Hz, 2H), 7.57 (t, <i>J</i> = 7.8 Hz, 2H), 7.45 (t, <i>J</i> = 7.8 Hz, 1H), 6.48 (s, appears as 2 rotamers, 1H), 5.12 (s, 2H), 4.32 (m, 3H), 3.55 (m, 2H), 2.15 (m, 1H), 1.89 (m, 3H), 1.28 (t, <i>J</i> = 7.0 Hz, 3H). <i>t</i><sub>R</sub> (method j): 1.10 min. MS (ES) <i>m</i>/<i>z</i>: 388.2 (MH+).</div></div><div id="sec7_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27">6.1.3.3 5-[2-((<i>S</i>)-2-Cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of 5-[2-((<i>S</i>)-2-carboxy-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid ethyl ester 84.5 g, 11.6 mmol) in DMF (105 mL) were added HATU (4.4 g, 11.6 mmol) and DIPEA (1.9 mL, 11.6 mmol). After 10 min, cyclobutylamine (1.0 mL, 11.6 mmol) was added, and after 30 min, the reaction mixture was concentrated. The residue was taken up in dichloromethane and extracted with aqueous LiCl (4% w/w), aqueous HCl (0.1 M), and saturated NaHCO<sub>3</sub>. The crude product obtained after evaporation of the solvent was purified by flash chromatography on silica using ethyl acetate/heptane 4:1 as the eluent to give the title compound as a colorless oil (3.2 g, 62%). <i>t</i><sub>R</sub> (method j): 1.26 min. MS (ES) <i>m</i>/<i>z</i>: 441.3 (MH+).</div></div><div id="sec7_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28">6.1.3.4 5-[2-((<i>S</i>)-2-Cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic Acid (<b>10</b>)</h5><div class="NLM_p last">To a solution of 5-[2-((<i>S</i>)-2-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid ethyl ester (3.2 g, 7.2 mmol) in THF (40 mL) and water (5 mL) was added NaOH (340 mg, 8.5 mmol) portionwise at 0 °C. After 4 h, the solution was neutralized with Amberlite IR-120 ion-exchange resin, filtered, and washed with methanol. After evaporation of the solvents, the product <b>10</b> was obtained as a yellow gum (3.7 g, 77%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.00 (d, appears as 2 rotamers, <i>J</i> = 7.5 Hz, 1H), 7.81 (d, <i>J</i> = 8.7 Hz, 2H), 7.48 (t, <i>J</i> = 8.7 Hz, 2H), 7.33 (t, <i>J</i> = 8.7 Hz, 1H), 6.24 (s, appears as 2 rotamers, 1H,), 4.99 (s, 2H), 4.22 (dd, <i>J</i> = 8.6 Hz, <i>J</i> = 3.5 Hz, 1H), 4.14 (m, 1H), 3.56 (m, 1H), 3.47 (m, 1H), 2.20–1.54 (several multiplets, 10H). <i>t</i><sub>R</sub> (method j): 1.04 min. MS (ES) <i>m</i>/<i>z</i>: 413.2 (MH+).</div></div></div><div id="sec7_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">6.1.4 Representative Procedure: Preparation of 4-{(<i>S</i>)-4-Carboxy-2-[(5-hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic Acid Ethyl Ester (<b>17a</b>)</h4><div id="sec7_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30">6.1.4.1 4-{(<i>S</i>)-4-<i>tert</i>-Butoxycarbonyl-2-[(5-hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of 1-phenyl-3-carboxy-5-pyrazolone <b>11</b> (2 g, 35.2 mmol) and 4-((<i>S</i>)-2-amino-4-<i>tert</i>-butoxycarbonyl-butyryl)-piperazine-1-carboxylic acid ethyl ester (<b>7</b>) (12.1 g, 35.2 mmol) in DMF (100 mL), HOBt (5.4 g, 35.2 mmol) and EDC (6.7 g, 35.2 mmol) were added, and the reaction mixture was stirred for 12 h at room temperature. Then, the reaction mixture was diluted with ethyl acetate and subsequently extracted with aqueous LiCl (4% w/w), aqueous HCl (0.1 M), and aqueous NaHCO<sub>3</sub>. The organic layer was dried over MgSO<sub>4</sub>, and the solvent was removed under reduced pressure to yield the product (14.8 g, 80%), which was directly subjected to the subsequent deprotection reaction.</div></div><div id="sec7_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31">6.1.4.2 4-{(<i>S</i>)-4-Carboxy-2-[(5-hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic Acid Ethyl Ester (<b>17a</b>)</h5><div class="NLM_p last">To a solution of 4-{(<i>S</i>)-4-<i>tert</i>-butoxycarbonyl-2-[(5-hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester (50 mg, 0.09 mmol) in dichloromethane (2 mL), trifluoroacetic acid (0.13 mL) was added. After it was stirred for 4 h, the reaction mixture was concentrated, and the crude product obtained was purified by preparative reversed-phase HPLC, eluting with a gradient of acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization, the product <b>17a</b> (9 mg, 20%) was obtained as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 12.05 (s br, 1H), 8.09 (d, <i>J</i> = 7.8 Hz, 1H), 7.78 (d, <i>J</i> = 8.1 Hz, 2H), 7.50 (t, <i>J</i> = 7.8 Hz, 2H), 7.35 (t, <i>J</i> = 7.1 Hz, 1H), 5.92 (s, 1H), 4.94 (dt, <i>J</i> = 4.5 Hz, <i>J</i> = 8.8 Hz, 1H), 4.06 (q, <i>J</i> = 6.8 Hz, 2H), 3.46 (m, 8H), 2.29 (m, 2H), 1.96 (m, 1H), 1.80 (m, 1H), 1.19 (t, <i>J</i> = 6.8 Hz, 3H). <i>t</i><sub>R</sub> (method e): 1.39 min. MS (ES) <i>m</i>/<i>z</i>: 474.2 (MH+).</div></div></div><div id="sec7_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">6.1.5 Representative Procedure: Preparation of 4-((<i>S</i>)-4-Carboxy-2-{[5-(1-ethoxycarbonyl-cyclobutoxy)-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic Acid Ethyl Ester (<b>4</b>)</h4><div class="NLM_p last">To a solution of 4-{(<i>S</i>)-4-<i>tert</i>-butoxycarbonyl-2-[(5-hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester (1.50 g, 2.8 mmol) in DMF (20 mL), ethyl 1-bromocyclobutanecarboxylate (1.22 g, 5.7 mmol) and cesium carbonate (1.85 g, 5.66 mmol) were added. The reaction mixture was stirred for 2 h at 100 °C, then cooled to room temperature, and diluted with water. The solution was extracted with dichloromethane, and the organic layer was washed with water and dried over MgSO<sub>4</sub>. After the solvents were removed under reduced pressure, the residue was purified by flash chromatography on silica using a heptane/ethyl acetate gradient to give the corresponding O-alkylation product (860 mg, 46%), which was dissolved in dichloromethane (5 mL) and stirred in the presence of of trifluoroacetic acid (0.4 mL). After they were stirred for 4 h at room temperature, the solvents were removed under reduced pressure, and the residue was purified by flash chromatography on silica using a dichloromethane/ethanol gradient. After lyophilization, the product <b>4</b> (320 mg, 40%) was obtained as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.76 (d, <i>J</i> = 9.0 Hz, 2H), 7.55 (t, <i>J</i> = 8.0 Hz, 2H), 7.42 (t, <i>J</i> = 7.3 Hz, 1H), 5.84 (s, 1H), 4.93 (m, 1H), 4.17 (q, <i>J</i> = 6.9 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 3.46 (m, 8H), 2.68 (m, 2H), 2.50 (m, 2H), 2.25 (m, 2H), 1.86 (m, 4H), 1.19 (t, <i>J</i> = 6.8 Hz, 3H), 1.12 (t, <i>J</i> = 6.8 Hz, 3H). <i>t</i><sub>R</sub> (method f): 2.08 min. MS (ES) <i>m</i>/<i>z</i>: 600.3 (MH+).</div></div><div id="sec7_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">6.1.6 Representative Procedure: Preparation of 4-[(<i>S</i>)-4-Carboxy-2-({5-[2-((<i>R</i>)-3-hydroxy-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic Acid Ethyl Ester (<b>17h</b>) via Route 1 (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>)</h4><div id="sec7_1_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34">6.1.6.1 4-{(<i>S</i>)-2-[(5-Benzyloxycarbonylmethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-4-<i>tert</i>-butoxycarbonyl-butyryl}-piperazine-1-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of 4-{(<i>S</i>)-4-<i>tert</i>-butoxycarbonyl-2-[(5-hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester (14.5 g, 27.3 mmol) in DMF (110 mL) were added benzyl bromoacetate (4.5 mL, 27.3 mmol) and cesium carbonate (17.8 g, 54.7 mmol). After it was stirred at room temperature for 12 h, the solution was reduced to a volume of 50 mL, diluted with ethyl acetate (400 mL), and extracted with aqueous LiCl (4% w/w). The crude product obtained after evaporation of the solvent was purified by flash chromatography on silica eluting with a gradient of <i>n</i>-heptane/ethyl acetate to give the title compound as a yellowish amorphous solid (13.2 g, 71%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.14 (d, <i>J</i> = 8.2 Hz, 1H), 7.77 (d, <i>J</i> = 8.0 Hz, 2H), 7.51 (t, <i>J</i> = 8.0 Hz, 2H), 7.40 (t, <i>J</i> = 8.0 Hz, 1H), 7.36 (m, 5H), 6.42 (s, 1H), 5.21 (s, 2H), 5.11 (s, 2H), 4.95 (m, 1H), 4.05 (m, 3H), 3.58 (m, 4H), 3.42 (m, 4H), 2.28 (m, 2H), 1.96 (m, 1H), 1.81 (m, 1H), 1.37 (s, 9H), 1.19 (t, <i>J</i> = 7.0 Hz, 3H). <i>t</i><sub>R</sub> (method j): 1.77 min. MS (ES) <i>m</i>/<i>z</i>: 678.3 (MH+).</div></div><div id="sec7_1_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35">6.1.6.2 4-{(<i>S</i>)-4-<i>tert</i>-Butoxycarbonyl-2-[(5-carboxymethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of 4-{(<i>S</i>)-2-[(5-benzyloxycarbonylmethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-4-<i>tert</i>-butoxycarbonyl-butyryl}-piperazine-1-carboxylic acid ethyl ester (13.2 g, 19.5 mmol) in ethyl acetate (75 mL) was added under argon Pd/C (1.1 g, 10%), and the suspension was stirred under an atmosphere of hydrogen (3 bar) for 16 h. The suspension was filtered over a plug of Celite and washed with ethyl acetate. The crude product obtained after evaporation of the solvent was dried under vacuo at 40 °C for 24 h to give the title compound as a of a colorless solid (12.1 g, 100%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.14 (d, <i>J</i> = 8.2 Hz, 1H), 7.80 (d, <i>J</i> = 8.0 Hz, 2H), 7.53 (t, <i>J</i> = 8.0 Hz, 2H), 7.41 (t, <i>J</i> = 8.0 Hz, 1H), 6.34 (s, 1H), 4.94 (m, 1H), 4.90 (s, 2H), 4.05 (m, 3H), 3.60 (m, 4H), 3.39 (m, 4H), 2.29 (m, 2H), 1.94 (m, 1H), 1.81 (m, 1H), 1.38 (s, 9H), 1.19 (t, <i>J</i> = 7.0 Hz, 3H). <i>t</i><sub>R</sub> (method j): 1.39 min. MS (ES) <i>m</i>/<i>z</i>: 588.3 (MH+).</div></div><div id="sec7_1_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36">6.1.6.3 4-[(<i>S</i>)-4-Carboxy-2-({5-[2-((<i>R</i>)-3-hydroxy-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic Acid Ethyl Ester (<b>17h</b>)</h5><div class="NLM_p last">To a solution of 4-{(<i>S</i>)-4-<i>tert</i>-butoxycarbonyl-2-[(5-carboxymethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester (90 mg, 0.15 mmol) in DMF (5 mL) were added DIPEA (54 μL, 0.30 mmol), HOBt (23 mg, 0.15 mmol), and EDC (29 mg, 0.15 mmol). After 20 min, (<i>R</i>)-(−)-3-pyrrolidinol hydrochloride (19 mg, 0.15 mmol) was added, and the reaction mixture was stirred for 12 h. After dilution with ethyl acetate, the reaction mixture was extracted with aqueous LiCl (4% w/w) and aqueous NaHCO<sub>3</sub>. The organic layer was dried over MgSO<sub>4</sub>, and the solvent was removed under reduced pressure. The crude product was dissolved in dichloromethane (1.5 mL) and treated with trifluoroacetic acid (127 μL). After they were stirred for 12 h, the solvents were removed under reduced pressure, and the residue was purified by preparative reversed-phase HPLC, eluting with a gradient of acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization, the product <b>17h</b> (45 mg, 49%) was obtained as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.13 (d, <i>J</i> = 8.3 Hz, 1H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.52 (t, <i>J</i> = 8.3 Hz, 2H), 7.39 (t, <i>J</i> = 7.4 Hz, 1H), 6.35 (s, 1H, appears as 2 rotamers), 4.95 (m, 4H), 4.29 (s, 1H, appears as 2 rotamers), 4.05 (q, <i>J</i> = 6.9 Hz, 2H), 3.44 (m, 12H), 2.29 (m, 2H), 1.96 (m, 2H), 1.84 (m, 2H), 1.19 (t, <i>J</i> = 6.8 Hz, 3H). <i>t</i><sub>R</sub> (method e): 1.22 min. MS (ES) <i>m</i>/<i>z</i>: 501.2 (MH+).</div></div></div><div id="sec7_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37">6.1.7 Representative Procedure: Preparation of 4-[(<i>S</i>)-4-Carboxy-2-({5-[2-((<i>S</i>)-2-methylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic Acid Ethyl Ester (<b>18b</b>) via Route 1 (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>)</h4><div id="sec7_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38">6.1.7.1 4-[(<i>S</i>)-2-({5-[2-((<i>S</i>)-2-Benzyloxycarbonyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-4-<i>tert</i>-butoxycarbonyl-butyryl]-piperazine-1-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of 4-{(<i>S</i>)-4-<i>tert</i>-butoxycarbonyl-2-[(5-carboxymethoxy-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester (9.5 g, 16.2 mmol) in DMF (80 mL) were added HOBt (2.5 g, 16.2 mmol), DIPEA (5.7 mL, 32.4 mmol), and <span class="smallcaps smallerCapital">l</span>-proline benzyl ester hydrochloride (3.9 g, 16.2 mmol) at 0 °C. At this temperature was added EDC (3.1 g, 16.2 mmol) portionwise, and the suspension was allowed to warm to room temperature over a period of 12 h. The solvent was evaporated, and the residue was dissolved in ethyl acetate and subsequently extracted with aqueous LiCl (4% w/w), aqueous HCl (0.1 M), and aqueous NaHCO<sub>3</sub>. The organic layer was dried over MgSO<sub>4</sub>, and the solvent was removed under reduced pressure to give the crude product as amorphous solid (11.6 g, 92%). An analytically pure sample could be obtained by purification of an aliquot by preparative HPLC. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.13 (d, <i>J</i> = 7.8 Hz, 1H), 7.84 (d, <i>J</i> = 7.3 Hz, 2H), 7.52 (t, <i>J</i> = 7.3 Hz, 2H), 7.40 (t, <i>J</i> = 7.3 Hz, 1H), 7.33 (m, 5H), 6.38 (s, appears as rotamers, 1H), 5.11 (m, 4H), 4.95 (m, 1H), 4.42 (dd, <i>J</i> = 9.0 Hz, <i>J</i> = 4.3 Hz, 1H), 4.05 (q, <i>J</i> = 7.3 Hz, 2H), 3.56 (m, 10H), 2.33–1.74 (several multiplets, 8H), 1.38 (s, 9H), 1.18 (t, <i>J</i> = 7.0 Hz, 3H). <i>t</i><sub>R</sub> (method j): 1.71 min. MS (ES) <i>m</i>/<i>z</i>: 775.3 (MH+).</div></div><div id="sec7_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39">6.1.7.2 4-[(<i>S</i>)-4-<i>tert</i>-Butoxycarbonyl-2-({5-[2-((<i>S</i>)-2-carboxy-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic Acid Ethyl Ester</h5><div class="NLM_p last">To a solution of 4-[(<i>S</i>)-2-({5-[2-((<i>S</i>)-2-benzyloxycarbonyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-4-<i>tert</i>-butoxycarbonyl-butyryl]-piperazine-1-carboxylic acid ethyl ester (11.6 g, 14.9 mmol) in ethyl acetate (75 mL) was added under argon Pd/C (1 g, 10%), and the suspension was stirred under an atmosphere of hydrogen (3 bar) for 24 h. The suspension was filtered over a plug of Celite and washed with ethyl acetate. The crude product was obtained after evaporation of the solvent (9.9 g, 89%) and used without further purification. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 12.56 (s br, 1H), 8.11 (d, <i>J</i> = 7.8 Hz, 1H), 7.85 (d, <i>J</i> = 7.3 Hz, 2H), 7.52 (t, <i>J</i> = 7.3 Hz, 2H), 7.39 (t, <i>J</i> = 7.3 Hz, 1H), 6.37 (s, appears as rotamers, 1H), 5.06 (s, 2H), 4.94 (m, 1H), 4.28 (dd, <i>J</i> = 9.0 Hz, <i>J</i> = 4.1 Hz, 1H), 4.05 (q, <i>J</i> = 7.1 Hz, 2H), 3.57 (m, 5H), 3.42 (m, 5H), 2.31–1.74 (several multiplets, 8H), 1.37 (s, 9H), 1.18 (t, <i>J</i> = 7.0 Hz, 3H). <i>t</i><sub>R</sub> (method j): 1.40 min. MS (ES) <i>m</i>/<i>z</i>: 685.3 (MH+).</div></div><div id="sec7_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40">6.1.7.3 4-[(<i>S</i>)-4-Carboxy-2-({5-[2-((<i>S</i>)-2-methylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic Acid Ethyl Ester (<b>18b</b>)</h5><div class="NLM_p last">To a solution of 4-[(<i>S</i>)-4-<i>tert</i>-butoxycarbonyl-2-({5-[2-((<i>S</i>)-2-carboxy-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic acid ethyl ester (133 mg, 0.19 mmol) in DMF (5 mL) were added DIPEA (80 μL, 0.49 mmol), HOBt (45 mg, 0.29 mmol), and EDC (56 mg, 0.29 mmol). After 20 min, methylamine hydrochloride (20 mg, 0.29 mmol) was added, and the reaction mixture was stirred for 12 h. After dilution with ethyl acetate, the reaction mixture was extracted with aqueous LiCl (4% w/w) and aqueous NaHCO<sub>3</sub>. The organic layer was dried over MgSO<sub>4</sub>, and the solvent was removed under reduced pressure. The crude product was dissolved in dichloromethane (4 mL) and treated with trifluoroacetic acid (128 μL). After this was stirred for 12 h, the solvents were removed under reduced pressure, and the residue was purified by preparative reversed-phase HPLC, eluting with a gradient of acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization, the product <b>18b</b> (46 mg, 37%) was obtained as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.13 (d, <i>J</i> = 8.4 Hz, 1H), 7.85 (d, <i>J</i> = 8.0 Hz, 2H), 7.76 (m, 1H), 7.53 (t, <i>J</i> = 7.6 Hz, 2H), 7.40 (t, <i>J</i> = 7.4 Hz, 1H), 6.41 (s, 1H), 5.00 (m, 3H), 4.22 (dd, <i>J</i> = 8.5 Hz, <i>J</i> = 3.2 Hz, 1H), 4.06 (q, <i>J</i> = 6.9 Hz, 2H), 3.51 (m, 10H), 2.55 (d, <i>J</i> = 4.6 Hz, 3H), 2.29 (m, 2H), 1.99 (m, 2H), 1.89 (m, 2H), 1.81 (m, 2H), 1.19 (t, <i>J</i> = 6.8 Hz, 3H). <i>t</i><sub>R</sub> (method e): 1.25 min. MS (ES) <i>m</i>/<i>z</i>: 642.3 (MH+).</div></div></div><div id="sec7_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41">6.1.8 Representative Procedure: Preparation of 4-[(<i>S</i>)-4-Carboxy-2-({5-[2-((<i>S</i>)-2-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-butyrylamino]-piperidine-1-carboxylic Acid Ethyl Ester (<b>19a</b>) via Route 2 (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>)</h4><div id="sec7_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42">6.1.8.1 (<i>S</i>)-2-({5-[2-((<i>S</i>)-2-Cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-pentanedioic Acid 5-<i>tert</i>-Butyl Ester 1-Methyl Ester</h5><div class="NLM_p last">To a solution of 5-[2-((<i>S</i>)-2-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (1.1 g, 2.7 mmol) in DMF (20 mL) were added DIPEA (1 mL, 6.1 mmol), HOBt (0.41 g, 2.7 mmol), EDC (0.51 g, 2.7 mmol), and H-Glu(OtBu)-OMe hydrochloride (0.68 g, 2.7 mmol). After it was stirred for 24 h, the solution was concentrated, taken up with dichloromethane, and subsequently extracted with aqueous LiCl (4% w/w), aqueous HCl (0.1 M), and saturated NaHCO<sub>3</sub>. The crude product was purified by flash chromatography on silica using an ethyl acetate/heptane 50:50 to 100:0 gradient to give the title compound as a colorless foam (1.88 g, 100%). <i>t</i><sub>R</sub> (method j): 1.55 min. MS (ES) <i>m</i>/<i>z</i>: 612.3 (MH+).</div></div><div id="sec7_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43">6.1.8.2 (<i>S</i>)-2-({5-[2-((<i>S</i>)-2-Cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl- 1<i>H</i>-pyrazole-3-carbonyl}-amino)-pentanedioic Acid 5-<i>tert</i>-Butyl Ester</h5><div class="NLM_p last">To a solution of (<i>S</i>)-2-({5-[2-((<i>S</i>)-2-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-pentanedioic acid 5-<i>tert</i>-butyl ester 1-methyl ester (1.84 g, 3.0 mmol) in THF (12 mL) was added LiOH (73 mg, 3.0 mmol) in water (4 mL). After 2 h, the reaction mixture was neutralized with Amberlite IR-120, filtered, and washed with methanol. After evaporation of the solvent, the title compound was obtained as a colorless oil (1.80 g, 100%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.24 (d, <i>J</i> = 7.5 Hz, 1H), 8.02 (d, <i>J</i> = 7.5 Hz, appears as rotamers, 1H), 7.91 (d, <i>J</i> = 8.3 Hz, 2H), 7.57 (t, <i>J</i> = 8.3 Hz, 2H), 7.43 (t, <i>J</i> = 8.3 Hz, 1H), 6.44 (s, 1H, appears as rotamers), 5.09 (s, 2H), 4.44- 4.11 (m, 3H), 3.60 (m, 1H), 3.48 (m, 2H), 2.32–1.52 (several multiplets, 14H), 1.37 (s, 9H). <i>t</i><sub>R</sub> (method j): 1.38 min. MS (ES) <i>m</i>/<i>z</i>: 598.2 (MH+).</div></div><div id="sec7_1_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44">6.1.8.3 4-[(<i>S</i>)-4-Carboxy-2-({5-[2-((<i>S</i>)-2-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-butyrylamino]-piperidine-1-carboxylic Acid Ethyl Ester (<b>19a</b>)</h5><div class="NLM_p last">To a solution of (<i>S</i>)-2-({5-[2-((<i>S</i>)-2-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1<i>H</i>-pyrazole-3-carbonyl}-amino)-pentanedioic acid 5-<i>tert</i>-butyl ester (150 mg, 0.25 mmol) in DMF (7 mL) were added DIPEA (62 μL, 1.1 mmol), HATU (95 mg, 0.36 mmol), and ethyl 4-amino-1-piperidinecarboxylate (43 mg, 0.25 mmol). After it was stirred for 12 h, the saturated NaHCO<sub>3</sub> solution was added, and the mixture loaded on a chem elut cartridge, the crude product being eluted with dichloromethane. The solution was concentrated to a volume of 1 mL and stirred in the presence of trifluoroacetic acid (190 μL). After it was stirred for 4 h, the solvents were removed under reduced pressure, and the residue was purified by preparative HPLC (C18 reverse phase column, elution with a water/acetonitrile gradient with 0.1% trifluoroacetic acid). After lyophilization, the product <b>19a</b> (35 mg, 20%) was obtained as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.09 (d, <i>J</i> = 8.0 Hz, 1H), 7.98 (d, <i>J</i> = 8.4 Hz, 1H), 7.85 (d, <i>J</i> = 8.4 Hz, 2H), 7.52 (t, <i>J</i> = 7.6 Hz, 2H), 7.38 (t, <i>J</i> = 7.6 Hz, 1H), 6.41 (s, 1H), 5.04 (s, 2H), 4.96 (m, 1H), 4.21 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 3.9 Hz, 1H), 4.14 (m, 1H), 4.05 (q, <i>J</i> = 6.9 Hz, 2H), 3.82 (m, 1H), 3.52 (m, 8H), 2.29 (m, 2H), 2.11 - 1.80 (m, 8H), 1.72 (m, 3H), 1.59 (m, 2H), 1.25 (m, 2H), 1.19 (t, <i>J</i> = 6.8 Hz, 3H). <i>t</i><sub>R</sub> (method b): 1.59 min. MS (ES) <i>m</i>/<i>z</i>: 696.5 (MH+).</div></div></div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45">6.2 Biology: Human P2Y<sub>12</sub> Recombinant Cell Membrane Binding Assay<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></h3><div class="NLM_p">As a source of P2Y<sub>12</sub>, a membrane preparation was prepared from CHO cells with recombinant expression of the human P2Y<sub>12</sub> receptor according to standard procedures. To a 96-well microtiter plate, added were the following: (a) 24 μL of assay buffer [10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 138 mM NaCl, 2.9 mN KCl, 12 mM NaHCO<sub>3</sub>, 1 mM EDTA-Na, and 0.1% BSA, pH 7.4], (b) 1 μL of compound in DMSO, (c) 50 μL of P2Y<sub>12</sub> CHO membrane (20 μg/mL) and after 15 min at room temperature, and (d) 25 μL of 1.61 nM [<sup>33</sup>P]2-MeS-ADP (Perkin-Elmer NEN custom synthesis, specific activity ∼2100 Ci/mmol) made in assay buffer. The final concentration of [<sup>33</sup>P]2-MeS-ADP was 0.8 nM, and the <i>K</i><sub>d</sub> value determined for [<sup>33</sup>P]2-MeS-ADP was 0.5 nM. After 20 min of incubation at room temperature, samples were transferred and aspirated to 96-well microtiter filterplates (Millipore HTS GF/B) and prewetted for 20 min with 300 μL of stop buffer (10 mM HEPES, 138 mM NaCl, pH 7.4). After they were washed four times with 400 μL/well of stop buffer, the filters were air-dried overnight. After the addition of 0.1 mL of Microscint 20 Scintillation Fluid (Perkin-Elmer #6013621), the filter plates were incubated for 2 h at room temperature and counted in a Microbeta Scintillation Counter. The binding of compound is expressed as a % inhibition of specific binding, defined by subtraction of the background with 1 mM ADP. <i>K</i><sub>i</sub> values were calculated from the IC<sub>50</sub> values using the Cheng–Prusoff equation assuming binding to a single binding site and were averaged from at least triplicate determination. The mean <i>K</i><sub>i</sub> value of the positive control used for each run was 0.4 μM, and the standard error of the mean (SEM) for this standard compound was ±0.016 μM (<i>n</i> = 61).</div><div id="sec7_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46">6.2.1 Inhibition of Human Platelet Aggregation</h4><div id="sec7_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47">6.2.1.1 hPRP Preparation</h5><div class="NLM_p last">Human whole blood was from the Sanofi-Aventis in-house blood donor service. The protocol was approved by the local ethics committee, and all blood donors signed informed consent. Whole blood was collected from healthy volunteers using 20 mL syringes containing 2 mL of acid–citrate–dextrose solution (ACD-A) (for 96-well assays) or 2 mL of buffered citrate (for the light transmission aggregometry, Born method). The anticoagulated whole blood was transferred into 15 mL polypropylene conical tubes (10 mL per tube). The tubes were centrifuged for 15 min at room temperature at 150<i>g</i> (for 96-well assays) or at 340<i>g</i> (for the Born method), leading to a supernatant of hPRP. The hPRP layer was collected from each tube and pooled for each donor. The platelet concentration was determined using a Coulter counter. The 15 mL tubes containing the pellet of cellular components were centrifuged again for 10 min at 1940<i>g</i>, leaving a supernatant of platelet poor plasma (PPP). The PPP was collected for each donor. The PRP was diluted with PPP to a final concentration of 3 × 10<sup>–8</sup> platelets/mL with the PPP.</div></div><div id="sec7_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48">6.2.1.2 IPs Preparation</h5><div class="NLM_p last">IPs were obtained by centrifugation of PRP at 430<i>g</i> for 20 min at room temperature. The resulting platelet pellet was dissolved in a modified Tyrode's buffer containing 145 mM NaCl, 5 mM KCl, 0.1 mM MgCl·6H<sub>2</sub>O, 5.5 mM glucose, and 15 mM Hepes. The buffer was adjusted to pH 7.4. Platelets were counted and adjusted to 300 × 10<sup>–3</sup> platelets/μL. To 320 μL of IPs, 20 μL of CaCl<sub>2</sub> (final concentration, 0.5 mM) was added and incubated at 37 °C for 2 min before adding 20 μL of fibrinogen (final concentration, 1 mg/mL). The respective P2Y<sub>12</sub> antagonist was added (20 μL) and incubated, and the response to platelet activating agonists (20 μL) was recorded.</div></div><div id="sec7_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49">6.2.1.3 Human Platelet Aggregation 96-Well Assay<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></h5><div class="NLM_p last">The human platelet aggregation assay was performed in 96-well plates using a microtiter plate reader (SpectraMax Plus 384 with SoftMax Pro software from Molecular Devices). In the plate, 15 μL of test compound at 10× final concentration in NaCl was mixed with 120 μL of fresh hPRP and incubated for 5 min. Following that incubation period, 15 μL of 40 μM ADP was added to the reaction mix, leading to a final concentration of 4 μM ADP. The plates were then transferred to the microplate reader, and aggregation was measured over 20 min. The instrument settings include the following: absorbance at 650 nm, run time 20 min with readings in 1 min intervals, and 50 s of shaking between readings, all performed at 37 °C. Results of the assay are expressed as % inhibition and are calculated using the AUC of the absorbance over 20 min. The IC<sub>50</sub> values were averaged from at least triplicate determination. The mean value of the positive control used for each run was 0.27 μM, and the SEM for this standard compound was ±0.026 μM (<i>n</i> = 96).</div></div><div id="sec7_2_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50">6.2.1.4 Human Platelet Aggregation Assay Light Transmission Aggregometry (Born Method).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></h5><div class="NLM_p last">The human platelet aggregation assay was performed in single use cuvettes using the platelet aggregation profiler (PAP-8, Bio/Data corporation, Horsham, PA). In the assay cuvette, 4 μL of the test compound at 100× final concentration in DMSO was mixed with 392 μL of fresh hPRP and incubated for 2 min at 37 °C with 1.200 rpm stirring. Following that incubation period, 4 μL of a 250 μM ADP solution was added to the reaction mix, leading to a final concentration of 2.5 μM ADP. After that, aggregation was measured over 6 min at 37 °C with 1.200 rpm stirring. Results of the assay are expressed as % inhibition and are calculated using the AUC of the absorbance over 6 min. The IC<sub>50</sub> values were averaged from at least triplicate determination. The determination of the activity on ADP-, Col-, and Thr-induced aggregation in IPs was performed analogously. The final concentration of ADP was 10 μM, of Col was 1 μg/mL, and of Thr was 0.1 U/mL.</div></div></div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51">6.3 Computational Procedures: Homology Modeling and Molecular Docking</h3><div class="NLM_p">A homology model of the P2Y<sub>12</sub> receptor was generated using the crystal structure of the CXCR4 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1odu">1odu</a>) as the structural template. Sequence alignment and 3D model generation were performed using the software Prime (Prime, v2.2, Schrödinger, LLC, New York, NY). Molecular docking was performed with the Induced Fit Docking procedure<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> based on Glide v5.7 (Glide, v5.7, Schrödinger, LLC) and Prime v2.2, as implemented in the Schrödinger package.</div><div id="sec7_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52">6.3.1 Generation of 3D Ligand Alignments</h4><div class="NLM_p last">For the generation of multiple ligand 3D superimpositions, we used the MARS approach,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> which is based on the pairwise alignment of all molecules within the data set using the software tool ROCS.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec7_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53">6.3.2 Generation of 3D QSAR Models</h4><div class="NLM_p last">Default settings were used for CoMFA and CoMSIA in Sybyl<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> if not otherwise indicated. Steric and electrostatic energies in CoMFA were calculated at grid points with 2 Å spacing, a positively charged carbon atom, and a distance-dependent dielectric constant with MMFF94 charges. For CoMSIA, steric, electrostatic, hydrophobic, donor, and acceptor fields were built using a Gaussian distance-dependent function. Cross-validated analyses were run using SAMPLS (LOO) or 10 cross-validation groups (LNO) with random selection of group members.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54"><a href="/doi/suppl/10.1021/jm300771j">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34473" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34473" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Experimental data for selected compounds <b>17</b>–<b>20</b> and additional biological characterization data. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300771j/suppl_file/jm300771j_si_001.pdf">jm300771j_si_001.pdf (190.51 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm300771j" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marc Nazaré</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3a775b485914745b405b485f7a495b54555c5314595557"><span class="__cf_email__" data-cfemail="8ec3effceda0c0eff4effcebcefdefe0e1e8e7a0ede1e3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gernot Zech</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gerhard Hessler</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Evers</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tilo Weiss</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Florian</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melitta Just</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jörg Czech</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Werngard Czechtizky</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jochen Görlitzer</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sven Ruf</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Markus Kohlmann</span> - <span class="hlFld-Affiliation affiliation">Sanofi-Aventis
Deutschland GmbH, Industriepark Höchst, Building
G878, D-65926 Frankfurt am
Main, Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d5386e3400-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02562" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02562" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank A. Sihorsch, M. Kämmerer-Dienst, C. Prosser, S. Herok, D. Thorn, H. Krause, G. Sibenhorn, S. Stamm, A. Haber, F. Hopfinger, M. Pfeiffer, and R. Katzenmeier for their excellent technical assistance.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i56" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i56"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i57" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i57"> Abbreviations Used</h2><tr><td class="NLM_term">ACD-A</td><td class="NLM_def"><p class="first last">acid–citrate–dextrose solution</p></td></tr><tr><td class="NLM_term">ADP</td><td class="NLM_def"><p class="first last">adenosine diphosphate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under curve</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary cell</p></td></tr><tr><td class="NLM_term">Col</td><td class="NLM_def"><p class="first last">collagen</p></td></tr><tr><td class="NLM_term">CoMFA</td><td class="NLM_def"><p class="first last">comparative molecular field analysis</p></td></tr><tr><td class="NLM_term">CoMSIA</td><td class="NLM_def"><p class="first last">comparative molecular similarity index analysis</p></td></tr><tr><td class="NLM_term">CXCR4</td><td class="NLM_def"><p class="first last">C-X-C chemokine receptor type 4</p></td></tr><tr><td class="NLM_term">EC</td><td class="NLM_def"><p class="first last">extracellular loop</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">isolated platelets</p></td></tr><tr><td class="NLM_term">MARS</td><td class="NLM_def"><p class="first last">multiple alignments by ROCS-based similarity</p></td></tr><tr><td class="NLM_term">ND</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">P2Y<sub>1</sub></td><td class="NLM_def"><p class="first last">P2Y purinoceptor 1</p></td></tr><tr><td class="NLM_term">P2Y<sub>12</sub></td><td class="NLM_def"><p class="first last">P2Y purinoceptor 12</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">hPRP</td><td class="NLM_def"><p class="first last">human platelet-rich plasma</p></td></tr><tr><td class="NLM_term">Thr</td><td class="NLM_def"><p class="first last">thrombin</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane domain</p></td></tr><tr><td class="NLM_term">TOTU</td><td class="NLM_def"><p class="first last"><i>O</i>-((ethoxycarbonyl)cyanomethyleneamino)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">Z</td><td class="NLM_def"><p class="first last">Cbz benzyloxy-carbonyl</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35836" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35836" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 24 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Gachet, C.</span><span> </span><span class="NLM_article-title">ADP receptors of platelets and their inhibition</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11487010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVeksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2001&pages=222-232&author=C.+Gachet&title=ADP+receptors+of+platelets+and+their+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">ADP receptors of platelets and their inhibition</span></div><div class="casAuthors">Gachet, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">222-232</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">A review, with 133 refs.  ADP plays a crucial role in hemostasis and thrombosis and its receptors are potential targets for antithrombotic drugs.  Two G-protein coupled P2 receptors contribute to platelet aggregation: the P2Y1 receptor initiates aggregation through mobilization of calcium stores, while the more recently identified P2Y12 receptor coupled to adenylyl cyclase inhibition is essential for a full aggregation response to ADP and the stabilization of aggregates.  The latter is defective in certain patients with a selective congenital deficiency of aggregation to ADP.  It is also the target of the antithrombotic drug clopidogrel and of ATP analogs and other compds. currently under evaluation.  In addn., the P2X1 ionotropic receptor is present in platelets but its role is not yet completely known.  Studies in P2Y1 knock-out mice and exptl. thrombosis models using selective P2Y1 antagonists have shown that the P2Y1 receptor, like the P2Y12 receptor, is a potential target for new antithrombotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg4r8uadkFYrVg90H21EOLACvtfcHk0licv5bpZK0HiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVeksb0%253D&md5=44cd9aeb3bc5bc61680ed46e07dc3c65</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGachet%26aufirst%3DC.%26atitle%3DADP%2520receptors%2520of%2520platelets%2520and%2520their%2520inhibition%26jtitle%3DThromb.%2520Haemostasis%26date%3D2001%26volume%3D86%26spage%3D222%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dangelmaier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunapuli, S. P.</span><span> </span><span class="NLM_article-title">Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11246558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvVKrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=341-348&author=C.+Dangelmaierauthor=J.+Jinauthor=J.+B.+Smithauthor=S.+P.+Kunapuli&title=Potentiation+of+thromboxane+A2-induced+platelet+secretion+by+Gi+signaling+through+the+phosphoinositide-3+kinase+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway</span></div><div class="casAuthors">Dangelmaier, Carol; Jin, Jianguo; Smith, J. Bryan; Kunapuli, Satya P.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-348</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">F. K. Schattauer Verlagsgesellschaft mbH</span>)
        </div><div class="casAbstract">Platelet activation results in shape change, aggregation, generation of thromboxane A2, and release of granule contents.  We have recently demonstrated that secreted ADP is essential for thromboxane A2-induced platelet aggregation.  The aim of this study was to investigate the role of secreted ADP interacting at P2 receptor subtypes in platelet secretion.  Platelet secretion induced by the thromboxane A2 mimetic U46619 was unaffected by adenosine-3'phosphate-5'-phosphate, a P2Y1 receptor selective antagonist.  However, AR-C66096, a selective antagonist of the P2TAC receptor, inhibited U46619-induced platelet secretion, indicating an important role for Gi signaling in platelet secretion.  Selective activation of either the P2TAC receptor or the α2A adrenergic receptor did not cause platelet secretion, but potentiated U46619-induced platelet secretion.  SC57101, a fibrinogen receptor antagonist, failed to inhibit platelet secretion, demonstrating that outside-in signaling was not required for platelet secretion.  Since Gi signaling results in redn. of basal cAMP levels through inhibition of adenylyl cyclase, we investigated whether this is the signaling event that potentiates platelet secretion.  SQ22536 or dideoxyadenosine, inhibitors of adenylyl cyclase, failed to potentiate U46619-induced primary platelet secretion, indicating that redn. in cAMP levels does not directly contribute to platelet secretion.  Wortmannin, a selective inhibitor of PI-3 kinase, minimally inhibited U46619-induced platelet secretion when it was solely mediated by Gq, but dramatically ablated the potentiation of Gi signaling.  We conclude that signaling through the P2TAC receptor by secreted ADP causes pos. feedback on platelet secretion through a PI-3 kinase pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6vVzbybNjp7Vg90H21EOLACvtfcHk0licv5bpZK0HiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvVKrsLs%253D&md5=a5d24f157416f630fcff3742c6ca77af</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDangelmaier%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DJ.%2BB.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DPotentiation%2520of%2520thromboxane%2520A2-induced%2520platelet%2520secretion%2520by%2520Gi%2520signaling%2520through%2520the%2520phosphoinositide-3%2520kinase%2520pathway%26jtitle%3DThromb.%2520Haemostasis%26date%3D2001%26volume%3D85%26spage%3D341%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cattaneo, M.</span><span> </span><span class="NLM_article-title">Advances in antiplatelet therapy: overview of new P2Y12 receptor antagonists in development</span> <span class="citation_source-journal">Eur. Heart J. Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. I</span><span class="NLM_x">) </span> <span class="NLM_fpage">I33</span><span class="NLM_x">–</span> <span class="NLM_lpage">I37</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=I33-I37&issue=Suppl.+I&author=M.+Cattaneo&title=Advances+in+antiplatelet+therapy%3A+overview+of+new+P2Y12+receptor+antagonists+in+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520antiplatelet%2520therapy%253A%2520overview%2520of%2520new%2520P2Y12%2520receptor%2520antagonists%2520in%2520development%26jtitle%3DEur.%2520Heart%2520J.%2520Suppl.%26date%3D2008%26volume%3D10%26issue%3DSuppl.%2520I%26spage%3DI33%26epage%3DI37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cattaneo, M.</span><span> </span><span class="NLM_article-title">ADP receptors: Inhibitory strategies for antiplatelet therapy</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1358%2Fdnp.2006.19.5.985936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=16941047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFejur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=253-259&author=M.+Cattaneo&title=ADP+receptors%3A+Inhibitory+strategies+for+antiplatelet+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">ADP receptors: inhibitory strategies for antiplatelet therapy</span></div><div class="casAuthors">Cattaneo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">253-259</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  The interaction of adenosine-5'-diphosphate (ADP) with its platelet receptors (P2Y1 and P2Y12) plays a very important role in thrombogenesis.  The thienopyridine ticlopidine was the first specific antagonist of the platelet P2Y12 ADP receptor to be tested in randomized clin. trials for the prevention of arterial thrombotic events.  Although ticlopidine reduces the incidence of vascular events in patients at risk, it also unfortunately has some significant drawbacks: a relatively high incidence of toxic effects, which may be fatal in some cases; delayed onset of action; and a high interindividual variability in response.  A second thienopyridine, clopidogrel, has superseded ticlopidine, because it is also an efficacious antithrombotic drug and is less toxic than ticlopidine.  However, clopidogrel is not completely free from faults: severe toxic effects, albeit occurring much less frequently than with ticlopidine, may still complicate its administration to patients; the onset of pharmacol. action can be accelerated by the use of large loading doses, but may still not be optimal; the high interpatient variability in response remains an important issue.  These concerns justify the continued search for agents that can further improve the clin. outcome of patients with atherosclerosis through greater efficacy and/or safety.  A new thienopyridyl compd., prasugrel, which is characterized by higher potency and faster onset of action compared with clopidogrel, is currently under clin. evaluation.  Two direct and reversible P2Y12 antagonists, cangrelor and AZD6140, feature very rapid onset and reversal of platelet inhibition, which make them attractive alternatives to thienopyridines, esp. when rapid inhibition of platelet aggregation or its quick reversal are required.  Along with new the P2Y12 antagonists, inhibitors of the other platelet receptor for ADP, the antagonists P2Y1, are under development and may prove to be effective antithrombotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmHmKVThnP17Vg90H21EOLACvtfcHk0lg6AztoCHowRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFejur0%253D&md5=0302a0902658503a11691a421fad9c08</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2006.19.5.985936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2006.19.5.985936%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DADP%2520receptors%253A%2520Inhibitory%2520strategies%2520for%2520antiplatelet%2520therapy%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2006%26volume%3D19%26spage%3D253%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cattaneo, M.</span><span> </span><span class="NLM_article-title">P2Y12 receptor antagonists: A rapidly expanding group of antiplatelet agents</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1010</span><span class="NLM_x">–</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1093%2Feurheartj%2Fehi851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=16569650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFGqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=1010-1012&author=M.+Cattaneo&title=P2Y12+receptor+antagonists%3A+A+rapidly+expanding+group+of+antiplatelet+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents</span></div><div class="casAuthors">Cattaneo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1010-1012</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The research of Husted et al. (2006) entitled "Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin" is reviewed with commentary and refs.  The G-coupled P2Y12 receptor plays an important role in ADP-induced platelet aggregation and mediates the potentiation of platelet secretion induced by strong agonists and the stabilization of thrombin-induced platelet aggregates.  In their study, Husted et al. investigated the effects of the oral administration of AZD6140, the first oral reversible P2Y12 antagonist, to patients with atherosclerosis.  The results showed that AZD6140 at doses above 50 mg BID more effectively inhibited platelet aggregation and with less variability than clopidogrel.  The inhibition of platelet aggregation was very rapid compared with that of clopidogrel.  The prolongation of the bleeding times was greater in AZD6140-treated patients compared with clopidogrel-treated patients, although no obvious dose-response relationship was obsd.  The incidence of bleeding events tended to be higher in patients treated with the three higher doses of AZD6140, compared with that obsd. in patients treated with 50 mg BID or clopidogrel.  An unexpected, relatively high frequency of dyspnea was also obsd., and this side effect appeared to increase with increasing doses of AZD6140.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVSSXQ4QTDKbVg90H21EOLACvtfcHk0lg6AztoCHowRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFGqtL0%253D&md5=f7d4c0febe0b7aa472d91c7336988e7d</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehi851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehi851%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DP2Y12%2520receptor%2520antagonists%253A%2520A%2520rapidly%2520expanding%2520group%2520of%2520antiplatelet%2520agents%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2006%26volume%3D27%26spage%3D1010%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dogne, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Leval, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benoit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delarge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masereel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David, J. L.</span><span> </span><span class="NLM_article-title">Recent advances in antiplatelet agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">589</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.2174%2F0929867024606948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11945125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD38XislGmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=577-589&author=J.+M.+Dogneauthor=X.+de+Levalauthor=P.+Benoitauthor=J.+Delargeauthor=B.+Masereelauthor=J.+L.+David&title=Recent+advances+in+antiplatelet+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in antiplatelet agents</span></div><div class="casAuthors">Dogne, Jean-Michel; De Leval, Xavier; Benoit, Patricia; Delarge, Jacques; Masereel, Bernard; David, Jean-Louis</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-589</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Platelet aggregation plays a key role in the pathogenesis of thromboembolic diseases such as myocardial infarction, stroke, unstable angina and peripheral artery disease.  Until recently, aspirin was the only antiplatelet agent available to prevent or treat these events.  Over the past several years, there has been a substantial expansion in the antiplatelet armamentarium as well as in the understanding of the clin. importance of antiplatelet therapy in limiting the complications of thrombosis.  Aspirin was one of the first agents to be adopted and it remains as the std. therapy with the higher amt. of available clin. information.  Following aspirin, ADP receptor antagonists like ticlopidine and clopidogrel as well as phosphodiesterase inhibitors dipyridamole and cilostazol have been introduced.  Glycoprotein (GP) IIb/IIIa receptor antagonists like eptifibatide, tirofiban and abciximab are the newer antiplatelet agents which act at the end of the common pathway of platelet aggregation.  Although results of clin. studies with the first oral GPIIb/IIIa antagonists were disappointing, agents of the new generation might expand the potential application of GPIIb/IIIa targeted therapy.  This review will highlight recent advances in the development of aspirin, phosphodiesterase inhibitors, ADP receptor antagonists and the platelet glycoprotein IIb/IIIa inhibitors.  The emphasis of this paper has been placed on the chem. aspects of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiRrsDrA0l5bVg90H21EOLACvtfcHk0lg6AztoCHowRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XislGmt7s%253D&md5=87aa6ec800724fef1c385969d75cc407</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.2174%2F0929867024606948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867024606948%26sid%3Dliteratum%253Aachs%26aulast%3DDogne%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BLeval%26aufirst%3DX.%26aulast%3DBenoit%26aufirst%3DP.%26aulast%3DDelarge%26aufirst%3DJ.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DDavid%26aufirst%3DJ.%2BL.%26atitle%3DRecent%2520advances%2520in%2520antiplatelet%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2002%26volume%3D9%26spage%3D577%26epage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInally, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindon, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teobald, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, W.</span><span> </span><span class="NLM_article-title">Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm981072s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=213-220&author=A.+H.+Ingallauthor=J.+Dixonauthor=A.+Baileyauthor=M.+E.+Coombsauthor=D.+Coxauthor=J.+I.+McInallyauthor=S.+F.+Huntauthor=N.+D.+Kindonauthor=B.+J.+Teobaldauthor=P.+A.+Willisauthor=R.+G.+Humphriesauthor=P.+Leffauthor=J.+A.+Cleggauthor=J.+A.+Smithauthor=W.+Tomlinson&title=Antagonists+of+the+platelet+P2T+receptor%3A+A+novel+approach+to+antithrombotic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of the Platelet P2T Receptor: A Novel Approach to Antithrombotic Therapy</span></div><div class="casAuthors">Ingall, Anthony H.; Dixon, John; Bailey, Andrew; Coombs, Mandy E.; Cox, David; McInally, Judith I.; Hunt, Simon F.; Kindon, Nicholas D.; Teobald, Barry J.; Willis, Paul A.; Humphries, Robert G.; Leff, Paul; Clegg, Jane A.; Smith, James A.; Tomlinson, Wendy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-220</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platelet P2T receptor plays a major role in platelet aggregation, and its antagonists are predicted to have significant therapeutic potential as antithrombotic agents.  We have explored analogs of ATP, which is a weak, nonselective but competitive P2T receptor antagonist.  Modification of the polyphosphate side chain to prevent breakdown to the agonist ADP and substitution of the adenine moiety to enhance affinity and selectivity for the P2T receptor led to the identification of compd. AR-C67085MX, having an IC50 of 2.5 nM against ADP-induced aggregation of human platelets.  This compd. was the first very potent antagonist of the P2T receptor, with a selectivity for that subtype of the P2 receptor family of >1000-fold.  Further modification of the structure produced compd. AR-C69931MX having an IC50 of 0.4 nM.  In vivo, at maximally effective antithrombotic doses, there is little prolongation of bleeding time (1.4-fold), which is in marked contrast to the 5-6-fold found with GPIIb/IIIa antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMgNOWrXPnEbVg90H21EOLACvtfcHk0liWnaGplYomdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFartg%253D%253D&md5=82328b71981a7200181f7719b74248f8</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1021%2Fjm981072s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm981072s%26sid%3Dliteratum%253Aachs%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DDixon%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCoombs%26aufirst%3DM.%2BE.%26aulast%3DCox%26aufirst%3DD.%26aulast%3DMcInally%26aufirst%3DJ.%2BI.%26aulast%3DHunt%26aufirst%3DS.%2BF.%26aulast%3DKindon%26aufirst%3DN.%2BD.%26aulast%3DTeobald%26aufirst%3DB.%2BJ.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26aulast%3DHumphries%26aufirst%3DR.%2BG.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DClegg%26aufirst%3DJ.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DTomlinson%26aufirst%3DW.%26atitle%3DAntagonists%2520of%2520the%2520platelet%2520P2T%2520receptor%253A%2520A%2520novel%2520approach%2520to%2520antithrombotic%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D213%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Storey, R. F.</span><span> </span><span class="NLM_article-title">Biology and pharmacology of the platelet P2Y12 receptor</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1255</span><span class="NLM_x">–</span> <span class="NLM_lpage">1259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.2174%2F138161206776361318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=16611109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFKktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1255-1259&author=R.+F.+Storey&title=Biology+and+pharmacology+of+the+platelet+P2Y12+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3cR"><div class="casContent"><span class="casTitleNuber">3c</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and pharmacology of the platelet P2Y12 receptor</span></div><div class="casAuthors">Storey, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1255-1259</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Platelets possess two receptors for ADP, P2Y1 and P2Y12.  ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus.  The P2Y1 receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation.  The P2Y12 receptor on the other hand is linked to Gi and plays a special role in the amplification of platelet activation initiated by numerous other pathways.  Platelet activation leads to a range of responses that play a crit. role in arterial thrombosis and the inflammatory responses assocd. with this, including platelet aggregation, dense and α granule secretion and procoagulant activity.  P2Y12 receptor activation yields powerful amplification of these processes such that P2Y12 receptor antagonists may have dramatic inhibitory effects on platelet function regardless of the activating stimuli.  This phenomenon, coupled with the restricted distribution of the P2Y12 receptor in humans, makes the receptor an ideal target for pharmaceutical therapy.  This has already been established by the therapeutic success of clopidogrel, which acts, via an active metabolite, on this receptor.  However, current therapeutic regimens of clopidogrel yield variable and incomplete P2Y12 receptor blockade and more effective strategies to block P2Y12 receptor activation offer the potential of greater clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplYkgbFspF0rVg90H21EOLACvtfcHk0liWnaGplYomdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFKktb0%253D&md5=040586da91cc8739b2b5afd63faadb93</span></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.2174%2F138161206776361318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161206776361318%26sid%3Dliteratum%253Aachs%26aulast%3DStorey%26aufirst%3DR.%2BF.%26atitle%3DBiology%2520and%2520pharmacology%2520of%2520the%2520platelet%2520P2Y12%2520receptor%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2006%26volume%3D12%26spage%3D1255%26epage%3D1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nicholas, R. A.</span><span> </span><span class="NLM_article-title">Identification of the P2Y(12) receptor: A novel member of the P2Y family of receptors activated by extracellular nucleotides</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=416-420&author=R.+A.+Nicholas&title=Identification+of+the+P2Y%2812%29+receptor%3A+A+novel+member+of+the+P2Y+family+of+receptors+activated+by+extracellular+nucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNicholas%26aufirst%3DR.%2BA.%26atitle%3DIdentification%2520of%2520the%2520P2Y%252812%2529%2520receptor%253A%2520A%2520novel%2520member%2520of%2520the%2520P2Y%2520family%2520of%2520receptors%2520activated%2520by%2520extracellular%2520nucleotides%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D416%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dorsam, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunapuli, S. P.</span><span> </span><span class="NLM_article-title">Central role of the P2Y12 receptor in platelet activation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=340-345&author=R.+T.+Dorsamauthor=S.+P.+Kunapuli&title=Central+role+of+the+P2Y12+receptor+in+platelet+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorsam%26aufirst%3DR.%2BT.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DCentral%2520role%2520of%2520the%2520P2Y12%2520receptor%2520in%2520platelet%2520activation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D113%26spage%3D340%26epage%3D345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Judge, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckland, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugidachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storey, R. F.</span><span> </span><span class="NLM_article-title">Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">1210</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1160%2FTH09-11-0770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20431852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=1210-1217&author=H.+M.+Judgeauthor=R.+J.+Bucklandauthor=A.+Sugidachiauthor=J.+A.+Jakubowskiauthor=R.+F.+Storey&title=Relationship+between+degree+of+P2Y12+receptor+blockade+and+inhibition+of+P2Y12-mediated+platelet+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function</span></div><div class="casAuthors">Judge, Heather M.; Buckland, Robert J.; Sugidachi, Atsuhiro; Jakubowski, Joseph A.; Storey, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1210-1217</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">The thienopyridine P2Y12 receptor antagonists clopidogrel and prasugrel prevent arterial thrombosis and are routinely used following percutaneous coronary intervention.  However, the optimal level of P2Y12 blockade to effectively inhibit platelet function is unknown.  These studies utilized the active metabolite of prasugrel (R-138727) to achieve a range of P2Y12 blockade in vitro and assessed several aspects of platelet function.  Blood from healthy volunteers was incubated with R-138727 (0-10 μM).  P2Y12 receptor no. was assessed using a 33P-2MeSADP binding assay.  Platelet aggregation (PA) was measured by optical aggregometry with ADP 2-20 μM.  VASP phosphorylation, annexin V binding, microparticle formation and P-selectin expression were assessed by flow cytometry.  Increasing nos. of unblocked receptors were required for a sustained aggregation response with decreasing concns. of ADP.A P2Y12 receptor blockade of 60-80% resulted in strong inhibition of final PA response, P-selectin expression, microparticle formation and vasodilator-stimulated phosphoprotein (VASP).  PA induced by ADP 2 μM and P-selectin expression were particularly sensitive to low levels of receptor blockade whereas the VASP phosphorylation assay was relatively insensitive, requiring 60% receptor blockade to achieve substantial inhibition.  Different assays varied in their ability to discriminate particular ranges of P2Y,2 blockade and 80% or greater P2Y12 receptor blockade is required for consistently strong inhibition of several aspects of platelet function.  These data guide the interpretation of results from different assays used to monitor the effects of P2Y12 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL7D0yAXFhrrVg90H21EOLACvtfcHk0liWnaGplYomdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSitr0%253D&md5=57f4df911dca83c118e03e70b1568b39</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1160%2FTH09-11-0770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1160%252FTH09-11-0770%26sid%3Dliteratum%253Aachs%26aulast%3DJudge%26aufirst%3DH.%2BM.%26aulast%3DBuckland%26aufirst%3DR.%2BJ.%26aulast%3DSugidachi%26aufirst%3DA.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26atitle%3DRelationship%2520between%2520degree%2520of%2520P2Y12%2520receptor%2520blockade%2520and%2520inhibition%2520of%2520P2Y12-mediated%2520platelet%2520function%26jtitle%3DThromb.%2520Haemostasis%26date%3D2010%26volume%3D103%26spage%3D1210%26epage%3D1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Andre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaRocca, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=398-406&author=P.+Andreauthor=S.+M.+Delaneyauthor=T.+LaRoccaauthor=D.+Vincentauthor=F.+DeGuzmanauthor=M.+Jurekauthor=B.+Kollerauthor=D.+R.+Phillipsauthor=P.+B.+Conley&title=P2Y12+regulates+platelet+adhesion%2Factivation%2C+thrombus+growth%2C+and+thrombus+stability+in+injured+arteries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DP.%26aulast%3DDelaney%26aufirst%3DS.%2BM.%26aulast%3DLaRocca%26aufirst%3DT.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DJurek%26aufirst%3DM.%26aulast%3DKoller%26aufirst%3DB.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DP2Y12%2520regulates%2520platelet%2520adhesion%252Factivation%252C%2520thrombus%2520growth%252C%2520and%2520thrombus%2520stability%2520in%2520injured%2520arteries%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D112%26spage%3D398%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span> </span><span class="NLM_article-title">Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis</span> <span class="citation_source-journal">Semin. Thromb. Hemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1055%2Fs-2005-869523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=15852221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvVSnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2005&pages=174-183&author=P.+Saviauthor=J.-M.+Herbert&title=Clopidogrel+and+ticlopidine%3A+P2Y12+adenosine+diphosphate-receptor+antagonists+for+the+prevention+of+atherothrombosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis</span></div><div class="casAuthors">Savi, Pierre; Herbert, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-183</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Ticlopidine and clopidogrel belong to the same chem. family of thienopyridine ADP (ADP)-receptor antagonists.  They have shown their efficacy as platelet antiaggregant and antithrombotic agents in many animal models, both ex vivo and in vivo.  Although ticlopidine was discovered more than 30 years ago, it was only recently that the mechanism of action of ADP-receptor antagonists was characterized in detail.  Ticlopidine and clopidogrel both behave in vivo as specific antagonists of P2Y12, one of the ADP receptors on platelets.  Metabolic steps that involve cytochrome P 450-dependent pathways are required to generate the active metabolite responsible for this in vivo activity.  The active moiety is a reactive thiol deriv. that targets P2Y12 on platelets.  The interaction is irreversible, accounting for the observation that platelets are definitely antiaggregated, even if no active metabolite is detectable in plasma.  The interaction is specific for P2Y12; other purinoceptors such as P2Y1 and P2Y13 are spared.  This results in inhibition of the binding of the P2Y12 agonist 2-methylthio-ADP and the ADP-induced downregulation of adenylyl cyclase.  Platelet aggregation is affected not only when triggered by ADP but also by aggregation inducers when used at concns. requiring released ADP as an amplifier.  The efficacy and safety of clopidogrel has been established in several large, randomized, controlled trials.  The clopidogrel vs. aspirin in patients at risk of ischemic events (CAPRIE) trial demonstrated the superiority of clopidogrel over acetylsalicylic acid (ASA) in patients at risk of ischemic events, including ischemic stroke, myocardial infarction (MI), and peripheral arterial disease.  The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial showed a sustained, incremental benefit when clopidogrel was added to std. therapy (including ASA) in patients with unstable angina and non-Q-wave MI.  The clopidogrel for the redn. of events during observation (CREDO) trial demonstrated the benefit of continuing clopidogrel (plus ASA) for 12 mo, as opposed to 1 mo, after percutaneous coronary intervention.  The proven efficacy of clopidogrel, coupled with its favorable safety and tolerability profile, has prompted its evaluation in an extensive, ongoing clin. trial program that will help to further characterize the benefit of clopidogrel in patients with a range of atherothrombotic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0RPp6l6_G_LVg90H21EOLACvtfcHk0lh8qp3o7NNjBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvVSnurc%253D&md5=e33ff9017bb1a345b8fb7f769af03a5b</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-869523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-869523%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26atitle%3DClopidogrel%2520and%2520ticlopidine%253A%2520P2Y12%2520adenosine%2520diphosphate-receptor%2520antagonists%2520for%2520the%2520prevention%2520of%2520atherothrombosis%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2005%26volume%3D31%26spage%3D174%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hollopeter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantzen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julius, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">409</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1038%2F35051599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11196645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2001&pages=202-207&author=G.+Hollopeterauthor=H.+M.+Jantzenauthor=D.+Vincentauthor=G.+Liauthor=L.+Englandauthor=V.+Ramakrishnanauthor=R.+B.+Yangauthor=P.+Nurdenauthor=A.+Nurdenauthor=D.+Juliusauthor=P.+B.+Conley&title=Identification+of+the+platelet+ADP+receptor+targeted+by+antithrombotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span></div><div class="casAuthors">Hollopeter, Gunther; Jantzen, Hans-Michiel; Vincent, Diana; Li, Georgia; England, Laura; Ramakrishnan, Vanitha; Yang, Ruey-Bing; Nurden, Paquita; Nurden, Alan; Julius, David; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">6817</span>),
    <span class="NLM_cas:pages">202-207</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelets have a crucial role in the maintenance of normal hemostasis, and perturbations of this system can lead to pathol. thrombus formation and vascular occlusion, resulting in stroke; myocardial infarction and unstable angina.  ADP released from damaged vessels and red blood cells induces platelet aggregation through activation of the integrin GPIIb-IIIa and subsequent binding of fibrinogen.  ADP is also secreted from platelets on activation, providing pos. feedback that potentiates the actions of many platelet activators.  ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes.  The P2Y1 receptor couples to Gq and. mobilizes intracellular calcium ions to mediate platelet shape change and aggregation.  The second ADP receptor required for aggregation (variously called P2YADP, P2YAC, P2Ycyc or P2TAC) is coupled to the inhibition of adenylyl cyclase through Gi.  The mol. identity of the Gi-linked receptor is still elusive, even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogrel and AR-C66096. Here the authors describe the cloning of this receptor, designated P2Y12, and provide evidence that a patient with a bleeding disorder has a defect in this gene.  Cloning of the P2Y12 receptor should facilitate the development- of better antiplatelet agents to treat cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNuDi2tNS7bVg90H21EOLACvtfcHk0lh8qp3o7NNjBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D&md5=fe30017f0d3bd9aacb4ad3bd6189c5d9</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1038%2F35051599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35051599%26sid%3Dliteratum%253Aachs%26aulast%3DHollopeter%26aufirst%3DG.%26aulast%3DJantzen%26aufirst%3DH.%2BM.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DEngland%26aufirst%3DL.%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DR.%2BB.%26aulast%3DNurden%26aufirst%3DP.%26aulast%3DNurden%26aufirst%3DA.%26aulast%3DJulius%26aufirst%3DD.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DIdentification%2520of%2520the%2520platelet%2520ADP%2520receptor%2520targeted%2520by%2520antithrombotic%2520drugs%26jtitle%3DNature%26date%3D2001%26volume%3D409%26spage%3D202%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">CAPRIE Steering Committee (CAPRIE).</span><span> </span><span class="NLM_article-title">A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1339</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=1996&pages=1329-1339&author=CAPRIE+Steering+Committee+%28CAPRIE%29.&title=A+randomised%2C+blinded%2C+trial+of+clopidogrel+versus+aspirin+in+patients+at+risk+of+ischaemic+events"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520randomised%252C%2520blinded%252C%2520trial%2520of%2520clopidogrel%2520versus%2520aspirin%2520in%2520patients%2520at%2520risk%2520of%2520ischaemic%2520events%26jtitle%3DLancet%26date%3D1996%26volume%3D348%26spage%3D1329%26epage%3D1339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span> </span><span class="NLM_article-title">The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (CURE). Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation</span>. N. Engl. J. Med.<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">494</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1056%2FNEJMoa010746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11519503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXms1arsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+Clopidogrel+in+Unstable+Angina+to+Prevent+Recurrent+Events+Trial+Investigators+%28CURE%29.+Effects+of+Clopidogrel+in+Addition+to+Aspirin+in+Patients+with+Acute+Coronary+Syndromes+without+ST-Segment+Elevation.+N.+Engl.+J.+Med.+2001%2C+345%2C+494%E2%80%93502."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</span></div><div class="casAuthors">Yusuf, Salim; Zhao, Feng; Mehta, Shamir R.; Chrolavicius, Susan; Tognoni, Gianni; Fox, Keith K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">494-502</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events.  We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients.  We randomly assigned 12,562 patients who had presented within 24 h after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addn. to aspirin for 3 to 12 mo.  The first primary outcome - a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke - occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001).  The second primary outcome - the first primary outcome or refractory ischemia - occurred in 16.5 percent of the patients in the clopidogrel group and 18.8 percent of the patients in the placebo group (relative risk, 0.86, P<0.001).  The percentages of patients with in-hospital refractory or severe ischemia, heart failure, and revascularization procedures were also significantly lower with clopidogrel.  There were significantly more patients with major bleeding in the clopidogrel group than in the placebo group (3.7 percent vs. 2.7 percent; relative risk, 1.38; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.1 percent vs. 1.8 percent, P=0.13) or hemorrhagic strokes.  The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.  However, the risk of major bleeding is increased among patients treated with clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoihXPVAbDPg7Vg90H21EOLACvtfcHk0liCCsRjrjtdDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXms1arsrY%253D&md5=3ddc47281ccad90f046038a4c3f98a21</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa010746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1056%252FNEJMoa010746%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Clopidogrel%2520in%2520Unstable%2520Angina%2520to%2520Prevent%2520Recurrent%2520Events%2520Trial%2520Investigators%2520%2528CURE%2529.%2520Effects%2520of%2520Clopidogrel%2520in%2520Addition%2520to%2520Aspirin%2520in%2520Patients%2520with%2520Acute%2520Coronary%2520Syndromes%2520without%2520ST-Segment%2520Elevation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D494%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereillo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzabiaga, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combalbert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffrand, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span> </span><span class="NLM_article-title">Identification and biological activity of the active metabolite of clopidogrel</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1055%2Fs-0037-1614133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11127873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFCjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2000&pages=891-896&author=P.+Saviauthor=J.+M.+Pereilloauthor=M.+F.+Uzabiagaauthor=J.+Combalbertauthor=C.+Picardauthor=J.+P.+Maffrandauthor=M.+Pascalauthor=J.-M.+Herbert&title=Identification+and+biological+activity+of+the+active+metabolite+of+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and biological activity of the active metabolite of clopidogrel</span></div><div class="casAuthors">Savi, P.; Pereillo, J. M.; Uzabiaga, M. F.; Combalbert, J.; Picard, C.; Maffrand, J. P.; Pascal, M.; Herbert, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">891-896</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">F. K. Schattauer Verlagsgesellschaft mbH</span>)
        </div><div class="casAbstract">Like ticlopidine, the ADP receptor antagonist clopidogrel is inactive in vitro and must be administered i.v. or orally to exhibit antiaggregatory and antithrombotic activities.  We have previously shown that hepatic metab. is necessary for activity.  This study demonstrates that an active metabolite can be generated from human liver microsomes incubated with clopidogrel.  Using several anal. methodologies (LC/MS, NMR, chiral supercrit. fluid chromatog.), we have identified its structure.  In vitro, this highly unstable compd., different from that formed from ticlopidine, exhibited all the biol. activities of clopidogrel obsd. ex vivo: Irreversible inhibition of the binding of 33P-2MeS-ADP to washed human platelets (IC50 = 0.53 μM), selective inhibition of ADP-induced platelet aggregation (IC50 = 1.8 μM) and ADP-induced adenylyl cyclase down-regulation.  The irreversible modification of the ADP-receptor site which is responsible for the biol. activity could be explained by the formation of a disulfide bridge between the reactive thiol group of the active metabolite and a cysteine residue of the platelet ADP receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp6q3TXPondbVg90H21EOLACvtfcHk0liCCsRjrjtdDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFCjsbs%253D&md5=822a367258ccea5111da1ad6e94847ca</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1055%2Fs-0037-1614133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0037-1614133%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DPereillo%26aufirst%3DJ.%2BM.%26aulast%3DUzabiaga%26aufirst%3DM.%2BF.%26aulast%3DCombalbert%26aufirst%3DJ.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DMaffrand%26aufirst%3DJ.%2BP.%26aulast%3DPascal%26aufirst%3DM.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26atitle%3DIdentification%2520and%2520biological%2520activity%2520of%2520the%2520active%2520metabolite%2520of%2520clopidogrel%26jtitle%3DThromb.%2520Haemostasis%26date%3D2000%26volume%3D84%26spage%3D891%26epage%3D896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meadows, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, D. L.</span><span> </span><span class="NLM_article-title">Clinical aspects of platelet inhibitors and thrombus formation</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=1261-1275&author=T.+A.+Meadowsauthor=D.+L.+Bhatt&title=Clinical+aspects+of+platelet+inhibitors+and+thrombus+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeadows%26aufirst%3DT.%2BA.%26aulast%3DBhatt%26aufirst%3DD.%2BL.%26atitle%3DClinical%2520aspects%2520of%2520platelet%2520inhibitors%2520and%2520thrombus%2520formation%26jtitle%3DCirc.%2520Res.%26date%3D2007%26volume%3D100%26spage%3D1261%26epage%3D1275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zachayus, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delesque-Touchard, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labouret, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hervé, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzabiaga, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereillo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culouscou, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span> </span><span class="NLM_article-title">The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">11069</span><span class="NLM_x">–</span> <span class="NLM_lpage">11074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1073%2Fpnas.0510446103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=16835302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFeltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=11069-11074&author=P.+Saviauthor=J.+L.+Zachayusauthor=N.+Delesque-Touchardauthor=C.+Labouretauthor=C.+Herv%C3%A9author=M.+F.+Uzabiagaauthor=J.+M.+Pereilloauthor=J.+M.+Culouscouauthor=F.+Bonoauthor=P.+Ferraraauthor=J.-M.+Herbert&title=The+active+metabolite+of+Clopidogrel+disrupts+P2Y12+receptor+oligomers+and+partitions+them+out+of+lipid+rafts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts</span></div><div class="casAuthors">Savi, Pierre; Zachayus, Jean-Luc; Delesque-Touchard, Nathalie; Labouret, Catherine; Herve, Caroline; Uzabigaga, Marie-Francoise; Pereillo, Jean-Marie; Culouscou, Jean-Michel; Bono, Francoise; Ferrara, Pascual; Herbert, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11069-11074</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">P2Y12, a G protein-coupled receptor that plays a central role in platelet activation has been recently identified as the receptor targeted by the antithrombotic drug, clopidogrel.  In this study, we further deciphered the mechanism of action of clopidogrel and of its active metabolite (Act-Met) on P2Y12 receptors.  Using biochem. approaches, we demonstrated the existence of homooligomeric complexes of P2Y12 receptors at the surface of mammalian cells and in freshly isolated platelets.  In vitro treatment with Act-Met or in vivo oral administration to rats with clopidogrel induced the breakdown of these oligomers into dimeric and monomeric entities in P2Y12 expressing HEK293 and platelets resp.  In addn., we showed the predominant assocn. of P2Y12 oligomers to cell membrane lipid rafts and the partitioning of P2Y12 out of rafts in response to clopidogrel and Act-Met.  The raft-assocd. P2Y12 oligomers represented the functional form of the receptor, as demonstrated by binding and signal transduction studies.  Finally, using a series of receptors individually mutated at each cysteine residue and a chimeric P2Y12/P2Y13 receptor, we pointed out the involvement of cysteine 97 within the first extracellular loop of P2Y12 in the mechanism of action of Act-Met.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiqt3k9u_2_7Vg90H21EOLACvtfcHk0liCCsRjrjtdDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFeltr4%253D&md5=607365838851caaf1b5881dd624042bf</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0510446103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0510446103%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DZachayus%26aufirst%3DJ.%2BL.%26aulast%3DDelesque-Touchard%26aufirst%3DN.%26aulast%3DLabouret%26aufirst%3DC.%26aulast%3DHerv%25C3%25A9%26aufirst%3DC.%26aulast%3DUzabiaga%26aufirst%3DM.%2BF.%26aulast%3DPereillo%26aufirst%3DJ.%2BM.%26aulast%3DCulouscou%26aufirst%3DJ.%2BM.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26atitle%3DThe%2520active%2520metabolite%2520of%2520Clopidogrel%2520disrupts%2520P2Y12%2520receptor%2520oligomers%2520and%2520partitions%2520them%2520out%2520of%2520lipid%2520rafts%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D11069%26epage%3D11074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Algaier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Kügelgen, I.</span><span> </span><span class="NLM_article-title">Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor</span> <span class="citation_source-journal">J. Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1908</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1111%2Fj.1538-7836.2008.03136.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=18752581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=1908-1914&author=I.+Algaierauthor=J.+A.+Jakubowskiauthor=F.+Asaiauthor=I.+Von+K%C3%BCgelgen&title=Interaction+of+the+active+metabolite+of+prasugrel%2C+R-138727%2C+with+cysteine+97+and+cysteine+175+of+the+human+P2Y12+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor</span></div><div class="casAuthors">Algaier, I.; Jakubowski, J. A.; Asai, F.; Von Kuegelgen, I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1908-1914</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: The P2Y12 receptor plays a crucial role in platelet aggregation and is the target of platelet aggregation inhibitors, including the thienopyridine compd. prasugrel.  Objective: The present study analyzed the effects of R-138727 (2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene]acetic acid), the active metabolite of prasugrel, on recombinant wild-type and mutant human P2Y12 receptors in order to identify the mol. site of action of R-138727.  Methods: The function of wild-type and mutant P2Y12 receptors stably expressed in Chinese hamster ovary cells was assessed by measuring the 2-methylthio-ADP-mediated inhibition of forskolin-stimulated cellular cAMP prodn.  Results: In cells expressing wild-type receptors, R-138727 potently inhibited receptor function with a half-maximal concn. below 1 μM.  The mode of action was irreversible.  The same effect of R-138727 was obsd. in cells expressing Cys17Ala/Cys270Ala constructs.  In contrast, in cells expressing either a Cys97Ala construct or a Cys175Ala construct, R-138727 failed to inhibit the response to the agonist.  When cells expressing wild-type receptors were pretreated with the P2 receptor antagonists ATP or suramin, no effect of R-138727 was obsd.  Similar expts. with N-acetylcysteine 10 μM showed no interference of N-acetylcysteine with R-138727.  Conclusions: The expts. demonstrate a potent and irreversible action of R-138727 at the recombinant human P2Y12 receptor.  The data suggest that R-138727 interacts with cysteine 97 (upper portion of the predicted third transmembrane region) and cysteine 175 (second extracellular loop) of the receptor, which are likely to form a disulfide bridge in native receptors.  Moreover, the data also suggest that this site of action of R-138727 is close to the ligand-binding site of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaS366zCyAcbVg90H21EOLACvtfcHk0lh06G_U-G3_QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyqs7zE&md5=e4449755928aae15774a850b56064142</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2008.03136.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2008.03136.x%26sid%3Dliteratum%253Aachs%26aulast%3DAlgaier%26aufirst%3DI.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DAsai%26aufirst%3DF.%26aulast%3DVon%2BK%25C3%25BCgelgen%26aufirst%3DI.%26atitle%3DInteraction%2520of%2520the%2520active%2520metabolite%2520of%2520prasugrel%252C%2520R-138727%252C%2520with%2520cysteine%252097%2520and%2520cysteine%2520175%2520of%2520the%2520human%2520P2Y12%2520receptor%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2008%26volume%3D6%26spage%3D1908%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamad, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Fresh from the pipeline. Ticagrelor</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=255-256&author=K.+Huberauthor=B.+Hamadauthor=P.+Kirkpatrick&title=Fresh+from+the+pipeline.+Ticagrelor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DHamad%26aufirst%3DB.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DFresh%2520from%2520the%2520pipeline.%2520Ticagrelor%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D255%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gurbel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kereiakes, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tantry, U. S.</span><span> </span><span class="NLM_article-title">Ticagrelor for the treatment of arterial thrombosis</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2251</span><span class="NLM_x">–</span> <span class="NLM_lpage">2259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1517%2F14656566.2010.511175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20707759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVansbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=2251-2259&author=P.+A.+Gurbelauthor=D.+J.+Kereiakesauthor=U.+S.+Tantry&title=Ticagrelor+for+the+treatment+of+arterial+thrombosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor for the treatment of arterial thrombosis</span></div><div class="casAuthors">Gurbel, Paul A.; Kereiakes, Dean J.; Tantry, Udaya S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2251-2259</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: High platelet reactivity has been linked to recurrent ischemic events in patients treated with conventional dual antiplatelet therapy, in patients with arterial diseases and particularly in patients treated with coronary artery stenting.  The limitations of clopidogrel have served as a major rationale for the development of new P2Y12 blockers that have superior pharmacodynamic profiles uninfluenced by concomitant therapies or specific genotypes.  Ticagrelor is the first direct-acting reversibly binding oral P2Y12 receptor antagonist.  Extensive Phase II investigations have addressed the pharmacokinetic, pharmacodynamic and safety-related properties of ticagrelor compared with clopidogrel.  The recently completed PLATO trial demonstrated promise for ticagrelor as a major treatment strategy for a wide spectrum of patients with acute coronary syndromes.  Ticagrelor is now being reviewed by the FDA as a P2Y12 receptor blocker to treat patients with coronary artery disease and, once accepted, will be in widespread use as an antiplatelet agent.  Thus, it is both appropriate and timely to review available data and provide a comprehensive review of ticagrelor.  Areas covered in this review: We discuss the rationale for the development of ticagrelor, a reversible and potent P2Y12 receptor blocker.  The data regarding ticagrelor based on preclin. and clin. studies are examd.  We researched articles about AZD6140' and ticagrelor' in PubMed from 2006 to 2010 and also reviewed data presented at recent cardiol. meetings.What the reader will gain: This is an updated and comprehensive review of ticagrelor.  The advantages and disadvantages of ticagrelor and available P2Y12 receptor blockers such as clopidogrel and prasugrel are discussed, thus providing a clear picture to readers.Take home message: Ticagrelor has an important role as an antiplatelet agent in the settings of acute coronary syndrome and percutaneous coronary intervention and once accepted will be in widespread use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdRFG4AInIx7Vg90H21EOLACvtfcHk0lh06G_U-G3_QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVansbbF&md5=a2dba4a166c5b7fe8c1930b3fff6ed6a</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2010.511175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2010.511175%26sid%3Dliteratum%253Aachs%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26aulast%3DKereiakes%26aufirst%3DD.%2BJ.%26aulast%3DTantry%26aufirst%3DU.%2BS.%26atitle%3DTicagrelor%2520for%2520the%2520treatment%2520of%2520arterial%2520thrombosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2010%26volume%3D11%26spage%3D2251%26epage%3D2259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ueno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolillo, D. J.</span><span> </span><span class="NLM_article-title">Elinogrel: Pharmacological principles, preclinical and early phase clinical testing</span> <span class="citation_source-journal">Future Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.2217%2Ffca.10.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20608816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosFClt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=445-453&author=M.+Uenoauthor=S.+V.+Raoauthor=D.+J.+Angiolillo&title=Elinogrel%3A+Pharmacological+principles%2C+preclinical+and+early+phase+clinical+testing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Elinogrel: pharmacological principles, preclinical and early phase clinical testing</span></div><div class="casAuthors">Ueno, Masafumi; Rao, Sunil V.; Angiolillo, Dominick J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Cardiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">445-453</span>CODEN:
                <span class="NLM_cas:coden">FCUAAZ</span>;
        ISSN:<span class="NLM_cas:issn">1479-6678</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Antiplatelet drug therapy represents the cornerstone of treatment for cardiovascular atherothrombotic disease processes.  Dual antiplatelet therapy with aspirin and oral ADP-receptor antagonists such as clopidogrel are currently the std. care for prevention of ischemic events in patients with acute coronary syndrome and who are undergoing percutaneous coronary intervention.  However, despite the clin. benefit assocd. with clopidogrel therapy, this drug has several limitations, including a broad interindividual response variability, drug-drug interactions, slow onset of action and irreversible platelet inhibition, emphasizing the need for novel P2Y12-receptor antagonists.  Elinogrel (PRT060128) is a reversible, potent and competitive inhibitor of the P2Y12 receptor with a fast onset and offset of action that can be administered by both oral and i.v. routes and rapidly achieves near complete platelet inhibition.  Preclin. and early-phase clin. testing have shown promising results with this novel compd., which awaits further testing in outcome-driven clin. trials.  This article provides an overview of the current level of knowledge regarding elinogrel, focusing on its pharmacol. properties and preclin. and early-phase clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRooj0tD1UfbVg90H21EOLACvtfcHk0lh06G_U-G3_QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosFClt7g%253D&md5=75d68933ec9311f6291e53da4be6f0f1</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.2217%2Ffca.10.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffca.10.67%26sid%3Dliteratum%253Aachs%26aulast%3DUeno%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DS.%2BV.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26atitle%3DElinogrel%253A%2520Pharmacological%2520principles%252C%2520preclinical%2520and%2520early%2520phase%2520clinical%2520testing%26jtitle%3DFuture%2520Cardiol.%26date%3D2010%26volume%3D6%26spage%3D445%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Oestreich, J. H.</span><span> </span><span class="NLM_article-title">Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=340-348&author=J.+H.+Oestreich&title=Elinogrel%2C+a+reversible+P2Y12+receptor+antagonist+for+the+treatment+of+acute+coronary+syndrome+and+prevention+of+secondary+thrombotic+events"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOestreich%26aufirst%3DJ.%2BH.%26atitle%3DElinogrel%252C%2520a%2520reversible%2520P2Y12%2520receptor%2520antagonist%2520for%2520the%2520treatment%2520of%2520acute%2520coronary%2520syndrome%2520and%2520prevention%2520of%2520secondary%2520thrombotic%2520events%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D11%26spage%3D340%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Berger, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilaru, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blankenship, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzger, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretler, D. D</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grines, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeymer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buszman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, P. W.</span><span> </span><span class="NLM_article-title">Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI)</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">998</span><span class="NLM_x">–</span> <span class="NLM_lpage">1004</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=998-1004&author=J.+S.+Bergerauthor=M.+T.+Roeauthor=C.+M.+Gibsonauthor=R.+Kilaruauthor=C.+L.+Greenauthor=L.+Meltonauthor=J.+D.+Blankenshipauthor=D.+C.+Metzgerauthor=C.+B.+Grangerauthor=D.+D+Gretlerauthor=C.+L.+Grinesauthor=K.+Huberauthor=U.+Zeymerauthor=P.+Buszmanauthor=R.+A.+Harringtonauthor=P.+W.+Armstrong&title=Safety+and+feasibility+of+adjunctive+antiplatelet+therapy+with+intravenous+elinogrel%2C+a+direct-acting+and+reversible+P2Y12+ADP-receptor+antagonist%2C+before+primary+percutaneous+intervention+in+patients+with+ST-elevation+myocardial+infarction%3A+The+Early+Rapid+ReversAl+of+Platelet+ThromboSis+with+Intravenous+Elinogrel+before+PCI+to+Optimize+REperfusion+in+Acute+Myocardial+Infarction+%28ERASE+MI%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DJ.%2BS.%26aulast%3DRoe%26aufirst%3DM.%2BT.%26aulast%3DGibson%26aufirst%3DC.%2BM.%26aulast%3DKilaru%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DC.%2BL.%26aulast%3DMelton%26aufirst%3DL.%26aulast%3DBlankenship%26aufirst%3DJ.%2BD.%26aulast%3DMetzger%26aufirst%3DD.%2BC.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DGretler%26aufirst%3DD.%2BD%26aulast%3DGrines%26aufirst%3DC.%2BL.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DZeymer%26aufirst%3DU.%26aulast%3DBuszman%26aufirst%3DP.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26atitle%3DSafety%2520and%2520feasibility%2520of%2520adjunctive%2520antiplatelet%2520therapy%2520with%2520intravenous%2520elinogrel%252C%2520a%2520direct-acting%2520and%2520reversible%2520P2Y12%2520ADP-receptor%2520antagonist%252C%2520before%2520primary%2520percutaneous%2520intervention%2520in%2520patients%2520with%2520ST-elevation%2520myocardial%2520infarction%253A%2520The%2520Early%2520Rapid%2520ReversAl%2520of%2520Platelet%2520ThromboSis%2520with%2520Intravenous%2520Elinogrel%2520before%2520PCI%2520to%2520Optimize%2520REperfusion%2520in%2520Acute%2520Myocardial%2520Infarction%2520%2528ERASE%2520MI%2529%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2009%26volume%3D158%26spage%3D998%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bryant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morser, J.</span><span> </span><span class="NLM_article-title">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1016%2Fj.thromres.2008.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=18495218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=523-532&author=J.+Bryantauthor=J.+M.+Postauthor=S.+Alexanderauthor=Y.+X.+Wangauthor=L.+Kentauthor=S.+Schirmauthor=J.+L.+Tsengauthor=B.+Subramanyamauthor=B.+Buckmanauthor=I.+Islamauthor=S.+Yuanauthor=M.+E.+Sullivanauthor=M.+Sniderauthor=J.+Morser&title=Novel+P2Y12+adenosine+diphosphate+receptor+antagonists+for+inhibition+of+platelet+aggregation+%28I%29%3A+in+vitro+effects+on+platelets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets</span></div><div class="casAuthors">Bryant, Judi; Post, Joseph M.; Alexander, Serene; Wang, Yi-Xin; Kent, Lorraine; Schirm, Sabine; Tseng, Jih-Lie; Subramanyam, Babu; Buckman, Brad; Islam, Imadul; Yuan, Shendong; Sullivan, Mark E.; Snider, Mike; Morser, John</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-532</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ADP plays a key role in platelet aggregation which has led to the development of antiplatelet drugs that target the P2Y12 receptor.  The aim of this study was to characterize the effects of two novel P2Y12 receptor antagonists, BX 667 and its active metabolite BX 048, on platelets.  BX 667 and BX 048 block the binding of 2MeSADP to platelets and antagonize ADP-induced platelet aggregation in human, dog and rat washed platelets.  Both compds. were shown to be reversible inhibitors of platelet aggregation.  BX 048 prevents the decrease in cAMP induced by treatment of platelets with ADP.  The specificity of BX 667 and BX 048 was demonstrated against cell lines expressing P2Y1 and P2Y6 as well as against a panel of receptors and enzymes.  Taken all together these data show that both BX 048 and BX 667 are potent P2Y12 antagonists with high specificity which, in the accompanying paper are demonstrated to behave predictably in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpePdQfPdqtrbVg90H21EOLACvtfcHk0lgMD5Uyi1aQoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbs%253D&md5=9667b7bdfa878d9cee94486f77c4dd9f</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DKent%26aufirst%3DL.%26aulast%3DSchirm%26aufirst%3DS.%26aulast%3DTseng%26aufirst%3DJ.%2BL.%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DSnider%26aufirst%3DM.%26aulast%3DMorser%26aufirst%3DJ.%26atitle%3DNovel%2520P2Y12%2520adenosine%2520diphosphate%2520receptor%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%2520%2528I%2529%253A%2520in%2520vitro%2520effects%2520on%2520platelets%26jtitle%3DThromb.%2520Res.%26date%3D2008%26volume%3D122%26spage%3D523%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Post, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincelette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergona, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dole, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, B.</span><span> </span><span class="NLM_article-title">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1016%2Fj.thromres.2008.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=18539312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=533-540&author=J.+M.+Postauthor=S.+Alexanderauthor=Y.+X.+Wangauthor=J.+Vinceletteauthor=R.+Vergonaauthor=L.+Kentauthor=J.+Bryantauthor=M.+E.+Sullivanauthor=W.+P.+Doleauthor=J.+Morserauthor=B.+Subramanyam&title=Novel+P2Y12+adenosine+diphosphate+receptor+antagonists+for+inhibition+of+platelet+aggregation+%28II%29%3A+Pharmacodynamic+and+pharmacokinetic+characterization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization</span></div><div class="casAuthors">Post, Joseph M.; Alexander, Serene; Wang, Yi-Xin; Vincelette, Jon; Vergona, Ron; Kent, Lorraine; Bryant, Judi; Sullivan, Mark E.; Dole, William P.; Morser, John; Subramanyam, Babu</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-540</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antiplatelet drugs are used to prevent aberrant platelet activation in pathophysiol. conditions such as myocardial infarction and ischemic stroke.  The key role that ADP plays in this process has led to the development of antiplatelet drugs that target the P2Y12 receptor.  The aim of this study was to characterize the pharmacodynamic (PD) and pharmacokinetic (PK) properties of the novel P2Y12 receptor antagonists, BX 667 and BX 048.  BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50 = 97, 317 and 3000 nM resp.).  BX 667 had nominal effects on collagen-induced aggregation and weakly inhibited arachidonic acid-induced aggregation.  BX 667 has an active metabolite, BX 048, that also potently inhibits ADP-induced aggregation (IC50 = 290 nM) in human blood.  BX 667 was shown to have high oral bioavailability in both dog and rat unlike BX 048.  Administration of BX 667 resulted in a rapid and sustained inhibition of platelet aggregation where the extent and duration of platelet inhibition was directly proportional to circulating plasma levels.  This report describes the PK/PD properties of BX 667 showing that it has the properties required for a potential antiplatelet therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjWxENonqg7bVg90H21EOLACvtfcHk0lgMD5Uyi1aQoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbg%253D&md5=87826ec634199235a94b2f89553fe806</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DVincelette%26aufirst%3DJ.%26aulast%3DVergona%26aufirst%3DR.%26aulast%3DKent%26aufirst%3DL.%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DDole%26aufirst%3DW.%2BP.%26aulast%3DMorser%26aufirst%3DJ.%26aulast%3DSubramanyam%26aufirst%3DB.%26atitle%3DNovel%2520P2Y12%2520adenosine%2520diphosphate%2520receptor%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%2520%2528II%2529%253A%2520Pharmacodynamic%2520and%2520pharmacokinetic%2520characterization%26jtitle%3DThromb.%2520Res.%26date%3D2008%26volume%3D122%26spage%3D533%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincelette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Cunha, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-McNulty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitch, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckman, B. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergona, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dole, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, J.</span><span> </span><span class="NLM_article-title">A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">855</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=17479197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlvVGrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=847-855&author=Y.+X.+Wangauthor=J.+Vinceletteauthor=V.+da+Cunhaauthor=B.+Martin-McNultyauthor=C.+Mallariauthor=R.+M.+Fitchauthor=S.+Alexanderauthor=I.+Islamauthor=B.+O.+Buckmanauthor=S.+Yuanauthor=J.+M.+Postauthor=B.+Subramanyamauthor=R.+Vergonaauthor=M.+E.+Sullivanauthor=W.+P.+Doleauthor=J.+Morserauthor=J.+Bryant&title=A+novel+P2Y%2812%29+adenosine+diphosphate+receptor+antagonist+that+inhibits+platelet+aggregation+and+thrombus+formation+in+rat+and+dog+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models</span></div><div class="casAuthors">Wang, Yi-Xin; Vincelette, Jon; da Cunha, Valdeci; Martin-McNulty, Baby; Mallari, Cornell; Fitch, Richard M.; Alexander, Serene; Islam, Imadul; Buckman, Brad O.; Yuan, Shendong; Post, Joseph M.; Subramanyam, Babu; Vergona, Ronald; Sullivan, Mark E.; Dole, William P.; Morser, John; Bryant, Judi</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">847-855</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">Irreversible platelet inhibitors, such as aspirin and clopidogrel, have limited antithrombotic efficacy in the clinic due to their bleeding risk.  We have developed an orally active reversible P2Y12 receptor antagonist, BX 667.  The aim of this study was to det. if the reversible antagonist BX 667 had a greater therapeutic index than the irreversible P2Y12 receptor antagonist clopidogrel.  Since BX 667 is rapidly converted to its active metabolite BX 048 in rats, we first injected BX 048 i.v. in a rat arterial venous (A-V) shunt model of thrombosis.  BX 048 dose- and concn.-dependently attenuated thrombosis.  When administered orally, BX 667 and clopidogrel had similar efficacy, but BX 667 caused less bleeding than clopidogrel.  In a rat model of a platelet-rich thrombus induced by vessel injury with FeCl2, both BX 667 and clopidogrel exhibited higher levels of thrombus inhibition after oral administration compared to their potency in the A-V shunt model.  Again, BX 667 caused less bleeding than clopidogrel.  In a dog cyclic flow model, i.v. injection of either BX 667 or clopidogrel dose-dependently reduced thrombus formation with lower bleeding for BX 667 than clopidogrel.  Inhibition of thrombosis was highly correlated with inhibition of ADP-induced platelet aggregation in these animal models.  In dogs pre-treated with aspirin, BX 667 maintained its wider therapeutic index, measured by inhibition of platelet aggregation over bleeding, compared to the aspirin-clopidogrel combination.  These data demonstrate that the reversible P2Y12 receptor antagonist, BX 667, has a wider therapeutic index than clopidogrel in exptl. models of thrombosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA0dlxE8Vj3LVg90H21EOLACvtfcHk0lgMD5Uyi1aQoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlvVGrtb4%253D&md5=96a72e2264df899f95bbf91ee6a8a0a6</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DVincelette%26aufirst%3DJ.%26aulast%3Dda%2BCunha%26aufirst%3DV.%26aulast%3DMartin-McNulty%26aufirst%3DB.%26aulast%3DMallari%26aufirst%3DC.%26aulast%3DFitch%26aufirst%3DR.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DBuckman%26aufirst%3DB.%2BO.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DVergona%26aufirst%3DR.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DDole%26aufirst%3DW.%2BP.%26aulast%3DMorser%26aufirst%3DJ.%26aulast%3DBryant%26aufirst%3DJ.%26atitle%3DA%2520novel%2520P2Y%252812%2529%2520adenosine%2520diphosphate%2520receptor%2520antagonist%2520that%2520inhibits%2520platelet%2520aggregation%2520and%2520thrombus%2520formation%2520in%2520rat%2520and%2520dog%2520models%26jtitle%3DThromb.%2520Haemostasis%26date%3D2007%26volume%3D97%26spage%3D847%26epage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cattaneo, M.</span><span> </span><span class="NLM_article-title">Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function</span> <span class="citation_source-journal">Semin. Thromb. Hemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1055%2Fs-0029-1220324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=19408189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFaisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=158-167&author=M.+Cattaneo&title=Light+transmission+aggregometry+and+ATP+release+for+the+diagnostic+assessment+of+platelet+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function</span></div><div class="casAuthors">Cattaneo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-167</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Light transmission aggregometry (LTA) is the gold std. for the study of patients with defects of platelet function.  Use of LTA in clin. practice for predicting the risk of thrombosis or monitoring the pharmacol. effects of antiplatelet agents should be discouraged, because not only is the monitoring of treatment with antiplatelet agents (with any lab. test) not indicated at present, but also the lack of standardization of the technique for LTA makes it addnl. unsuitable for this purpose.  The need for standardization of LTA has recently been emphasized by the results of four surveys, which showed that there is a wide variation in the methodol. used worldwide.  A modification of the traditional LTA is the lumiaggregometer, which measures platelet secretion in parallel with platelet aggregation.  This technique is probably preferable to traditional LTA in the diagnostic workup of patients with inherited defects of platelet function, because it is more sensitive to the most common disorders, which are characterized by abnormalities of platelet secretion.  LTA (or lumiaggregometry) is useful as a first screening test of patients with the clin. suspicion of defects of platelet function because it helps to provide an interim diagnostic hypothesis, which can then be confirmed or discounted using appropriate and specific tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCR4jtci4drVg90H21EOLACvtfcHk0liaz6cE6ogMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFaisrs%253D&md5=c75f4813ef0f90f0f46556bc2bda1912</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1220324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1220324%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DLight%2520transmission%2520aggregometry%2520and%2520ATP%2520release%2520for%2520the%2520diagnostic%2520assessment%2520of%2520platelet%2520function%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2009%26volume%3D35%26spage%3D158%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Breet, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Werkum, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouman, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruven, H. J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bal, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deneer, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmsze, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heyden, J. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rensing, B. J. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suttorp, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackeng, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ten Berg, J. M.</span><span> </span><span class="NLM_article-title">Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">754</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1001%2Fjama.2010.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20179285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFyisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2010&pages=754-762&author=N.+J.+Breetauthor=J.+W.+van+Werkumauthor=H.+J.+Boumanauthor=J.+C.+Kelderauthor=H.+J.+T.+Ruvenauthor=E.+T.+Balauthor=V.+H.+Deneerauthor=A.+M.+Harmszeauthor=J.+A.+S.+van+der+Heydenauthor=B.+J.+W.+M.+Rensingauthor=M.+J.+Suttorpauthor=C.+M.+Hackengauthor=J.+M.+ten+Berg&title=Comparison+of+Platelet+Function+Tests+in+Predicting+Clinical+Outcome+in+Patients+Undergoing+Coronary+Stent+Implantation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation</span></div><div class="casAuthors">Breet, Nicoline J.; van Werkum, Jochem W.; Bouman, Heleen J.; Kelder, Johannes C.; Ruven, Henk J. T.; Bal, Egbert T.; Deneer, Vera H.; Harmsze, Ankie M.; van der Heyden, Jan A. S.; Rensing, Benno J. W. M.; Suttorp, Maarten J.; Hackeng, Christian M.; ten Berg, Jurien M.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">754-762</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context High on-treatment platelet reactivity is assocd. with atherothrombotic events following coronary stent implantation.  Objective To evaluate the capability of multiple platelet function tests to predict clin. outcome.  Design, Setting, and Patients Prospective, observational, single-center cohort study of 1069 consecutive patients taking clopidogrel undergoing elective coronary stent implantation between Dec. 2005 and Dec. 2007.  On-treatment platelet reactivity was measured in parallel by light transmittance aggregometry, VerifyNow P2Y12 and Plateletworks assays, and the IMPACT-R and the platelet function anal. system (PFA-100) (with the Dade PFA collagen/ADP [ADP] cartridge and Innovance PFA P2Y).  Cut-off values for high on-treatment platelet reactivity were established by receiver operating characteristic curve anal.  Main Outcome Measurement The primary end point was defined as a composite of all-cause death, nonfatal acute myocardial infarction, stent thrombosis, and ischemic stroke.  The primary safety end point included TIMI (Thrombolysis In Myocardial Infarction) criteria major and minor bleeding.  Results At 1-yr follow-up, the primary end point occurred more frequently in patients with high on-treatment platelet reactivity when assessed by light transmittance aggregometry (11.7%; 95% confidence interval [CI], 8.9%-15.0% vs 6.0%; 95% CI, 4.2%-8.2%; P < .001), VerifyNow (13.3%; 95% CI, 10.2%-17.0% vs 5.7%; 95% CI, 4.1%-7.8%; P < .001) and Plateletworks (12.6%; 95% CI, 8.8%-17.2% vs 6.1%; 95% CI, 3.8%-9.2%; P = .005), which also had modest ability to discriminate between patients having and not having a primary event: light transmittance aggregometry (area under the curve [AUC], 0.63; 95% CI, 0.58-0.68), VerifyNow (AUC, 0.62; 95% CI, 0.57-0.67), and Plateletworks (AUC, 0.61; 95% CI, 0.53-0.69).  The IMPACT-R, Dade PFA collagen/ADP, and Innovance PFA P2Y were unable to discriminate between patients with and without primary end point at 1-yr follow-up (all AUCs included 0.50 in the CI).  None of the tests identified patients at risk for bleeding.  Conclusions Of the platelet function tests assessed, only light transmittance aggregometry, VerifyNow, and Plateletworks were significantly assocd. with the primary end point.  However, the predictive accuracy of these tests was only modest.  None of the tests provided accurate prognostic information to identify low-risk patients at higher risk of bleeding following stent implantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogpQQJv7aPwrVg90H21EOLACvtfcHk0liaz6cE6ogMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFyisbw%253D&md5=3168abf2b1e74d50a8488a1628a9c52d</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1001%2Fjama.2010.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2010.181%26sid%3Dliteratum%253Aachs%26aulast%3DBreet%26aufirst%3DN.%2BJ.%26aulast%3Dvan%2BWerkum%26aufirst%3DJ.%2BW.%26aulast%3DBouman%26aufirst%3DH.%2BJ.%26aulast%3DKelder%26aufirst%3DJ.%2BC.%26aulast%3DRuven%26aufirst%3DH.%2BJ.%2BT.%26aulast%3DBal%26aufirst%3DE.%2BT.%26aulast%3DDeneer%26aufirst%3DV.%2BH.%26aulast%3DHarmsze%26aufirst%3DA.%2BM.%26aulast%3Dvan%2Bder%2BHeyden%26aufirst%3DJ.%2BA.%2BS.%26aulast%3DRensing%26aufirst%3DB.%2BJ.%2BW.%2BM.%26aulast%3DSuttorp%26aufirst%3DM.%2BJ.%26aulast%3DHackeng%26aufirst%3DC.%2BM.%26aulast%3Dten%2BBerg%26aufirst%3DJ.%2BM.%26atitle%3DComparison%2520of%2520Platelet%2520Function%2520Tests%2520in%2520Predicting%2520Clinical%2520Outcome%2520in%2520Patients%2520Undergoing%2520Coronary%2520Stent%2520Implantation%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2010%26volume%3D303%26spage%3D754%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, K. J.</span><span> </span><span class="NLM_article-title">A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: An integrated analysis</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2010&pages=29-37&author=J.+A.+Jakubowskiauthor=Y.+G.+Liauthor=D.+S.+Smallauthor=C.+D.+Payneauthor=M.+E.+Tomlinauthor=J.+Luoauthor=K.+J.+Winters&title=A+comparison+of+the+VerifyNow+P2Y12+point-of-care+device+and+light+transmission+aggregometry+to+monitor+platelet+function+with+prasugrel+and+clopidogrel%3A+An+integrated+analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DY.%2BG.%26aulast%3DSmall%26aufirst%3DD.%2BS.%26aulast%3DPayne%26aufirst%3DC.%2BD.%26aulast%3DTomlin%26aufirst%3DM.%2BE.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26atitle%3DA%2520comparison%2520of%2520the%2520VerifyNow%2520P2Y12%2520point-of-care%2520device%2520and%2520light%2520transmission%2520aggregometry%2520to%2520monitor%2520platelet%2520function%2520with%2520prasugrel%2520and%2520clopidogrel%253A%2520An%2520integrated%2520analysis%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2010%26volume%3D56%26spage%3D29%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burney, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiebsch, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ennis, M. D.</span><span> </span><span class="NLM_article-title">Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4657</span><span class="NLM_x">–</span> <span class="NLM_lpage">4663</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4657-4663&author=J.+J.+Parlowauthor=M.+W.+Burneyauthor=B.+L.+Caseauthor=T.+J.+Girardauthor=K.+A.+Hallauthor=R.+R.+Hiebschauthor=R.+M.+Huffauthor=R.+M.+Lachanceauthor=D.+A.+Mischkeauthor=S.+R.+Rappauthor=R.+S.+Woerndleauthor=M.+D.+Ennis&title=Piperazinyl-glutamate-pyridines+as+potent+orally+bioavailable+P2Y12+antagonists+for+inhibition+of+platelet+aggregation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DBurney%26aufirst%3DM.%2BW.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DGirard%26aufirst%3DT.%2BJ.%26aulast%3DHall%26aufirst%3DK.%2BA.%26aulast%3DHiebsch%26aufirst%3DR.%2BR.%26aulast%3DHuff%26aufirst%3DR.%2BM.%26aulast%3DLachance%26aufirst%3DR.%2BM.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%2BS.%26aulast%3DEnnis%26aufirst%3DM.%2BD.%26atitle%3DPiperazinyl-glutamate-pyridines%2520as%2520potent%2520orally%2520bioavailable%2520P2Y12%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4657%26epage%3D4663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burney, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiebsch, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ennis, M. D.</span><span> </span><span class="NLM_article-title">Part II: Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1388</span><span class="NLM_x">–</span> <span class="NLM_lpage">1394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1388-1394&author=J.+J.+Parlowauthor=M.+W.+Burneyauthor=B.+L.+Caseauthor=T.+J.+Girardauthor=K.+A.+Hallauthor=P.+K.+Harrisauthor=R.+R.+Hiebschauthor=R.+M.+Huffauthor=R.+M.+Lachanceauthor=D.+A.+Mischkeauthor=S.+R.+Rappauthor=R.+S.+Woerndleauthor=M.+D.+Ennis&title=Part+II%3A+Piperazinyl-glutamate-pyridines+as+potent+orally+bioavailable+P2Y12+antagonists+for+inhibition+of+platelet+aggregation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DBurney%26aufirst%3DM.%2BW.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DGirard%26aufirst%3DT.%2BJ.%26aulast%3DHall%26aufirst%3DK.%2BA.%26aulast%3DHarris%26aufirst%3DP.%2BK.%26aulast%3DHiebsch%26aufirst%3DR.%2BR.%26aulast%3DHuff%26aufirst%3DR.%2BM.%26aulast%3DLachance%26aufirst%3DR.%2BM.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%2BS.%26aulast%3DEnnis%26aufirst%3DM.%2BD.%26atitle%3DPart%2520II%253A%2520Piperazinyl-glutamate-pyridines%2520as%2520potent%2520orally%2520bioavailable%2520P2Y12%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1388%26epage%3D1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burney, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiebsch, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ennis, M. D.</span><span> </span><span class="NLM_article-title">Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2010</span><span class="NLM_x">–</span> <span class="NLM_lpage">2037</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901518t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2010-2037&author=J.+J.+Parlowauthor=M.+W.+Burneyauthor=B.+L.+Caseauthor=T.+J.+Girardauthor=K.+A.+Hallauthor=P.+K.+Harrisauthor=R.+R.+Hiebschauthor=R.+M.+Huffauthor=R.+M.+Lachanceauthor=D.+A.+Mischkeauthor=S.+R.+Rappauthor=R.+S.+Woerndleauthor=M.+D.+Ennis&title=Piperazinyl+glutamate+pyridines+as+potent+orally+bioavailable+P2Y12+antagonists+for+inhibition+of+platelet+aggregation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1021%2Fjm901518t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901518t%26sid%3Dliteratum%253Aachs%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DBurney%26aufirst%3DM.%2BW.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DGirard%26aufirst%3DT.%2BJ.%26aulast%3DHall%26aufirst%3DK.%2BA.%26aulast%3DHarris%26aufirst%3DP.%2BK.%26aulast%3DHiebsch%26aufirst%3DR.%2BR.%26aulast%3DHuff%26aufirst%3DR.%2BM.%26aulast%3DLachance%26aufirst%3DR.%2BM.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%2BS.%26aulast%3DEnnis%26aufirst%3DM.%2BD.%26atitle%3DPiperazinyl%2520glutamate%2520pyridines%2520as%2520potent%2520orally%2520bioavailable%2520P2Y12%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2010%26epage%3D2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="note"><p class="first last">Part of this work has been patented by the authors:</p></div><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nazare, M.; Zech, G.; Goerlitzer, J.; Just, M.; Weiss, T.; Hessler, G.; Czechtizky, W.; Ruf, S.</span><span> </span><span class="NLM_article-title">Pyrazole-carboxamide derivatives as P2Y12 antagonist</span>. WO2009080227,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Nazare&author=G.+Zech&author=J.+Goerlitzer&author=M.+Just&author=T.+Weiss&author=G.+Hessler&author=W.+Czechtizky&author=S.+Ruf&title=Pyrazole-carboxamide+derivatives+as+P2Y12+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNazare%26aufirst%3DM.%26atitle%3DPyrazole-carboxamide%2520derivatives%2520as%2520P2Y12%2520antagonist%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nazare, M.; Zech, G.; Just, M.; Weiss, T.; Hessler, G.; Kohlmann, M.</span><span> </span><span class="NLM_article-title">Heterocyclic pyrazole-carboxamides as P2Y12 antagonists</span>. WO2009080226,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Nazare&author=G.+Zech&author=M.+Just&author=T.+Weiss&author=G.+Hessler&author=M.+Kohlmann&title=Heterocyclic+pyrazole-carboxamides+as+P2Y12+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNazare%26aufirst%3DM.%26atitle%3DHeterocyclic%2520pyrazole-carboxamides%2520as%2520P2Y12%2520antagonists%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Caroff, E.; Hilpert, K.; Meyer, E.</span><span> </span><span class="NLM_article-title">2-Phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists</span>. WO2008050301,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Caroff&author=K.+Hilpert&author=E.+Meyer&title=2-Phenyl-6-aminocarbonyl-pyrimidine+derivatives+and+their+use+as+P2Y12+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26atitle%3D2-Phenyl-6-aminocarbonyl-pyrimidine%2520derivatives%2520and%2520their%2520use%2520as%2520P2Y12%2520receptor%2520antagonists%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Caroff, E.; Hilpert, K.; Meyer, E.</span><span> </span><span class="NLM_article-title">Preparation of N-(2-pyridylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists</span>. WO2008044217,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Caroff&author=K.+Hilpert&author=E.+Meyer&title=Preparation+of+N-%282-pyridylcarbonyl%29+amino+acid+piperazides+and+their+use+as+P2Y12+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26atitle%3DPreparation%2520of%2520N-%25282-pyridylcarbonyl%2529%2520amino%2520acid%2520piperazides%2520and%2520their%2520use%2520as%2520P2Y12%2520receptor%2520antagonists%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Caroff, E.; Fretz, H.; Hilpert, K.; Houille, O.; Hubler, F.; Meyer, E.</span><span> </span><span class="NLM_article-title">Pyrimidine derivatives and their use as P2Y12 receptor antagonists</span>. WO2006114774,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=E.+Caroff&author=H.+Fretz&author=K.+Hilpert&author=O.+Houille&author=F.+Hubler&author=E.+Meyer&title=Pyrimidine+derivatives+and+their+use+as+P2Y12+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26atitle%3DPyrimidine%2520derivatives%2520and%2520their%2520use%2520as%2520P2Y12%2520receptor%2520antagonists%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Deflorian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor</span> <span class="citation_source-journal">J. Comput.-Aided. Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=329-338&author=F.+Deflorianauthor=K.+A.+Jacobson&title=Comparison+of+three+GPCR+structural+templates+for+modeling+of+the+P2Y12+nucleotide+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DComparison%2520of%2520three%2520GPCR%2520structural%2520templates%2520for%2520modeling%2520of%2520the%2520P2Y12%2520nucleotide%2520receptor%26jtitle%3DJ.%2520Comput.-Aided.%2520Mol.%2520Des.%26date%3D2011%26volume%3D25%26spage%3D329%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Wheatley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wootten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conner, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simms, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poyner, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barwell, J.</span><span> </span><span class="NLM_article-title">Lifting the lid on GPCRs: The role of extracellular loops</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1111%2Fj.1476-5381.2011.01629.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=21864311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVKqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=1688-1703&author=M.+Wheatleyauthor=D.+Woottenauthor=M.+T.+Connerauthor=J.+Simmsauthor=R.+Kendrickauthor=R.+T.+Loganauthor=D.+R.+Poynerauthor=J.+Barwell&title=Lifting+the+lid+on+GPCRs%3A+The+role+of+extracellular+loops"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Lifting the lid on GPCRs: the role of extracellular loops</span></div><div class="casAuthors">Wheatley, M.; Wootten, D.; Conner, M. T.; Simms, J.; Kendrick, R.; Logan, R. T.; Poyner, D. R.; Barwell, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1688-1703</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  GPCRs exhibit a common architecture of seven transmembrane helixes (TMs) linked by intracellular loops and extracellular loops (ECLs).  Given their peripheral location to the site of G-protein interaction, it might be assumed that ECL segments merely link the important TMs within the helical bundle of the receptor.  However, compelling evidence has emerged in recent years revealing a crit. role for ECLs in many fundamental aspects of GPCR function, which supported by recent GPCR crystal structures has provided mechanistic insights.  This review will present current understanding of the key roles of ECLs in ligand binding, activation and regulation of both family A and family B GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD7EIc0sohgrVg90H21EOLACvtfcHk0lhxwi3PohDwRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVKqur0%253D&md5=32433dbd28c1b128dc019772f5606a59</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01629.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01629.x%26sid%3Dliteratum%253Aachs%26aulast%3DWheatley%26aufirst%3DM.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DConner%26aufirst%3DM.%2BT.%26aulast%3DSimms%26aufirst%3DJ.%26aulast%3DKendrick%26aufirst%3DR.%26aulast%3DLogan%26aufirst%3DR.%2BT.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26aulast%3DBarwell%26aufirst%3DJ.%26atitle%3DLifting%2520the%2520lid%2520on%2520GPCRs%253A%2520The%2520role%2520of%2520extracellular%2520loops%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D1688%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">Combined 3D-QSAR, Molecular Docking, and Molecular Dynamics Study on Piperazinyl-Glutamate-Pyridines/Pyrimidines as Potent P2Y12 Antagonists for Inhibition of Platelet Aggregation</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2560</span><span class="NLM_x">–</span> <span class="NLM_lpage">2572</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci2002878" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2560-2572&author=M.+Haoauthor=Y.+Liauthor=Y.+Wangauthor=Y.+Yanauthor=S.+Zhangauthor=G.+Liauthor=L.+Yang&title=Combined+3D-QSAR%2C+Molecular+Docking%2C+and+Molecular+Dynamics+Study+on+Piperazinyl-Glutamate-Pyridines%2FPyrimidines+as+Potent+P2Y12+Antagonists+for+Inhibition+of+Platelet+Aggregation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Combined 3D-QSAR, Molecular Docking, and Molecular Dynamics Study on Piperazinyl-Glutamate-Pyridines/Pyrimidines as Potent P2Y12 Antagonists for Inhibition of Platelet Aggregation</span></div><div class="casAuthors">Hao, Ming; Li, Yan; Wang, Yonghua; Yan, Yulian; Zhang, Shuwei; Li, Guohui; Yang, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2560-2572</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An unusually large data set of 397 piperazinyl-glutamate-pyridines/pyrimidines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation was studied for the first time based on the combination of three-dimensional quant. structure-activity relationship (3D-QSAR), mol. docking, and mol. dynamics (MD) methods.  The comparative mol. field anal. (CoMFA) and comparative mol. similarity index anal. (CoMSIA) studies have been performed with a training set of 317 compds., estg. three superimposition methods.  The best CoMFA and CoMSIA models, derived from superimposition I, shows leave-one-out cross-validation correlation coeffs. (Q2) of 0.571 and 0.592 as well as the conventional correlation coeffs. (R2ncv) of 0.814 and 0.834, resp.  In addn., the satisfactory results, based on the bootstrapping anal. and 10-fold cross-validation, further indicate the highly statistical significance of the optimal models.  The external predictive abilities of these models were evaluated using a prediction set of 80 compds., producing the predicted correlation coeffs. (R2pred) of 0.664 and 0.668, resp.  The key amino acid residues were identified by mol. docking, and the stability and rationality of the derived mol. conformations were also validated by MD simulation.  The good concordance between the docking results and CoMFA/CoMSIA contour maps provides helpful clues about the rational modification of mols. in order to design more potent P2Y12 antagonists.  We hope the developed models could provide some instructions for further synthesis of highly potent P2Y12 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZNom6OC6JTrVg90H21EOLACvtfcHk0lhxwi3PohDwRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7nM&md5=94d60809a0e6b3acd40e04c3200bda7d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fci2002878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2002878%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DL.%26atitle%3DCombined%25203D-QSAR%252C%2520Molecular%2520Docking%252C%2520and%2520Molecular%2520Dynamics%2520Study%2520on%2520Piperazinyl-Glutamate-Pyridines%252FPyrimidines%2520as%2520Potent%2520P2Y12%2520Antagonists%2520for%2520Inhibition%2520of%2520Platelet%2520Aggregation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2560%26epage%3D2572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Takasaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamohara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushime, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, K.</span><span> </span><span class="NLM_article-title">Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">432</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=432-439&author=J.+Takasakiauthor=M.+Kamoharaauthor=T.+Saitoauthor=M.+Matsumotoauthor=S.+Matsumotoauthor=T.+Ohishiauthor=T.+Sogaauthor=H.+Matsushimeauthor=K.+Furuichi&title=Molecular+cloning+of+the+platelet+P2T%28AC%29+ADP+receptor%3A+pharmacological+comparison+with+another+ADP+receptor%2C+the+P2Y%281%29+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakasaki%26aufirst%3DJ.%26aulast%3DKamohara%26aufirst%3DM.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DMatsushime%26aufirst%3DH.%26aulast%3DFuruichi%26aufirst%3DK.%26atitle%3DMolecular%2520cloning%2520of%2520the%2520platelet%2520P2T%2528AC%2529%2520ADP%2520receptor%253A%2520pharmacological%2520comparison%2520with%2520another%2520ADP%2520receptor%252C%2520the%2520P2Y%25281%2529%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D432%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labouret, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delesque, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J. M.</span><span> </span><span class="NLM_article-title">P2Y(12), a new platelet ADP receptor, target of clopidogrel</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2001&pages=379-383&author=P.+Saviauthor=C.+Labouretauthor=N.+Delesqueauthor=F.+Guetteauthor=J.+Lupkerauthor=J.+M.+Herbert&title=P2Y%2812%29%2C+a+new+platelet+ADP+receptor%2C+target+of+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DLabouret%26aufirst%3DC.%26aulast%3DDelesque%26aufirst%3DN.%26aulast%3DGuette%26aufirst%3DF.%26aulast%3DLupker%26aufirst%3DJ.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26atitle%3DP2Y%252812%2529%252C%2520a%2520new%2520platelet%2520ADP%2520receptor%252C%2520target%2520of%2520clopidogrel%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2001%26volume%3D283%26spage%3D379%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashby, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunapuli, S. P.</span><span> </span><span class="NLM_article-title">Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">644</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1016%2Fj.ejphar.2010.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20599922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVejs7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=644&publication_year=2010&pages=10-16&author=Y.+Maoauthor=L.+Zhangauthor=J.+Jinauthor=B.+Ashbyauthor=S.+P.+Kunapuli&title=Mutational+analysis+of+residues+important+for+ligand+interaction+with+the+human+P2Y%2812%29+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational analysis of residues important for ligand interaction with the human P2Y12 receptor</span></div><div class="casAuthors">Mao, Yingying; Zhang, Lili; Jin, Jianguo; Ashby, Barrie; Kunapuli, Satya P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">644</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">10-16</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The P2Y12 receptor, a Gi protein-coupled receptor, plays a central role in platelet activation.  In this study, we did a mutational anal. of residues possibly involved in the ligand interactions with the human P2Y12 receptor.  Mutant receptors were stably expressed in CHO-K1 cells with an HA-tag at the N-terminus.  Expression of wild-type and mutant receptors was confirmed by detecting the HA-tag on the cell membrane.  Residues in transmembrane helical domains (TMs) 3, 5, 6, and 7, which are homologous to residues important for P2Y1 receptor activation and ligand recognition, were replaced by site-directed mutagenesis.  ADP-induced inhibition of forskolin-stimulated cAMP levels in the presence or absence of antagonist AR-C69931MX were investigated for each of the mutant receptors.  F104S and S288P significantly increased agonist-induced receptor function without affecting the antagonism by AR-C69931MX.  Arg256 in TM6 and Arg 265 in extracellular loop 3 (EL3) are more important for antagonist recognition than effect on agonist-mediated receptor function.  Compared to wild-type P2Y12 receptor, mutations in Arg 256 or/and Arg 265 significantly increased the sensitivity to antagonist AR-C69931MX.  Our study shows that the cytosolic side of TM3 and the exofacial side of TM5 are crit. for P2Y12 receptor function, which is different from P2Y1.  Arg 256 in TM6 and Arg265 in EL3 appear to play a role in antagonist recognition rather than effects on agonist-induced receptor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoBsxmabYAsbVg90H21EOLACvtfcHk0lhxwi3PohDwRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVejs7jI&md5=7b5975b7e89a4daf402f8b63c99c1437</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DAshby%26aufirst%3DB.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DMutational%2520analysis%2520of%2520residues%2520important%2520for%2520ligand%2520interaction%2520with%2520the%2520human%2520P2Y%252812%2529%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D644%26spage%3D10%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hoffmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sixel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Pasquale, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Kügelgen, I.</span><span> </span><span class="NLM_article-title">Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1213</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2008&pages=1201-1213&author=K.+Hoffmannauthor=U.+Sixelauthor=F.+Di+Pasqualeauthor=I.+von+K%C3%BCgelgen&title=Involvement+of+basic+amino+acid+residues+in+transmembrane+regions+6+and+7+in+agonist+and+antagonist+recognition+of+the+human+platelet+P2Y%2812%29-receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DSixel%26aufirst%3DU.%26aulast%3DDi%2BPasquale%26aufirst%3DF.%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DI.%26atitle%3DInvolvement%2520of%2520basic%2520amino%2520acid%2520residues%2520in%2520transmembrane%2520regions%25206%2520and%25207%2520in%2520agonist%2520and%2520antagonist%2520recognition%2520of%2520the%2520human%2520platelet%2520P2Y%252812%2529-receptor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D76%26spage%3D1201%26epage%3D1213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Graff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinkhardt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harder, S.</span><span> </span><span class="NLM_article-title">Pharmacodynamic profile of antiplatelet agents: Marked differences between single versus costimulation with platelet activators</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1016%2Fj.thromres.2004.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=15183041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks12qsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=295-302&author=J.+Graffauthor=U.+Klinkhardtauthor=S.+Harder&title=Pharmacodynamic+profile+of+antiplatelet+agents%3A+Marked+differences+between+single+versus+costimulation+with+platelet+activators"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators</span></div><div class="casAuthors">Graff, Jochen; Klinkhardt, Ute; Harder, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: In pharmacodynamic studies with antiplatelet agents, platelets are usually activated in vitro with single agonists (e.g., ADP) solely.  We questioned whether differences occur between single and combined stimulation of platelets [involving the major thrombin-receptors, protease-activated receptors (PAR)1 and PAR4], and whether the pharmacodynamic response to common antiplatelet drugs vary when a combined stimulus is applied instead of a single agonist.  Methods: We investigated the influence of different antiplatelet agents (aspirin [500 mg]) in vivo, the P2Y12-antagonist AR-C 69931MX (4 nM) and the GPII/IIIa-antagonist (abciximab [5 μg/mL] in vitro) on the degranulation response (CD62) and expression of the activated GPIIb/IIIa-receptor (PAC-1) after stimulation with ADP (2 μM), collagen (4 μg/mL), a PAR1-activating peptide (3 μM TRAP) and a PAR4-activating peptide (200 μM AYPGKF) alone or in a combination of each two agonists by flow cytometry in healthy subjects.  Results: (1) Combined activation of TRAP with AYPGKF resulted in synergistic CD62 and PAC-1 expression.  Only AYPGKF but neither TRAP nor ADP acted synergistically with collagen.  (2) AR-C 69931MX inhibited platelet degranulation (CD62) in all inducer combinations with ADP or the combination TRAP with AYPGKF.  The effect was considerably smaller or absent for the combination of collagen with a second inducer. (3) Aspirin intake reduced platelet degranulation and PAC-1 expression only for AYPGKF costimulation with collagen.  Conclusion: Because a variety of different agonists influence platelet activation and its distinct functions at a time, investigations which regard the concert of these agonists might be closer to the in vivo situation and better reflect the pharmacodynamic profile of an antiplatelet agent than using one single inducing agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom-mGmTjy7v7Vg90H21EOLACvtfcHk0lgnTsNNu6HNJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks12qsrs%253D&md5=31f5f53e58e43be4f3a655c376bfb1ba</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2004.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2004.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DGraff%26aufirst%3DJ.%26aulast%3DKlinkhardt%26aufirst%3DU.%26aulast%3DHarder%26aufirst%3DS.%26atitle%3DPharmacodynamic%2520profile%2520of%2520antiplatelet%2520agents%253A%2520Marked%2520differences%2520between%2520single%2520versus%2520costimulation%2520with%2520platelet%2520activators%26jtitle%3DThromb.%2520Res.%26date%3D2004%26volume%3D113%26spage%3D295%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Storey, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newby, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heptinstall, S.</span><span> </span><span class="NLM_article-title">Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood</span> <span class="citation_source-journal">Platelets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=443-447&author=R.+F.+Storeyauthor=L.+J.+Newbyauthor=S.+Heptinstall&title=Effects+of+P2Y%281%29+and+P2Y%2812%29+receptor+antagonists+on+platelet+aggregation+induced+by+different+agonists+in+human+whole+blood"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DNewby%26aufirst%3DL.%2BJ.%26aulast%3DHeptinstall%26aufirst%3DS.%26atitle%3DEffects%2520of%2520P2Y%25281%2529%2520and%2520P2Y%252812%2529%2520receptor%2520antagonists%2520on%2520platelet%2520aggregation%2520induced%2520by%2520different%2520agonists%2520in%2520human%2520whole%2520blood%26jtitle%3DPlatelets%26date%3D2001%26volume%3D12%26spage%3D443%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sugidachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoneda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otsuguro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, H.</span><span> </span><span class="NLM_article-title">Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1038%2Fsj.bjp.0703761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11156560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFCisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2001&pages=47-54&author=A.+Sugidachiauthor=F.+Asaiauthor=K.+Yonedaauthor=R.+Iwamuraauthor=T.+Ogawaauthor=K.+Otsuguroauthor=H.+Koike&title=Antiplatelet+action+of+R-99224%2C+an+active+metabolite+of+a+novel+thienopyridine-type+G%28i%29-linked+P2T+antagonist%2C+CS-747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747</span></div><div class="casAuthors">Sugidachi, Atsuhiro; Asai, Fumitoshi; Yoneda, Kenji; Iwamura, Ryo; Ogawa, Taketoshi; Otsuguro, Ken-Ichi; Koike, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CS-747 is a novel thienopyridine-type platelet ADP inhibitor which lacks in vitro activity.  This study examd. pharmacol. profiles of R-99224, a hepatic metabolite of CS-747.  R-99224 produced a concn.-dependent inhibition of in vitro platelet aggregation in washed human platelets (0.03-1 μg ml-1), which was relatively specific to ADP compared to collagen and thrombin.  R-99224 (0.1-3 μg ml-1) also elicited a similar inhibition of ADP-induced aggregation in rat platelets.  The inhibition by R-99224 (10 μg ml-1) persisted even after platelets were washed three times.  I.v. injection of R-99224 (0.1-3 mg kg-1) to rats resulted in a dose-dependent inhibition of ex vivo ADP-induced platelet aggregation.  R-99224 (0.1-100 μM) decreased binding of [3H]-2-methylthio-ADP ([3H]-2-MeS-ADP), a stable ligand for platelet ADP receptors, to washed human platelets.  The inhibition by R-99224 reached a plateau at a concn. of 3 μM (1.4 μg ml-1), but complete inhibition was not achieved even at the highest concn. used (100 μM).  R-99224 (10 μM) in combination with ARL-66096 (0.3 μM), an ATP analog-type Gi-linked P2T receptor antagonist, produced no addnl. inhibition of [3H]-2-MeS-ADP binding.  In contrast, [3H]-2-MeS-ADP binding was completely abolished by R-99224 (10 μM) in combination with A3P5PS (300 μM), a selective P2Y1 antagonist, suggesting that R-99224 selectively binds to the Gi-linked P2T receptor.  R-99224 (0.01-3 μg ml-1) inhibited ADP-induced [125I]-fibrinogen binding to human platelets in a concn.-dependent manner.  R-99224 (0.1-1 μg ml-1) also inhibited the ADP-induced decrease in cAMP levels in PGE1-stimulated platelets, whereas the agent did not affect ADP (10 μM)-induced Ca2+ mobilization.  These findings suggest that R-99224 is a selective and irreversible antagonist of Gi-linked P2T receptors and that R-99224 is a responsible mol. for in vivo actions of CS-747.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzAkm8uWF_4LVg90H21EOLACvtfcHk0lgnTsNNu6HNJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFCisLY%253D&md5=c8c37c95516f245f0c345c910ad7d6ff</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703761%26sid%3Dliteratum%253Aachs%26aulast%3DSugidachi%26aufirst%3DA.%26aulast%3DAsai%26aufirst%3DF.%26aulast%3DYoneda%26aufirst%3DK.%26aulast%3DIwamura%26aufirst%3DR.%26aulast%3DOgawa%26aufirst%3DT.%26aulast%3DOtsuguro%26aufirst%3DK.%26aulast%3DKoike%26aufirst%3DH.%26atitle%3DAntiplatelet%2520action%2520of%2520R-99224%252C%2520an%2520active%2520metabolite%2520of%2520a%2520novel%2520thienopyridine-type%2520G%2528i%2529-linked%2520P2T%2520antagonist%252C%2520CS-747%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D132%26spage%3D47%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucchesi, B. R.</span><span> </span><span class="NLM_article-title">Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">492</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11046080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsl2ksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=492-499&author=J.+Huangauthor=E.+M.+Driscollauthor=M.+L.+Gonzalesauthor=A.+M.+Parkauthor=B.+R.+Lucchesi&title=Prevention+of+arterial+thrombosis+by+intravenously+administered+platelet+P2T+receptor+antagonist+AR-C69931MX+in+a+canine+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model</span></div><div class="casAuthors">Huang, Jinbao; Driscoll, Edward M.; Gonzales, Michael L.; Park, Andrew M.; Lucchesi, Benedict R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">492-499</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P2Y1, P2X1, and P2T receptors mediate ADP-induced platelet aggregation.  The antithrombotic effects of AR-C69931MX (N6-[2-(methylthio)ethyl]-2-[3,3,3-trifluoropropylthio]-5'-adenylic acid, monoanhydride with dichloromethylenebiphosphonic acid), a selective P2T platelet receptor antagonist, was assessed in a canine model of arterial thrombosis.  Placebo or AR-C69931MX (4.0 μg/kg/min for 6 h) pretreatment was administered as an i.v. infusion beginning 15 min before inducing vessel wall injury.  A 300-μA anodal current was applied to the intima of the carotid artery for 180 min or discontinued 30 min after cessation of blood flow due to thrombus formation.  Each of five control animals developed occlusive thrombi within 3 h after induction of vessel wall injury.  In contrast, carotid artery blood flow in five of six AR-C69931MX-treated animals was maintained for the duration of the protocol.  Ex vivo platelet aggregation in response to ADP was inhibited at the first measurement time point of 75 min after the start of drug infusion and remained inhibited during drug administration.  Bleeding time values were increased in the drug-treated group.  Values for both the ex vivo platelet aggregation and the bleeding times returned to control values shortly after discontinuation of AR-C69931MX.  The results indicate that AR-C69931MX antagonizes the ex vivo and in vivo aggregatory actions of ADP, and displays a rapid onset and offset of action with the ability to prevent occlusive arterial thrombus formation.  AR-C69931MX may be suitable for the management of patients who require short-term modulation of platelet function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi9DvtaJndgbVg90H21EOLACvtfcHk0lgnTsNNu6HNJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsl2ksLg%253D&md5=64169692c627b4a8d79535601a0c9f93</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DE.%2BM.%26aulast%3DGonzales%26aufirst%3DM.%2BL.%26aulast%3DPark%26aufirst%3DA.%2BM.%26aulast%3DLucchesi%26aufirst%3DB.%2BR.%26atitle%3DPrevention%2520of%2520arterial%2520thrombosis%2520by%2520intravenously%2520administered%2520platelet%2520P2T%2520receptor%2520antagonist%2520AR-C69931MX%2520in%2520a%2520canine%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D492%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Soloviev, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harasaki, H.</span><span> </span><span class="NLM_article-title">Whole blood platelet aggregation in humans and animals: A comparative study</span> <span class="citation_source-journal">J. Surg. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1006%2Fjsre.1998.5543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=10090827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFKrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=180-187&author=M.+V.+Solovievauthor=Y.+Okazakiauthor=H.+Harasaki&title=Whole+blood+platelet+aggregation+in+humans+and+animals%3A+A+comparative+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Whole Blood Platelet Aggregation in Humans and Animals: A Comparative Study</span></div><div class="casAuthors">Soloviev, Maxim V.; Okazaki, Yukio; Harasaki, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-187</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Many animal species are used to evaluate the performance and blood compatibility of cardiovascular devices, but interspecies differences in platelet activity have not been well characterized.  This study measures platelet response to six agonists in human, dog, and calf blood.  We used whole blood impedance lumi-aggregometry to measure platelet aggregation and ATP release in blood samples from adult humans (n = 19), mongrel dogs (n = 19), and Holstein calves (n = 7).  The agonists were collagen, ristocetin, arachidonic acid, thrombin, and three concns. of both ADP and epinephrine.  Only collagen (1 μg/mL) and ADP (5, 10, and 20 μM) caused aggregation and ATP release in all samples.  Canine platelets responded to all six agonists at all doses.  Human platelets responded to everything except epinephrine at 2 and 100 μM. Bovine platelets responded only to collagen, ADP, and thrombin.  In bovine platelets, aggregation from collagen and ATP release from thrombin were significantly lower than the corresponding responses in human and canine blood.  The aggregation induced by 10 μM ADP was significantly higher in canine than in human platelets.  Human, canine, and bovine platelets have very different responses to agonists.  In these models, collagen (1 μg/mL) and ADP (10 μM) are the agonists of choice for investigating whole blood platelet aggregation because they provide the most consistent results between species.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqK0W4AU8abVg90H21EOLACvtfcHk0lhzidbrC45MHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFKrsL4%253D&md5=30f69ee4bd2b4d422a0fc151725c346d</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1006%2Fjsre.1998.5543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjsre.1998.5543%26sid%3Dliteratum%253Aachs%26aulast%3DSoloviev%26aufirst%3DM.%2BV.%26aulast%3DOkazaki%26aufirst%3DY.%26aulast%3DHarasaki%26aufirst%3DH.%26atitle%3DWhole%2520blood%2520platelet%2520aggregation%2520in%2520humans%2520and%2520animals%253A%2520A%2520comparative%2520study%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D1999%26volume%3D82%26spage%3D180%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Klabunde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giegerich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, A.</span><span> </span><span class="NLM_article-title">MARS: Computing three-dimensional alignments for multiple ligands using pairwise similarities</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">–</span> <span class="NLM_lpage">2030</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci3000369" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVaktrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=2022-2030&author=T.+Klabundeauthor=C.+Giegerichauthor=A.+Evers&title=MARS%3A+Computing+three-dimensional+alignments+for+multiple+ligands+using+pairwise+similarities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">MARS: Computing Three-Dimensional Alignments for Multiple Ligands Using Pairwise Similarities</span></div><div class="casAuthors">Klabunde, Thomas; Giegerich, Clemens; Evers, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2022-2030</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The three-dimensional (3D) superimposition of mols. of one biol. target reflecting their relative bioactive orientation is key for several ligand-based drug design studies (e.g., QSAR studies, pharmacophore modeling).  However, with the lack of sufficient ligand-protein complex structures, an exptl. alignment is difficult or often impossible to obtain.  Several computational 3D alignment tools have been developed by academic or com. groups to address this challenge.  Here, we present a new approach, MARS (Multiple Alignments by ROCS-based Similarity), that is based on the pairwise alignment of all mols. within the data set using the tool ROCS (Rapid Overlay of Chem. Structures).  Each pairwise alignment is scored, and the results are captured in a score matrix.  The ideal superimposition of the compds. in the set is then identified by the anal. of the score matrix building stepwise a superimposition of all mols.  The algorithm exploits similarities among all mols. in the data set to compute an optimal 3D alignment.  This alignment tool presented here can be used for several applications, including pharmacophore model generation, 3D QSAR modeling, 3D clustering, identification of structural outliers, and addn. of compds. to an already existing alignment.  Case studies are shown, validating the 3D alignments for six different data sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBgAGzrLYIwrVg90H21EOLACvtfcHk0lhzidbrC45MHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVaktrrO&md5=a5c741f942d8c7e5a091b02043308b34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fci3000369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3000369%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DGiegerich%26aufirst%3DC.%26aulast%3DEvers%26aufirst%3DA.%26atitle%3DMARS%253A%2520Computing%2520three-dimensional%2520alignments%2520for%2520multiple%2520ligands%2520using%2520pairwise%2520similarities%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D2022%26epage%3D2030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, R.</span><span> </span><span class="NLM_article-title">Novel procedure for modeling ligand/receptor induced fit effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+procedure+for+modeling+ligand%2Freceptor+induced+fit+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0lhzidbrC45MHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520procedure%2520for%2520modeling%2520ligand%252Freceptor%2520induced%2520fit%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Rush, T. S.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosyak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, A.</span><span> </span><span class="NLM_article-title">A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1489</span><span class="NLM_x">–</span> <span class="NLM_lpage">1495</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040163o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Ols78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1489-1495&author=T.+S.+Rushauthor=J.+A.+Grantauthor=L.+Mosyakauthor=A.+Nicholls&title=A+shape-based+3-D+scaffold+hopping+method+and+its+application+to+a+bacterial+protein-protein+interaction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Shape-Based 3-D Scaffold Hopping Method and Its Application to a Bacterial Protein-Protein Interaction</span></div><div class="casAuthors">Rush, Thomas S., III; Grant, J. Andrew; Mosyak, Lidia; Nicholls, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1489-1495</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, the authors describe the first prospective application of the shape-comparison program ROCS (Rapid Overlay of Chem. Structures) to find new scaffolds for small mol. inhibitors of the ZipA-FtsZ protein-protein interaction, a proposed antibacterial target.  The shape comparisons are made relative to the crystallog. detd., bioactive conformation of a high-throughput screening (HTS) hit.  The use of ROCS led to the identification of a set of novel, weakly binding inhibitors with scaffolds presenting synthetic opportunities to further optimize biol. affinity and lacking development issues assocd. with the HTS lead.  These ROCS-identified scaffolds would have been missed using other structural similarity approaches such as ISIS 2D fingerprints.  X-ray crystallog. anal. of one of the new inhibitors bound to ZipA reveals that the shape comparison approach very accurately predicted the binding mode.  These exptl. results validate this use of ROCS for chemotype switching or "lead hopping" and suggest that it is of general interest for lead identification in drug discovery endeavors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4EX9jFtct37Vg90H21EOLACvtfcHk0lh9uSY7J223QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Ols78%253D&md5=05b6e54a657a3b8c768e63852d871ef6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm040163o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040163o%26sid%3Dliteratum%253Aachs%26aulast%3DRush%26aufirst%3DT.%2BS.%26aulast%3DGrant%26aufirst%3DJ.%2BA.%26aulast%3DMosyak%26aufirst%3DL.%26aulast%3DNicholls%26aufirst%3DA.%26atitle%3DA%2520shape-based%25203-D%2520scaffold%2520hopping%2520method%2520and%2520its%2520application%2520to%2520a%2520bacterial%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1489%26epage%3D1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span> <span class="citation_source-book">SYBYL Molecular Modelling Package</span>, Version 8.0; <span class="NLM_publisher-name">Tripos</span>: <span class="NLM_publisher-loc">St. Louis, MO</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SYBYL+Molecular+Modelling+Package%2C+Version+8.0%3B+Tripos%3A+St.+Louis%2C+MO%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DSYBYL%2520Molecular%2520Modelling%2520Package%26pub%3DTripos%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d'],'ref3':['cit3a','cit3b','cit3c','cit3d','cit3e'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b','cit5c','cit5d'],'ref6':['cit6a','cit6b','cit6c','cit6d'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b','cit8c'],'ref9':['cit9a','cit9b','cit9c'],'ref10':['cit10a','cit10b','cit10c'],'ref11':['cit11a','cit11b','cit11c'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18a','cit18b'],'ref19':['cit19a','cit19b','cit19c'],'ref20':['cit20a','cit20b'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingyun  Liu</span>, <span class="hlFld-ContribAuthor ">Tao  Huang</span>, <span class="hlFld-ContribAuthor ">Xianghu  Zhao</span>, <span class="hlFld-ContribAuthor ">Jingjing  Wu</span>, and <span class="hlFld-ContribAuthor ">Song  Cao</span>  . </span><span class="cited-content_cbyCitation_article-title">Bismuth(III)-Promoted Trifluoromethylthiolation of Pyrazolin-5-ones with Trifluoromethanesulfenamide. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2017,</strong> <em>2 </em>
                                    (11)
                                     , 7755-7759. <a href="https://doi.org/10.1021/acsomega.7b01453" title="DOI URL">https://doi.org/10.1021/acsomega.7b01453</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.7b01453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.7b01453%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DBismuth%252528III%252529-Promoted%252BTrifluoromethylthiolation%252Bof%252BPyrazolin-5-ones%252Bwith%252BTrifluoromethanesulfenamide%26aulast%3DLiu%26aufirst%3DQingyun%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D29092017%26date%3D31102017%26date%3D30112017%26volume%3D2%26issue%3D11%26spage%3D7755%26epage%3D7759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean  Conroy</span>, <span class="hlFld-ContribAuthor ">Nicholas  Kindon</span>, <span class="hlFld-ContribAuthor ">Barrie  Kellam</span>, and <span class="hlFld-ContribAuthor ">Michael J.  Stocks</span>  . </span><span class="cited-content_cbyCitation_article-title">Drug-like Antagonists of P2Y Receptors—From Lead Identification to Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 9981-10005. <a href="https://doi.org/10.1021/acs.jmedchem.5b01972" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01972</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01972%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug-like%252BAntagonists%252Bof%252BP2Y%252BReceptors%2525E2%252580%252594From%252BLead%252BIdentification%252Bto%252BDrug%252BDevelopment%26aulast%3DConroy%26aufirst%3DSean%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D21122015%26date%3D01082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D9981%26epage%3D10005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eva  Caroff</span>, <span class="hlFld-ContribAuthor ">Francis  Hubler</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Meyer</span>, <span class="hlFld-ContribAuthor ">Dorte  Renneberg</span>, <span class="hlFld-ContribAuthor ">Carmela  Gnerre</span>, <span class="hlFld-ContribAuthor ">Alexander  Treiber</span>, <span class="hlFld-ContribAuthor ">Markus  Rey</span>, <span class="hlFld-ContribAuthor ">Patrick  Hess</span>, <span class="hlFld-ContribAuthor ">Beat  Steiner</span>, <span class="hlFld-ContribAuthor ">Kurt  Hilpert</span>, and <span class="hlFld-ContribAuthor ">Markus A.  Riederer</span>  . </span><span class="cited-content_cbyCitation_article-title">4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (23)
                                     , 9133-9153. <a href="https://doi.org/10.1021/acs.jmedchem.5b00933" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00933</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00933%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-%252528%252528R%252529-2-%25257B%25255B6-%252528%252528S%252529-3-Methoxypyrrolidin-1-yl%252529-2-phenylpyrimidine-4-carbonyl%25255Damino%25257D-3-phosphonopropionyl%252529piperazine-1-carboxylic%252BAcid%252BButyl%252BEster%252B%252528ACT-246475%252529%252Band%252BIts%252BProdrug%252B%252528ACT-281959%252529%25252C%252Ba%252BNovel%252BP2Y12%252BReceptor%252BAntagonist%252Bwith%252Ba%252BWider%252BTherapeutic%252BWindow%252Bin%252Bthe%252BRat%252BThan%252BClopidogrel%26aulast%3DCaroff%26aufirst%3DEva%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D17062015%26date%3D18112015%26date%3D10122015%26date%3D09112015%26volume%3D58%26issue%3D23%26spage%3D9133%26epage%3D9153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Bach</span>, <span class="hlFld-ContribAuthor ">Thomas  Antonsson</span>, <span class="hlFld-ContribAuthor ">Ruth  Bylund</span>, <span class="hlFld-ContribAuthor ">Jan-Arne  Björkman</span>, <span class="hlFld-ContribAuthor ">Krister  Österlund</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Giordanetto</span>, <span class="hlFld-ContribAuthor ">J. J. J.  van Giezen</span>, <span class="hlFld-ContribAuthor ">Søren M.  Andersen</span>, <span class="hlFld-ContribAuthor ">Helen  Zachrisson</span>, and <span class="hlFld-ContribAuthor ">Fredrik  Zetterberg</span>  . </span><span class="cited-content_cbyCitation_article-title">Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (17)
                                     , 7015-7024. <a href="https://doi.org/10.1021/jm400820m" title="DOI URL">https://doi.org/10.1021/jm400820m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400820m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400820m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLead%252BOptimization%252Bof%252BEthyl%252B6-Aminonicotinate%252BAcyl%252BSulfonamides%252Bas%252BAntagonists%252Bof%252Bthe%252BP2Y12%252BReceptor.%252BSeparation%252Bof%252Bthe%252BAntithrombotic%252BEffect%252Band%252BBleeding%252Bfor%252BCandidate%252BDrug%252BAZD1283%26aulast%3DBach%26aufirst%3DPeter%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D03062013%26date%3D29082013%26date%3D12092013%26date%3D30072013%26volume%3D56%26issue%3D17%26spage%3D7015%26epage%3D7024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivar  von Kügelgen</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular pharmacology of P2Y receptor subtypes. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>187 </em>, 114361. <a href="https://doi.org/10.1016/j.bcp.2020.114361" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114361%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DMolecular%252Bpharmacology%252Bof%252BP2Y%252Breceptor%252Bsubtypes%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DIvar%26date%3D2021%26volume%3D187%26spage%3D114361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Yuan</span>, <span class="hlFld-ContribAuthor ">Liang-Sen  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Jiang</span>, <span class="hlFld-ContribAuthor ">Lin  Zuo</span>, <span class="hlFld-ContribAuthor ">Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Jian-Guo  Hu</span>, <span class="hlFld-ContribAuthor ">Aiwen  Lei</span>. </span><span class="cited-content_cbyCitation_article-title">Electrochemical synthesis of versatile ammonium oxides under metal catalyst-, exogenous-oxidant-, and exogenous-electrolyte-free conditions. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (22)
                                     , 2768-2771. <a href="https://doi.org/10.1039/D1CC00486G" title="DOI URL">https://doi.org/10.1039/D1CC00486G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CC00486G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CC00486G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DElectrochemical%252Bsynthesis%252Bof%252Bversatile%252Bammonium%252Boxides%252Bunder%252Bmetal%252Bcatalyst-%25252C%252Bexogenous-oxidant-%25252C%252Band%252Bexogenous-electrolyte-free%252Bconditions%26aulast%3DYuan%26aufirst%3DYong%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D22%26spage%3D2768%26epage%3D2771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcel Mirel  Popa</span>, <span class="hlFld-ContribAuthor ">Sergiu  Shova</span>, <span class="hlFld-ContribAuthor ">Madalina  Hrubaru</span>, <span class="hlFld-ContribAuthor ">Loredana  Barbu</span>, <span class="hlFld-ContribAuthor ">Constantin  Draghici</span>, <span class="hlFld-ContribAuthor ">Florea  Dumitrascu</span>, <span class="hlFld-ContribAuthor ">Denisa E.  Dumitrescu</span>. </span><span class="cited-content_cbyCitation_article-title">Introducing chirality in halogenated 3-arylsydnones and their corresponding 1-arylpyrazoles obtained by 1,3-dipolar cycloaddition. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (27)
                                     , 15656-15664. <a href="https://doi.org/10.1039/D0RA02368J" title="DOI URL">https://doi.org/10.1039/D0RA02368J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA02368J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA02368J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DIntroducing%252Bchirality%252Bin%252Bhalogenated%252B3-arylsydnones%252Band%252Btheir%252Bcorresponding%252B1-arylpyrazoles%252Bobtained%252Bby%252B1%25252C3-dipolar%252Bcycloaddition%26aulast%3DPopa%26aufirst%3DMarcel%2BMirel%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D27%26spage%3D15656%26epage%3D15664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Cacciari</span>, <span class="hlFld-ContribAuthor ">Pamela  Crepaldi</span>, <span class="hlFld-ContribAuthor ">Chun Yan  Cheng</span>, <span class="hlFld-ContribAuthor ">Elena  Bossi</span>, <span class="hlFld-ContribAuthor ">Giampiero  Spalluto</span>, <span class="hlFld-ContribAuthor ">Stephanie  Federico</span>, <span class="hlFld-ContribAuthor ">Kenneth A.  Jacobson</span>, <span class="hlFld-ContribAuthor ">Marco  Cattaneo</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry</span><span> <strong>2019,</strong> <em>15 </em>
                                    (8)
                                     , 863-872. <a href="https://doi.org/10.2174/1573406415666190208124534" title="DOI URL">https://doi.org/10.2174/1573406415666190208124534</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573406415666190208124534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573406415666190208124534%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%26atitle%3DStructure%252BActivity%252BRelationship%252Bof%252B4-Amino-2-thiopyrimidine%252BDerivatives%252Bas%252BPlatelet%252BAggregation%252BInhibitors%26aulast%3DCacciari%26aufirst%3DBarbara%26date%3D2019%26volume%3D15%26issue%3D8%26spage%3D863%26epage%3D872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivar  von Kügelgen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacology of P2Y receptors. </span><span class="cited-content_cbyCitation_journal-name">Brain Research Bulletin</span><span> <strong>2019,</strong> <em>151 </em>, 12-24. <a href="https://doi.org/10.1016/j.brainresbull.2019.03.010" title="DOI URL">https://doi.org/10.1016/j.brainresbull.2019.03.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.brainresbull.2019.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.brainresbull.2019.03.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBrain%2520Research%2520Bulletin%26atitle%3DPharmacology%252Bof%252BP2Y%252Breceptors%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DIvar%26date%3D2019%26volume%3D151%26spage%3D12%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Imadul  Islam</span>, <span class="hlFld-ContribAuthor ">Shendong  Yuan</span>, <span class="hlFld-ContribAuthor ">Robert G.  Wei</span>, <span class="hlFld-ContribAuthor ">Wei  Xu</span>, <span class="hlFld-ContribAuthor ">Michael  Morrissey</span>, <span class="hlFld-ContribAuthor ">Raju  Mohan</span>, <span class="hlFld-ContribAuthor ">Dewan  Zheng</span>, <span class="hlFld-ContribAuthor ">Andrea  DiMella</span>, <span class="hlFld-ContribAuthor ">Laura  Dunning</span>, <span class="hlFld-ContribAuthor ">Michael  Snider</span>, <span class="hlFld-ContribAuthor ">Babu  Subramanyam</span>, <span class="hlFld-ContribAuthor ">Jih-Lie  Tseng</span>, <span class="hlFld-ContribAuthor ">Judi A.  Bryant</span>, <span class="hlFld-ContribAuthor ">Brad O.  Buckman</span>. </span><span class="cited-content_cbyCitation_article-title">Reversible, orally available ADP receptor (P2Y12) antagonists Part I: Hit to lead process. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (9)
                                     , 1459-1463. <a href="https://doi.org/10.1016/j.bmcl.2018.03.090" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.03.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.03.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.03.090%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DReversible%25252C%252Borally%252Bavailable%252BADP%252Breceptor%252B%252528P2Y12%252529%252Bantagonists%252BPart%252BI%25253A%252BHit%252Bto%252Blead%252Bprocess%26aulast%3DIslam%26aufirst%3DImadul%26date%3D2018%26volume%3D28%26issue%3D9%26spage%3D1459%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aruna  Sharma</span>, <span class="hlFld-ContribAuthor ">Dharma  Kishore</span>, <span class="hlFld-ContribAuthor ">Bhawani  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">An Expedient Method for the Synthesis of 1,2,4-Triazolo-fused 1,5-Benzodiazepine, 1,5-Benzoxazepine, and 1,5-Benzothiazepine Scaffolds: A Novel Seven-membered Ring System of Biological Interest. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2018,</strong> <em>55 </em>
                                    (3)
                                     , 586-592. <a href="https://doi.org/10.1002/jhet.3060" title="DOI URL">https://doi.org/10.1002/jhet.3060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3060%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DAn%252BExpedient%252BMethod%252Bfor%252Bthe%252BSynthesis%252Bof%252B1%25252C2%25252C4-Triazolo-fused%252B1%25252C5-Benzodiazepine%25252C%252B1%25252C5-Benzoxazepine%25252C%252Band%252B1%25252C5-Benzothiazepine%252BScaffolds%25253A%252BA%252BNovel%252BSeven-membered%252BRing%252BSystem%252Bof%252BBiological%252BInterest%26aulast%3DSharma%26aufirst%3DAruna%26date%3D2018%26date%3D2018%26volume%3D55%26issue%3D3%26spage%3D586%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R. N.  Vydzhak</span>, <span class="hlFld-ContribAuthor ">S. Ya.  Panchishin</span>, <span class="hlFld-ContribAuthor ">V. S.  Brovarets</span>. </span><span class="cited-content_cbyCitation_article-title">Alkylation of 4-(phenylthio)-1H-pyrazol-5-ols with methyl bromoacetate. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of General Chemistry</span><span> <strong>2017,</strong> <em>87 </em>
                                    (2)
                                     , 231-238. <a href="https://doi.org/10.1134/S107036321702013X" title="DOI URL">https://doi.org/10.1134/S107036321702013X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S107036321702013X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS107036321702013X%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520General%2520Chemistry%26atitle%3DAlkylation%252Bof%252B4-%252528phenylthio%252529-1H-pyrazol-5-ols%252Bwith%252Bmethyl%252Bbromoacetate%26aulast%3DVydzhak%26aufirst%3DR.%2BN.%26date%3D2017%26date%3D2017%26volume%3D87%26issue%3D2%26spage%3D231%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivar  von Kügelgen</span>. </span><span class="cited-content_cbyCitation_article-title">Structure, Pharmacology and Roles in Physiology of the P2Y12 Receptor. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 123-138. <a href="https://doi.org/10.1007/5584_2017_98" title="DOI URL">https://doi.org/10.1007/5584_2017_98</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/5584_2017_98&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F5584_2017_98%26sid%3Dliteratum%253Aachs%26atitle%3DStructure%25252C%252BPharmacology%252Band%252BRoles%252Bin%252BPhysiology%252Bof%252Bthe%252BP2Y12%252BReceptor%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DIvar%26date%3D2017%26date%3D2017%26spage%3D123%26epage%3D138%26pub%3DSpringer%2520Singapore%26atitle%3DProtein%252BReviews%26aulast%3DAtassi%26aufirst%3DM.%2BZouhair%26date%3D2017%26volume%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E.A.  Meyer</span>, <span class="hlFld-ContribAuthor ">E.  Caroff</span>, <span class="hlFld-ContribAuthor ">M.A.  Riederer</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Antiplatelet Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 556-599. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12431-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12431-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12431-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12431-X%26sid%3Dliteratum%253Aachs%26atitle%3DAdvances%252Bin%252BAntiplatelet%252BAgents%26aulast%3DMeyer%26aufirst%3DE.A.%26date%3D2017%26spage%3D556%26epage%3D599%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fredrik  Zetterberg</span>, <span class="hlFld-ContribAuthor ">Peder  Svensson</span>. </span><span class="cited-content_cbyCitation_article-title">State of affairs: Design and structure–activity relationships of reversible P2Y 12 receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (12)
                                     , 2739-2754. <a href="https://doi.org/10.1016/j.bmcl.2016.04.030" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.04.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.04.030%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DState%252Bof%252Baffairs%25253A%252BDesign%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Bof%252Breversible%252BP2Y%252B12%252Breceptor%252Bantagonists%26aulast%3DZetterberg%26aufirst%3DFredrik%26date%3D2016%26volume%3D26%26issue%3D12%26spage%3D2739%26epage%3D2754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Huang</span>, <span class="hlFld-ContribAuthor ">Xianghu  Zhao</span>, <span class="hlFld-ContribAuthor ">Xinfei  Ji</span>, <span class="hlFld-ContribAuthor ">Wei  Wu</span>, <span class="hlFld-ContribAuthor ">Song  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of fluorovinyl pyrazolyl (thio)ethers by the reaction of gem -difluoroalkenes with pyrazolin-5-ones (thiones). </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2016,</strong> <em>182 </em>, 61-68. <a href="https://doi.org/10.1016/j.jfluchem.2015.12.007" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2015.12.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2015.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2015.12.007%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bfluorovinyl%252Bpyrazolyl%252B%252528thio%252529ethers%252Bby%252Bthe%252Breaction%252Bof%252Bgem%252B-difluoroalkenes%252Bwith%252Bpyrazolin-5-ones%252B%252528thiones%252529%26aulast%3DHuang%26aufirst%3DTao%26date%3D2016%26volume%3D182%26spage%3D61%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Paoletta</span>, <span class="hlFld-ContribAuthor ">Davide  Sabbadin</span>, <span class="hlFld-ContribAuthor ">Ivar  von Kügelgen</span>, <span class="hlFld-ContribAuthor ">Sonja  Hinz</span>, <span class="hlFld-ContribAuthor ">Vsevolod  Katritch</span>, <span class="hlFld-ContribAuthor ">Kristina  Hoffmann</span>, <span class="hlFld-ContribAuthor ">Aliaa  Abdelrahman</span>, <span class="hlFld-ContribAuthor ">Jens  Straßburger</span>, <span class="hlFld-ContribAuthor ">Younis  Baqi</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Raymond C.  Stevens</span>, <span class="hlFld-ContribAuthor ">Stefano  Moro</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>, <span class="hlFld-ContribAuthor ">Kenneth A.  Jacobson</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2015,</strong> <em>29 </em>
                                    (8)
                                     , 737-756. <a href="https://doi.org/10.1007/s10822-015-9858-z" title="DOI URL">https://doi.org/10.1007/s10822-015-9858-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-015-9858-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-015-9858-z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DModeling%252Bligand%252Brecognition%252Bat%252Bthe%252BP2Y12%252Breceptor%252Bin%252Blight%252Bof%252BX-ray%252Bstructural%252Binformation%26aulast%3DPaoletta%26aufirst%3DSilvia%26date%3D2015%26date%3D2015%26volume%3D29%26issue%3D8%26spage%3D737%26epage%3D756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Huang</span>, <span class="hlFld-ContribAuthor ">Xinfei  Ji</span>, <span class="hlFld-ContribAuthor ">Wei  Wu</span>, <span class="hlFld-ContribAuthor ">Fang  Liang</span>, <span class="hlFld-ContribAuthor ">Song  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free one-pot sequential direct diarylation of pyrazolin-5-ones with diaryliodonium salts. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2015,</strong> <em>5 </em>
                                    (82)
                                     , 66598-66601. <a href="https://doi.org/10.1039/C5RA14368C" title="DOI URL">https://doi.org/10.1039/C5RA14368C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5RA14368C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5RA14368C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DMetal-free%252Bone-pot%252Bsequential%252Bdirect%252Bdiarylation%252Bof%252Bpyrazolin-5-ones%252Bwith%252Bdiaryliodonium%252Bsalts%26aulast%3DHuang%26aufirst%3DTao%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D82%26spage%3D66598%26epage%3D66601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyang  Tang</span>, <span class="hlFld-ContribAuthor ">Jing  Chang</span>, <span class="hlFld-ContribAuthor ">Cuibo  Liu</span>, <span class="hlFld-ContribAuthor ">Bin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Base initiated aromatization/CO bond formation: a new entry to O-pyrazole polyfluoroarylated ethers. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2014,</strong> <em>55 </em>
                                    (48)
                                     , 6534-6537. <a href="https://doi.org/10.1016/j.tetlet.2014.09.129" title="DOI URL">https://doi.org/10.1016/j.tetlet.2014.09.129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2014.09.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2014.09.129%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DBase%252Binitiated%252Baromatization%25252FCO%252Bbond%252Bformation%25253A%252Ba%252Bnew%252Bentry%252Bto%252BO-pyrazole%252Bpolyfluoroarylated%252Bethers%26aulast%3DTang%26aufirst%3DXiangyang%26date%3D2014%26volume%3D55%26issue%3D48%26spage%3D6534%26epage%3D6537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eva  Caroff</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Meyer</span>, <span class="hlFld-ContribAuthor ">Alexander  Treiber</span>, <span class="hlFld-ContribAuthor ">Kurt  Hilpert</span>, <span class="hlFld-ContribAuthor ">Markus A.  Riederer</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y12 antagonists for inhibition of platelet aggregation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (17)
                                     , 4323-4331. <a href="https://doi.org/10.1016/j.bmcl.2014.06.070" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.06.070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.06.070%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOptimization%252Bof%252B2-phenyl-pyrimidine-4-carboxamides%252Btowards%252Bpotent%25252C%252Borally%252Bbioavailable%252Band%252Bselective%252BP2Y12%252Bantagonists%252Bfor%252Binhibition%252Bof%252Bplatelet%252Baggregation%26aulast%3DCaroff%26aufirst%3DEva%26date%3D2014%26volume%3D24%26issue%3D17%26spage%3D4323%26epage%3D4331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Merritt B.  Andrus</span>. </span><span class="cited-content_cbyCitation_article-title">N-Ethylmorpholine. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 1-7. <a href="https://doi.org/10.1002/047084289X.rn01645" title="DOI URL">https://doi.org/10.1002/047084289X.rn01645</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/047084289X.rn01645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F047084289X.rn01645%26sid%3Dliteratum%253Aachs%26atitle%3DN-Ethylmorpholine%26aulast%3DAndrus%26aufirst%3DMerritt%2BB.%26date%3D2014%26date%3D2014%26spage%3D1%26epage%3D7%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DEncyclopedia%252Bof%252BReagents%252Bfor%252BOrganic%252BSynthesis%26date%3D2001%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Allorie T.  Caldwell</span>, <span class="hlFld-ContribAuthor ">E. Blake  Watkins</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of P2Y12 Receptor Antagonists as Antiplatelet Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 87-99. <a href="https://doi.org/10.1016/B978-0-12-800167-7.00007-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-800167-7.00007-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-800167-7.00007-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-800167-7.00007-9%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BP2Y12%252BReceptor%252BAntagonists%252Bas%252BAntiplatelet%252BAgents%26aulast%3DCaldwell%26aufirst%3DAllorie%2BT.%26date%3D2014%26spage%3D87%26epage%3D99%26pub%3DElsevier%26date%3D2014%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Structures of <b>1</b> (Ticagrelor), <b>2</b> (Elinogrel), and <b>3</b> (BX 667) and Their Respective Affinity in the P2Y<sub>12</sub> Binding Assay and Antiaggregatory Activity in the Human Platelet-Rich Plasma (hPRP) Assay Used Throughout This Investigation (See the <a class="ref internalNav" href="#sec7" aria-label="Experimental Section">Experimental Section</a>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Binding hypothesis of quinoline <b>3</b> in the P2Y<sub>12</sub> receptor obtained from docking into a receptor homology model. (b) Three-dimensional alignment of quinoline <b>3</b> and phenylpyrazolone <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Schematic representation of the regions to be investigated based on the phenylpyrazolone backbone. (b) Proposed binding mode of pyrazole <b>4</b> into the P2Y<sub>12</sub> homology model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes to Key Building Blocks<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TOTU, <i>N</i>-ethylmorpholine, DMF, room temp, 16 h, 90%. (b) H<sub>2</sub> (3 bar), Pd/C (10%), ethanol, room temp, 6 h, 90%. (c) Benzyl 2-bromoacetate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 12 h, 95%. (d) H<sub>2</sub> (3 bar), Pd/C (10%), EtOAc, room temp, 6 h, 76%. (e) Benzyl (2<i>S</i>)-pyrrolidine-2-carboxylate, EDC, HOBt, EtN<i>i</i>Pr<sub>2</sub>, DMF, room temp, 16 h, 84%. (f) H<sub>2</sub> (3 bar), Pd/C (10%), EtOAc, room temp, 6 h, 98%. (g) Cyclobutyl amine, HATU, EtN<i>i</i>Pr<sub>2</sub>, DMF, room temp, 16 h, 95%. (h) NaOH, H<sub>2</sub>O/THF, room temp, 16 h, 95%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes Used for the Assembly of the Final P2Y<sub>12</sub> Antagonists<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EDC, HOBt, EtN<i>i</i>Pr<sub>2</sub>, <b>16</b>, DMF, room temp. (b) Benzyl 2-bromoacetate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, room temp. (c) H<sub>2</sub> (3 bar), Pd/C (10%), EtOAc, room temp. (d) EDC, HOBt, EtN<i>i</i>Pr<sub>2</sub>, DMF, room temp or HATU, EtN<i>i</i>Pr<sub>2</sub>, DMF, room temp. (e) NaOH, H<sub>2</sub>O/THF, room temp.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/medium/jm-2012-00771j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Shows steric and electrostatic std*coeff contour maps from the CoMSIA model with our initial lead compound <b>4</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>), 139 nM]: Green contours refer to regions where additional steric bulk is favorable for affinity, while yellow contours indicate disfavored areas. Red contours indicate regions where negatively charged substituents are favorable. (b) The same as panel a with all 63 compounds aligned. (c) The same as panel a with <b>18d</b> [<i>K</i><sub>i</sub> (P2Y<sub>12</sub>), 66 nM]. (d) The same as panel a with <b>18g</b> [molecule shown in green; <i>K</i><sub>i</sub> (P2Y<sub>12</sub>), 105 nM] and <b>18h</b> [yellow; <i>K</i><sub>i</sub> (P2Y<sub>12</sub>), 958 nM].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-20/jm300771j/production/images/large/jm-2012-00771j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300771j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25772" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25772" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 24 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Gachet, C.</span><span> </span><span class="NLM_article-title">ADP receptors of platelets and their inhibition</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11487010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVeksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2001&pages=222-232&author=C.+Gachet&title=ADP+receptors+of+platelets+and+their+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">ADP receptors of platelets and their inhibition</span></div><div class="casAuthors">Gachet, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">222-232</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">A review, with 133 refs.  ADP plays a crucial role in hemostasis and thrombosis and its receptors are potential targets for antithrombotic drugs.  Two G-protein coupled P2 receptors contribute to platelet aggregation: the P2Y1 receptor initiates aggregation through mobilization of calcium stores, while the more recently identified P2Y12 receptor coupled to adenylyl cyclase inhibition is essential for a full aggregation response to ADP and the stabilization of aggregates.  The latter is defective in certain patients with a selective congenital deficiency of aggregation to ADP.  It is also the target of the antithrombotic drug clopidogrel and of ATP analogs and other compds. currently under evaluation.  In addn., the P2X1 ionotropic receptor is present in platelets but its role is not yet completely known.  Studies in P2Y1 knock-out mice and exptl. thrombosis models using selective P2Y1 antagonists have shown that the P2Y1 receptor, like the P2Y12 receptor, is a potential target for new antithrombotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg4r8uadkFYrVg90H21EOLACvtfcHk0lghLfYBOthdGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVeksb0%253D&md5=44cd9aeb3bc5bc61680ed46e07dc3c65</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGachet%26aufirst%3DC.%26atitle%3DADP%2520receptors%2520of%2520platelets%2520and%2520their%2520inhibition%26jtitle%3DThromb.%2520Haemostasis%26date%3D2001%26volume%3D86%26spage%3D222%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dangelmaier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunapuli, S. P.</span><span> </span><span class="NLM_article-title">Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11246558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvVKrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=341-348&author=C.+Dangelmaierauthor=J.+Jinauthor=J.+B.+Smithauthor=S.+P.+Kunapuli&title=Potentiation+of+thromboxane+A2-induced+platelet+secretion+by+Gi+signaling+through+the+phosphoinositide-3+kinase+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway</span></div><div class="casAuthors">Dangelmaier, Carol; Jin, Jianguo; Smith, J. Bryan; Kunapuli, Satya P.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-348</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">F. K. Schattauer Verlagsgesellschaft mbH</span>)
        </div><div class="casAbstract">Platelet activation results in shape change, aggregation, generation of thromboxane A2, and release of granule contents.  We have recently demonstrated that secreted ADP is essential for thromboxane A2-induced platelet aggregation.  The aim of this study was to investigate the role of secreted ADP interacting at P2 receptor subtypes in platelet secretion.  Platelet secretion induced by the thromboxane A2 mimetic U46619 was unaffected by adenosine-3'phosphate-5'-phosphate, a P2Y1 receptor selective antagonist.  However, AR-C66096, a selective antagonist of the P2TAC receptor, inhibited U46619-induced platelet secretion, indicating an important role for Gi signaling in platelet secretion.  Selective activation of either the P2TAC receptor or the α2A adrenergic receptor did not cause platelet secretion, but potentiated U46619-induced platelet secretion.  SC57101, a fibrinogen receptor antagonist, failed to inhibit platelet secretion, demonstrating that outside-in signaling was not required for platelet secretion.  Since Gi signaling results in redn. of basal cAMP levels through inhibition of adenylyl cyclase, we investigated whether this is the signaling event that potentiates platelet secretion.  SQ22536 or dideoxyadenosine, inhibitors of adenylyl cyclase, failed to potentiate U46619-induced primary platelet secretion, indicating that redn. in cAMP levels does not directly contribute to platelet secretion.  Wortmannin, a selective inhibitor of PI-3 kinase, minimally inhibited U46619-induced platelet secretion when it was solely mediated by Gq, but dramatically ablated the potentiation of Gi signaling.  We conclude that signaling through the P2TAC receptor by secreted ADP causes pos. feedback on platelet secretion through a PI-3 kinase pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6vVzbybNjp7Vg90H21EOLACvtfcHk0lhUxbIKd0peOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvVKrsLs%253D&md5=a5d24f157416f630fcff3742c6ca77af</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDangelmaier%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DJ.%2BB.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DPotentiation%2520of%2520thromboxane%2520A2-induced%2520platelet%2520secretion%2520by%2520Gi%2520signaling%2520through%2520the%2520phosphoinositide-3%2520kinase%2520pathway%26jtitle%3DThromb.%2520Haemostasis%26date%3D2001%26volume%3D85%26spage%3D341%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cattaneo, M.</span><span> </span><span class="NLM_article-title">Advances in antiplatelet therapy: overview of new P2Y12 receptor antagonists in development</span> <span class="citation_source-journal">Eur. Heart J. Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. I</span><span class="NLM_x">) </span> <span class="NLM_fpage">I33</span><span class="NLM_x">–</span> <span class="NLM_lpage">I37</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=I33-I37&issue=Suppl.+I&author=M.+Cattaneo&title=Advances+in+antiplatelet+therapy%3A+overview+of+new+P2Y12+receptor+antagonists+in+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520antiplatelet%2520therapy%253A%2520overview%2520of%2520new%2520P2Y12%2520receptor%2520antagonists%2520in%2520development%26jtitle%3DEur.%2520Heart%2520J.%2520Suppl.%26date%3D2008%26volume%3D10%26issue%3DSuppl.%2520I%26spage%3DI33%26epage%3DI37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cattaneo, M.</span><span> </span><span class="NLM_article-title">ADP receptors: Inhibitory strategies for antiplatelet therapy</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1358%2Fdnp.2006.19.5.985936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=16941047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFejur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=253-259&author=M.+Cattaneo&title=ADP+receptors%3A+Inhibitory+strategies+for+antiplatelet+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">ADP receptors: inhibitory strategies for antiplatelet therapy</span></div><div class="casAuthors">Cattaneo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">253-259</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  The interaction of adenosine-5'-diphosphate (ADP) with its platelet receptors (P2Y1 and P2Y12) plays a very important role in thrombogenesis.  The thienopyridine ticlopidine was the first specific antagonist of the platelet P2Y12 ADP receptor to be tested in randomized clin. trials for the prevention of arterial thrombotic events.  Although ticlopidine reduces the incidence of vascular events in patients at risk, it also unfortunately has some significant drawbacks: a relatively high incidence of toxic effects, which may be fatal in some cases; delayed onset of action; and a high interindividual variability in response.  A second thienopyridine, clopidogrel, has superseded ticlopidine, because it is also an efficacious antithrombotic drug and is less toxic than ticlopidine.  However, clopidogrel is not completely free from faults: severe toxic effects, albeit occurring much less frequently than with ticlopidine, may still complicate its administration to patients; the onset of pharmacol. action can be accelerated by the use of large loading doses, but may still not be optimal; the high interpatient variability in response remains an important issue.  These concerns justify the continued search for agents that can further improve the clin. outcome of patients with atherosclerosis through greater efficacy and/or safety.  A new thienopyridyl compd., prasugrel, which is characterized by higher potency and faster onset of action compared with clopidogrel, is currently under clin. evaluation.  Two direct and reversible P2Y12 antagonists, cangrelor and AZD6140, feature very rapid onset and reversal of platelet inhibition, which make them attractive alternatives to thienopyridines, esp. when rapid inhibition of platelet aggregation or its quick reversal are required.  Along with new the P2Y12 antagonists, inhibitors of the other platelet receptor for ADP, the antagonists P2Y1, are under development and may prove to be effective antithrombotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmHmKVThnP17Vg90H21EOLACvtfcHk0lhUxbIKd0peOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFejur0%253D&md5=0302a0902658503a11691a421fad9c08</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2006.19.5.985936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2006.19.5.985936%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DADP%2520receptors%253A%2520Inhibitory%2520strategies%2520for%2520antiplatelet%2520therapy%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2006%26volume%3D19%26spage%3D253%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cattaneo, M.</span><span> </span><span class="NLM_article-title">P2Y12 receptor antagonists: A rapidly expanding group of antiplatelet agents</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1010</span><span class="NLM_x">–</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1093%2Feurheartj%2Fehi851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=16569650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFGqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=1010-1012&author=M.+Cattaneo&title=P2Y12+receptor+antagonists%3A+A+rapidly+expanding+group+of+antiplatelet+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents</span></div><div class="casAuthors">Cattaneo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1010-1012</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The research of Husted et al. (2006) entitled "Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin" is reviewed with commentary and refs.  The G-coupled P2Y12 receptor plays an important role in ADP-induced platelet aggregation and mediates the potentiation of platelet secretion induced by strong agonists and the stabilization of thrombin-induced platelet aggregates.  In their study, Husted et al. investigated the effects of the oral administration of AZD6140, the first oral reversible P2Y12 antagonist, to patients with atherosclerosis.  The results showed that AZD6140 at doses above 50 mg BID more effectively inhibited platelet aggregation and with less variability than clopidogrel.  The inhibition of platelet aggregation was very rapid compared with that of clopidogrel.  The prolongation of the bleeding times was greater in AZD6140-treated patients compared with clopidogrel-treated patients, although no obvious dose-response relationship was obsd.  The incidence of bleeding events tended to be higher in patients treated with the three higher doses of AZD6140, compared with that obsd. in patients treated with 50 mg BID or clopidogrel.  An unexpected, relatively high frequency of dyspnea was also obsd., and this side effect appeared to increase with increasing doses of AZD6140.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVSSXQ4QTDKbVg90H21EOLACvtfcHk0lhUxbIKd0peOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFGqtL0%253D&md5=f7d4c0febe0b7aa472d91c7336988e7d</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehi851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehi851%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DP2Y12%2520receptor%2520antagonists%253A%2520A%2520rapidly%2520expanding%2520group%2520of%2520antiplatelet%2520agents%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2006%26volume%3D27%26spage%3D1010%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dogne, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Leval, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benoit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delarge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masereel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David, J. L.</span><span> </span><span class="NLM_article-title">Recent advances in antiplatelet agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">589</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.2174%2F0929867024606948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11945125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD38XislGmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=577-589&author=J.+M.+Dogneauthor=X.+de+Levalauthor=P.+Benoitauthor=J.+Delargeauthor=B.+Masereelauthor=J.+L.+David&title=Recent+advances+in+antiplatelet+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in antiplatelet agents</span></div><div class="casAuthors">Dogne, Jean-Michel; De Leval, Xavier; Benoit, Patricia; Delarge, Jacques; Masereel, Bernard; David, Jean-Louis</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-589</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Platelet aggregation plays a key role in the pathogenesis of thromboembolic diseases such as myocardial infarction, stroke, unstable angina and peripheral artery disease.  Until recently, aspirin was the only antiplatelet agent available to prevent or treat these events.  Over the past several years, there has been a substantial expansion in the antiplatelet armamentarium as well as in the understanding of the clin. importance of antiplatelet therapy in limiting the complications of thrombosis.  Aspirin was one of the first agents to be adopted and it remains as the std. therapy with the higher amt. of available clin. information.  Following aspirin, ADP receptor antagonists like ticlopidine and clopidogrel as well as phosphodiesterase inhibitors dipyridamole and cilostazol have been introduced.  Glycoprotein (GP) IIb/IIIa receptor antagonists like eptifibatide, tirofiban and abciximab are the newer antiplatelet agents which act at the end of the common pathway of platelet aggregation.  Although results of clin. studies with the first oral GPIIb/IIIa antagonists were disappointing, agents of the new generation might expand the potential application of GPIIb/IIIa targeted therapy.  This review will highlight recent advances in the development of aspirin, phosphodiesterase inhibitors, ADP receptor antagonists and the platelet glycoprotein IIb/IIIa inhibitors.  The emphasis of this paper has been placed on the chem. aspects of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiRrsDrA0l5bVg90H21EOLACvtfcHk0lhb0LHBMG_q5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XislGmt7s%253D&md5=87aa6ec800724fef1c385969d75cc407</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.2174%2F0929867024606948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867024606948%26sid%3Dliteratum%253Aachs%26aulast%3DDogne%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BLeval%26aufirst%3DX.%26aulast%3DBenoit%26aufirst%3DP.%26aulast%3DDelarge%26aufirst%3DJ.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DDavid%26aufirst%3DJ.%2BL.%26atitle%3DRecent%2520advances%2520in%2520antiplatelet%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2002%26volume%3D9%26spage%3D577%26epage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInally, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindon, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teobald, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, W.</span><span> </span><span class="NLM_article-title">Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm981072s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=213-220&author=A.+H.+Ingallauthor=J.+Dixonauthor=A.+Baileyauthor=M.+E.+Coombsauthor=D.+Coxauthor=J.+I.+McInallyauthor=S.+F.+Huntauthor=N.+D.+Kindonauthor=B.+J.+Teobaldauthor=P.+A.+Willisauthor=R.+G.+Humphriesauthor=P.+Leffauthor=J.+A.+Cleggauthor=J.+A.+Smithauthor=W.+Tomlinson&title=Antagonists+of+the+platelet+P2T+receptor%3A+A+novel+approach+to+antithrombotic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of the Platelet P2T Receptor: A Novel Approach to Antithrombotic Therapy</span></div><div class="casAuthors">Ingall, Anthony H.; Dixon, John; Bailey, Andrew; Coombs, Mandy E.; Cox, David; McInally, Judith I.; Hunt, Simon F.; Kindon, Nicholas D.; Teobald, Barry J.; Willis, Paul A.; Humphries, Robert G.; Leff, Paul; Clegg, Jane A.; Smith, James A.; Tomlinson, Wendy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-220</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platelet P2T receptor plays a major role in platelet aggregation, and its antagonists are predicted to have significant therapeutic potential as antithrombotic agents.  We have explored analogs of ATP, which is a weak, nonselective but competitive P2T receptor antagonist.  Modification of the polyphosphate side chain to prevent breakdown to the agonist ADP and substitution of the adenine moiety to enhance affinity and selectivity for the P2T receptor led to the identification of compd. AR-C67085MX, having an IC50 of 2.5 nM against ADP-induced aggregation of human platelets.  This compd. was the first very potent antagonist of the P2T receptor, with a selectivity for that subtype of the P2 receptor family of >1000-fold.  Further modification of the structure produced compd. AR-C69931MX having an IC50 of 0.4 nM.  In vivo, at maximally effective antithrombotic doses, there is little prolongation of bleeding time (1.4-fold), which is in marked contrast to the 5-6-fold found with GPIIb/IIIa antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMgNOWrXPnEbVg90H21EOLACvtfcHk0lhb0LHBMG_q5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFartg%253D%253D&md5=82328b71981a7200181f7719b74248f8</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1021%2Fjm981072s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm981072s%26sid%3Dliteratum%253Aachs%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DDixon%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCoombs%26aufirst%3DM.%2BE.%26aulast%3DCox%26aufirst%3DD.%26aulast%3DMcInally%26aufirst%3DJ.%2BI.%26aulast%3DHunt%26aufirst%3DS.%2BF.%26aulast%3DKindon%26aufirst%3DN.%2BD.%26aulast%3DTeobald%26aufirst%3DB.%2BJ.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26aulast%3DHumphries%26aufirst%3DR.%2BG.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DClegg%26aufirst%3DJ.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DTomlinson%26aufirst%3DW.%26atitle%3DAntagonists%2520of%2520the%2520platelet%2520P2T%2520receptor%253A%2520A%2520novel%2520approach%2520to%2520antithrombotic%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D213%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Storey, R. F.</span><span> </span><span class="NLM_article-title">Biology and pharmacology of the platelet P2Y12 receptor</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1255</span><span class="NLM_x">–</span> <span class="NLM_lpage">1259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.2174%2F138161206776361318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=16611109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFKktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1255-1259&author=R.+F.+Storey&title=Biology+and+pharmacology+of+the+platelet+P2Y12+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3cR"><div class="casContent"><span class="casTitleNuber">3c</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and pharmacology of the platelet P2Y12 receptor</span></div><div class="casAuthors">Storey, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1255-1259</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Platelets possess two receptors for ADP, P2Y1 and P2Y12.  ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus.  The P2Y1 receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation.  The P2Y12 receptor on the other hand is linked to Gi and plays a special role in the amplification of platelet activation initiated by numerous other pathways.  Platelet activation leads to a range of responses that play a crit. role in arterial thrombosis and the inflammatory responses assocd. with this, including platelet aggregation, dense and α granule secretion and procoagulant activity.  P2Y12 receptor activation yields powerful amplification of these processes such that P2Y12 receptor antagonists may have dramatic inhibitory effects on platelet function regardless of the activating stimuli.  This phenomenon, coupled with the restricted distribution of the P2Y12 receptor in humans, makes the receptor an ideal target for pharmaceutical therapy.  This has already been established by the therapeutic success of clopidogrel, which acts, via an active metabolite, on this receptor.  However, current therapeutic regimens of clopidogrel yield variable and incomplete P2Y12 receptor blockade and more effective strategies to block P2Y12 receptor activation offer the potential of greater clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplYkgbFspF0rVg90H21EOLACvtfcHk0lhb0LHBMG_q5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFKktb0%253D&md5=040586da91cc8739b2b5afd63faadb93</span></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.2174%2F138161206776361318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161206776361318%26sid%3Dliteratum%253Aachs%26aulast%3DStorey%26aufirst%3DR.%2BF.%26atitle%3DBiology%2520and%2520pharmacology%2520of%2520the%2520platelet%2520P2Y12%2520receptor%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2006%26volume%3D12%26spage%3D1255%26epage%3D1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nicholas, R. A.</span><span> </span><span class="NLM_article-title">Identification of the P2Y(12) receptor: A novel member of the P2Y family of receptors activated by extracellular nucleotides</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=416-420&author=R.+A.+Nicholas&title=Identification+of+the+P2Y%2812%29+receptor%3A+A+novel+member+of+the+P2Y+family+of+receptors+activated+by+extracellular+nucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNicholas%26aufirst%3DR.%2BA.%26atitle%3DIdentification%2520of%2520the%2520P2Y%252812%2529%2520receptor%253A%2520A%2520novel%2520member%2520of%2520the%2520P2Y%2520family%2520of%2520receptors%2520activated%2520by%2520extracellular%2520nucleotides%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D416%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dorsam, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunapuli, S. P.</span><span> </span><span class="NLM_article-title">Central role of the P2Y12 receptor in platelet activation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=340-345&author=R.+T.+Dorsamauthor=S.+P.+Kunapuli&title=Central+role+of+the+P2Y12+receptor+in+platelet+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorsam%26aufirst%3DR.%2BT.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DCentral%2520role%2520of%2520the%2520P2Y12%2520receptor%2520in%2520platelet%2520activation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D113%26spage%3D340%26epage%3D345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Judge, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckland, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugidachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storey, R. F.</span><span> </span><span class="NLM_article-title">Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">1210</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1160%2FTH09-11-0770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20431852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=1210-1217&author=H.+M.+Judgeauthor=R.+J.+Bucklandauthor=A.+Sugidachiauthor=J.+A.+Jakubowskiauthor=R.+F.+Storey&title=Relationship+between+degree+of+P2Y12+receptor+blockade+and+inhibition+of+P2Y12-mediated+platelet+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function</span></div><div class="casAuthors">Judge, Heather M.; Buckland, Robert J.; Sugidachi, Atsuhiro; Jakubowski, Joseph A.; Storey, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1210-1217</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">The thienopyridine P2Y12 receptor antagonists clopidogrel and prasugrel prevent arterial thrombosis and are routinely used following percutaneous coronary intervention.  However, the optimal level of P2Y12 blockade to effectively inhibit platelet function is unknown.  These studies utilized the active metabolite of prasugrel (R-138727) to achieve a range of P2Y12 blockade in vitro and assessed several aspects of platelet function.  Blood from healthy volunteers was incubated with R-138727 (0-10 μM).  P2Y12 receptor no. was assessed using a 33P-2MeSADP binding assay.  Platelet aggregation (PA) was measured by optical aggregometry with ADP 2-20 μM.  VASP phosphorylation, annexin V binding, microparticle formation and P-selectin expression were assessed by flow cytometry.  Increasing nos. of unblocked receptors were required for a sustained aggregation response with decreasing concns. of ADP.A P2Y12 receptor blockade of 60-80% resulted in strong inhibition of final PA response, P-selectin expression, microparticle formation and vasodilator-stimulated phosphoprotein (VASP).  PA induced by ADP 2 μM and P-selectin expression were particularly sensitive to low levels of receptor blockade whereas the VASP phosphorylation assay was relatively insensitive, requiring 60% receptor blockade to achieve substantial inhibition.  Different assays varied in their ability to discriminate particular ranges of P2Y,2 blockade and 80% or greater P2Y12 receptor blockade is required for consistently strong inhibition of several aspects of platelet function.  These data guide the interpretation of results from different assays used to monitor the effects of P2Y12 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL7D0yAXFhrrVg90H21EOLACvtfcHk0liqss7RDhvrZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSitr0%253D&md5=57f4df911dca83c118e03e70b1568b39</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1160%2FTH09-11-0770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1160%252FTH09-11-0770%26sid%3Dliteratum%253Aachs%26aulast%3DJudge%26aufirst%3DH.%2BM.%26aulast%3DBuckland%26aufirst%3DR.%2BJ.%26aulast%3DSugidachi%26aufirst%3DA.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26atitle%3DRelationship%2520between%2520degree%2520of%2520P2Y12%2520receptor%2520blockade%2520and%2520inhibition%2520of%2520P2Y12-mediated%2520platelet%2520function%26jtitle%3DThromb.%2520Haemostasis%26date%3D2010%26volume%3D103%26spage%3D1210%26epage%3D1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Andre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaRocca, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=398-406&author=P.+Andreauthor=S.+M.+Delaneyauthor=T.+LaRoccaauthor=D.+Vincentauthor=F.+DeGuzmanauthor=M.+Jurekauthor=B.+Kollerauthor=D.+R.+Phillipsauthor=P.+B.+Conley&title=P2Y12+regulates+platelet+adhesion%2Factivation%2C+thrombus+growth%2C+and+thrombus+stability+in+injured+arteries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DP.%26aulast%3DDelaney%26aufirst%3DS.%2BM.%26aulast%3DLaRocca%26aufirst%3DT.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DJurek%26aufirst%3DM.%26aulast%3DKoller%26aufirst%3DB.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DP2Y12%2520regulates%2520platelet%2520adhesion%252Factivation%252C%2520thrombus%2520growth%252C%2520and%2520thrombus%2520stability%2520in%2520injured%2520arteries%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D112%26spage%3D398%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span> </span><span class="NLM_article-title">Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis</span> <span class="citation_source-journal">Semin. Thromb. Hemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1055%2Fs-2005-869523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=15852221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvVSnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2005&pages=174-183&author=P.+Saviauthor=J.-M.+Herbert&title=Clopidogrel+and+ticlopidine%3A+P2Y12+adenosine+diphosphate-receptor+antagonists+for+the+prevention+of+atherothrombosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis</span></div><div class="casAuthors">Savi, Pierre; Herbert, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-183</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Ticlopidine and clopidogrel belong to the same chem. family of thienopyridine ADP (ADP)-receptor antagonists.  They have shown their efficacy as platelet antiaggregant and antithrombotic agents in many animal models, both ex vivo and in vivo.  Although ticlopidine was discovered more than 30 years ago, it was only recently that the mechanism of action of ADP-receptor antagonists was characterized in detail.  Ticlopidine and clopidogrel both behave in vivo as specific antagonists of P2Y12, one of the ADP receptors on platelets.  Metabolic steps that involve cytochrome P 450-dependent pathways are required to generate the active metabolite responsible for this in vivo activity.  The active moiety is a reactive thiol deriv. that targets P2Y12 on platelets.  The interaction is irreversible, accounting for the observation that platelets are definitely antiaggregated, even if no active metabolite is detectable in plasma.  The interaction is specific for P2Y12; other purinoceptors such as P2Y1 and P2Y13 are spared.  This results in inhibition of the binding of the P2Y12 agonist 2-methylthio-ADP and the ADP-induced downregulation of adenylyl cyclase.  Platelet aggregation is affected not only when triggered by ADP but also by aggregation inducers when used at concns. requiring released ADP as an amplifier.  The efficacy and safety of clopidogrel has been established in several large, randomized, controlled trials.  The clopidogrel vs. aspirin in patients at risk of ischemic events (CAPRIE) trial demonstrated the superiority of clopidogrel over acetylsalicylic acid (ASA) in patients at risk of ischemic events, including ischemic stroke, myocardial infarction (MI), and peripheral arterial disease.  The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial showed a sustained, incremental benefit when clopidogrel was added to std. therapy (including ASA) in patients with unstable angina and non-Q-wave MI.  The clopidogrel for the redn. of events during observation (CREDO) trial demonstrated the benefit of continuing clopidogrel (plus ASA) for 12 mo, as opposed to 1 mo, after percutaneous coronary intervention.  The proven efficacy of clopidogrel, coupled with its favorable safety and tolerability profile, has prompted its evaluation in an extensive, ongoing clin. trial program that will help to further characterize the benefit of clopidogrel in patients with a range of atherothrombotic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0RPp6l6_G_LVg90H21EOLACvtfcHk0liqss7RDhvrZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvVSnurc%253D&md5=e33ff9017bb1a345b8fb7f769af03a5b</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-869523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-869523%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26atitle%3DClopidogrel%2520and%2520ticlopidine%253A%2520P2Y12%2520adenosine%2520diphosphate-receptor%2520antagonists%2520for%2520the%2520prevention%2520of%2520atherothrombosis%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2005%26volume%3D31%26spage%3D174%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hollopeter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantzen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julius, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">409</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1038%2F35051599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11196645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2001&pages=202-207&author=G.+Hollopeterauthor=H.+M.+Jantzenauthor=D.+Vincentauthor=G.+Liauthor=L.+Englandauthor=V.+Ramakrishnanauthor=R.+B.+Yangauthor=P.+Nurdenauthor=A.+Nurdenauthor=D.+Juliusauthor=P.+B.+Conley&title=Identification+of+the+platelet+ADP+receptor+targeted+by+antithrombotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span></div><div class="casAuthors">Hollopeter, Gunther; Jantzen, Hans-Michiel; Vincent, Diana; Li, Georgia; England, Laura; Ramakrishnan, Vanitha; Yang, Ruey-Bing; Nurden, Paquita; Nurden, Alan; Julius, David; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">6817</span>),
    <span class="NLM_cas:pages">202-207</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelets have a crucial role in the maintenance of normal hemostasis, and perturbations of this system can lead to pathol. thrombus formation and vascular occlusion, resulting in stroke; myocardial infarction and unstable angina.  ADP released from damaged vessels and red blood cells induces platelet aggregation through activation of the integrin GPIIb-IIIa and subsequent binding of fibrinogen.  ADP is also secreted from platelets on activation, providing pos. feedback that potentiates the actions of many platelet activators.  ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes.  The P2Y1 receptor couples to Gq and. mobilizes intracellular calcium ions to mediate platelet shape change and aggregation.  The second ADP receptor required for aggregation (variously called P2YADP, P2YAC, P2Ycyc or P2TAC) is coupled to the inhibition of adenylyl cyclase through Gi.  The mol. identity of the Gi-linked receptor is still elusive, even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogrel and AR-C66096. Here the authors describe the cloning of this receptor, designated P2Y12, and provide evidence that a patient with a bleeding disorder has a defect in this gene.  Cloning of the P2Y12 receptor should facilitate the development- of better antiplatelet agents to treat cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNuDi2tNS7bVg90H21EOLACvtfcHk0liqss7RDhvrZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D&md5=fe30017f0d3bd9aacb4ad3bd6189c5d9</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1038%2F35051599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35051599%26sid%3Dliteratum%253Aachs%26aulast%3DHollopeter%26aufirst%3DG.%26aulast%3DJantzen%26aufirst%3DH.%2BM.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DEngland%26aufirst%3DL.%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DR.%2BB.%26aulast%3DNurden%26aufirst%3DP.%26aulast%3DNurden%26aufirst%3DA.%26aulast%3DJulius%26aufirst%3DD.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DIdentification%2520of%2520the%2520platelet%2520ADP%2520receptor%2520targeted%2520by%2520antithrombotic%2520drugs%26jtitle%3DNature%26date%3D2001%26volume%3D409%26spage%3D202%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">CAPRIE Steering Committee (CAPRIE).</span><span> </span><span class="NLM_article-title">A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1339</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=1996&pages=1329-1339&author=CAPRIE+Steering+Committee+%28CAPRIE%29.&title=A+randomised%2C+blinded%2C+trial+of+clopidogrel+versus+aspirin+in+patients+at+risk+of+ischaemic+events"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520randomised%252C%2520blinded%252C%2520trial%2520of%2520clopidogrel%2520versus%2520aspirin%2520in%2520patients%2520at%2520risk%2520of%2520ischaemic%2520events%26jtitle%3DLancet%26date%3D1996%26volume%3D348%26spage%3D1329%26epage%3D1339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span> </span><span class="NLM_article-title">The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (CURE). Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation</span>. N. Engl. J. Med.<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">494</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1056%2FNEJMoa010746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11519503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXms1arsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+Clopidogrel+in+Unstable+Angina+to+Prevent+Recurrent+Events+Trial+Investigators+%28CURE%29.+Effects+of+Clopidogrel+in+Addition+to+Aspirin+in+Patients+with+Acute+Coronary+Syndromes+without+ST-Segment+Elevation.+N.+Engl.+J.+Med.+2001%2C+345%2C+494%E2%80%93502."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</span></div><div class="casAuthors">Yusuf, Salim; Zhao, Feng; Mehta, Shamir R.; Chrolavicius, Susan; Tognoni, Gianni; Fox, Keith K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">494-502</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events.  We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients.  We randomly assigned 12,562 patients who had presented within 24 h after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addn. to aspirin for 3 to 12 mo.  The first primary outcome - a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke - occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001).  The second primary outcome - the first primary outcome or refractory ischemia - occurred in 16.5 percent of the patients in the clopidogrel group and 18.8 percent of the patients in the placebo group (relative risk, 0.86, P<0.001).  The percentages of patients with in-hospital refractory or severe ischemia, heart failure, and revascularization procedures were also significantly lower with clopidogrel.  There were significantly more patients with major bleeding in the clopidogrel group than in the placebo group (3.7 percent vs. 2.7 percent; relative risk, 1.38; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.1 percent vs. 1.8 percent, P=0.13) or hemorrhagic strokes.  The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.  However, the risk of major bleeding is increased among patients treated with clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoihXPVAbDPg7Vg90H21EOLACvtfcHk0lizTGe9-jiwtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXms1arsrY%253D&md5=3ddc47281ccad90f046038a4c3f98a21</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa010746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1056%252FNEJMoa010746%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Clopidogrel%2520in%2520Unstable%2520Angina%2520to%2520Prevent%2520Recurrent%2520Events%2520Trial%2520Investigators%2520%2528CURE%2529.%2520Effects%2520of%2520Clopidogrel%2520in%2520Addition%2520to%2520Aspirin%2520in%2520Patients%2520with%2520Acute%2520Coronary%2520Syndromes%2520without%2520ST-Segment%2520Elevation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D494%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereillo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzabiaga, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combalbert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffrand, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span> </span><span class="NLM_article-title">Identification and biological activity of the active metabolite of clopidogrel</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1055%2Fs-0037-1614133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11127873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFCjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2000&pages=891-896&author=P.+Saviauthor=J.+M.+Pereilloauthor=M.+F.+Uzabiagaauthor=J.+Combalbertauthor=C.+Picardauthor=J.+P.+Maffrandauthor=M.+Pascalauthor=J.-M.+Herbert&title=Identification+and+biological+activity+of+the+active+metabolite+of+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and biological activity of the active metabolite of clopidogrel</span></div><div class="casAuthors">Savi, P.; Pereillo, J. M.; Uzabiaga, M. F.; Combalbert, J.; Picard, C.; Maffrand, J. P.; Pascal, M.; Herbert, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">891-896</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">F. K. Schattauer Verlagsgesellschaft mbH</span>)
        </div><div class="casAbstract">Like ticlopidine, the ADP receptor antagonist clopidogrel is inactive in vitro and must be administered i.v. or orally to exhibit antiaggregatory and antithrombotic activities.  We have previously shown that hepatic metab. is necessary for activity.  This study demonstrates that an active metabolite can be generated from human liver microsomes incubated with clopidogrel.  Using several anal. methodologies (LC/MS, NMR, chiral supercrit. fluid chromatog.), we have identified its structure.  In vitro, this highly unstable compd., different from that formed from ticlopidine, exhibited all the biol. activities of clopidogrel obsd. ex vivo: Irreversible inhibition of the binding of 33P-2MeS-ADP to washed human platelets (IC50 = 0.53 μM), selective inhibition of ADP-induced platelet aggregation (IC50 = 1.8 μM) and ADP-induced adenylyl cyclase down-regulation.  The irreversible modification of the ADP-receptor site which is responsible for the biol. activity could be explained by the formation of a disulfide bridge between the reactive thiol group of the active metabolite and a cysteine residue of the platelet ADP receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp6q3TXPondbVg90H21EOLACvtfcHk0lizTGe9-jiwtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFCjsbs%253D&md5=822a367258ccea5111da1ad6e94847ca</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1055%2Fs-0037-1614133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0037-1614133%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DPereillo%26aufirst%3DJ.%2BM.%26aulast%3DUzabiaga%26aufirst%3DM.%2BF.%26aulast%3DCombalbert%26aufirst%3DJ.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DMaffrand%26aufirst%3DJ.%2BP.%26aulast%3DPascal%26aufirst%3DM.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26atitle%3DIdentification%2520and%2520biological%2520activity%2520of%2520the%2520active%2520metabolite%2520of%2520clopidogrel%26jtitle%3DThromb.%2520Haemostasis%26date%3D2000%26volume%3D84%26spage%3D891%26epage%3D896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meadows, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, D. L.</span><span> </span><span class="NLM_article-title">Clinical aspects of platelet inhibitors and thrombus formation</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=1261-1275&author=T.+A.+Meadowsauthor=D.+L.+Bhatt&title=Clinical+aspects+of+platelet+inhibitors+and+thrombus+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeadows%26aufirst%3DT.%2BA.%26aulast%3DBhatt%26aufirst%3DD.%2BL.%26atitle%3DClinical%2520aspects%2520of%2520platelet%2520inhibitors%2520and%2520thrombus%2520formation%26jtitle%3DCirc.%2520Res.%26date%3D2007%26volume%3D100%26spage%3D1261%26epage%3D1275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zachayus, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delesque-Touchard, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labouret, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hervé, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzabiaga, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereillo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culouscou, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span> </span><span class="NLM_article-title">The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">11069</span><span class="NLM_x">–</span> <span class="NLM_lpage">11074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1073%2Fpnas.0510446103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=16835302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFeltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=11069-11074&author=P.+Saviauthor=J.+L.+Zachayusauthor=N.+Delesque-Touchardauthor=C.+Labouretauthor=C.+Herv%C3%A9author=M.+F.+Uzabiagaauthor=J.+M.+Pereilloauthor=J.+M.+Culouscouauthor=F.+Bonoauthor=P.+Ferraraauthor=J.-M.+Herbert&title=The+active+metabolite+of+Clopidogrel+disrupts+P2Y12+receptor+oligomers+and+partitions+them+out+of+lipid+rafts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts</span></div><div class="casAuthors">Savi, Pierre; Zachayus, Jean-Luc; Delesque-Touchard, Nathalie; Labouret, Catherine; Herve, Caroline; Uzabigaga, Marie-Francoise; Pereillo, Jean-Marie; Culouscou, Jean-Michel; Bono, Francoise; Ferrara, Pascual; Herbert, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11069-11074</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">P2Y12, a G protein-coupled receptor that plays a central role in platelet activation has been recently identified as the receptor targeted by the antithrombotic drug, clopidogrel.  In this study, we further deciphered the mechanism of action of clopidogrel and of its active metabolite (Act-Met) on P2Y12 receptors.  Using biochem. approaches, we demonstrated the existence of homooligomeric complexes of P2Y12 receptors at the surface of mammalian cells and in freshly isolated platelets.  In vitro treatment with Act-Met or in vivo oral administration to rats with clopidogrel induced the breakdown of these oligomers into dimeric and monomeric entities in P2Y12 expressing HEK293 and platelets resp.  In addn., we showed the predominant assocn. of P2Y12 oligomers to cell membrane lipid rafts and the partitioning of P2Y12 out of rafts in response to clopidogrel and Act-Met.  The raft-assocd. P2Y12 oligomers represented the functional form of the receptor, as demonstrated by binding and signal transduction studies.  Finally, using a series of receptors individually mutated at each cysteine residue and a chimeric P2Y12/P2Y13 receptor, we pointed out the involvement of cysteine 97 within the first extracellular loop of P2Y12 in the mechanism of action of Act-Met.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiqt3k9u_2_7Vg90H21EOLACvtfcHk0lizTGe9-jiwtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFeltr4%253D&md5=607365838851caaf1b5881dd624042bf</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0510446103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0510446103%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DZachayus%26aufirst%3DJ.%2BL.%26aulast%3DDelesque-Touchard%26aufirst%3DN.%26aulast%3DLabouret%26aufirst%3DC.%26aulast%3DHerv%25C3%25A9%26aufirst%3DC.%26aulast%3DUzabiaga%26aufirst%3DM.%2BF.%26aulast%3DPereillo%26aufirst%3DJ.%2BM.%26aulast%3DCulouscou%26aufirst%3DJ.%2BM.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26atitle%3DThe%2520active%2520metabolite%2520of%2520Clopidogrel%2520disrupts%2520P2Y12%2520receptor%2520oligomers%2520and%2520partitions%2520them%2520out%2520of%2520lipid%2520rafts%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D11069%26epage%3D11074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Algaier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Kügelgen, I.</span><span> </span><span class="NLM_article-title">Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor</span> <span class="citation_source-journal">J. Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1908</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1111%2Fj.1538-7836.2008.03136.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=18752581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=1908-1914&author=I.+Algaierauthor=J.+A.+Jakubowskiauthor=F.+Asaiauthor=I.+Von+K%C3%BCgelgen&title=Interaction+of+the+active+metabolite+of+prasugrel%2C+R-138727%2C+with+cysteine+97+and+cysteine+175+of+the+human+P2Y12+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor</span></div><div class="casAuthors">Algaier, I.; Jakubowski, J. A.; Asai, F.; Von Kuegelgen, I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1908-1914</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: The P2Y12 receptor plays a crucial role in platelet aggregation and is the target of platelet aggregation inhibitors, including the thienopyridine compd. prasugrel.  Objective: The present study analyzed the effects of R-138727 (2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene]acetic acid), the active metabolite of prasugrel, on recombinant wild-type and mutant human P2Y12 receptors in order to identify the mol. site of action of R-138727.  Methods: The function of wild-type and mutant P2Y12 receptors stably expressed in Chinese hamster ovary cells was assessed by measuring the 2-methylthio-ADP-mediated inhibition of forskolin-stimulated cellular cAMP prodn.  Results: In cells expressing wild-type receptors, R-138727 potently inhibited receptor function with a half-maximal concn. below 1 μM.  The mode of action was irreversible.  The same effect of R-138727 was obsd. in cells expressing Cys17Ala/Cys270Ala constructs.  In contrast, in cells expressing either a Cys97Ala construct or a Cys175Ala construct, R-138727 failed to inhibit the response to the agonist.  When cells expressing wild-type receptors were pretreated with the P2 receptor antagonists ATP or suramin, no effect of R-138727 was obsd.  Similar expts. with N-acetylcysteine 10 μM showed no interference of N-acetylcysteine with R-138727.  Conclusions: The expts. demonstrate a potent and irreversible action of R-138727 at the recombinant human P2Y12 receptor.  The data suggest that R-138727 interacts with cysteine 97 (upper portion of the predicted third transmembrane region) and cysteine 175 (second extracellular loop) of the receptor, which are likely to form a disulfide bridge in native receptors.  Moreover, the data also suggest that this site of action of R-138727 is close to the ligand-binding site of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaS366zCyAcbVg90H21EOLACvtfcHk0lj1IQC8bTyGmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyqs7zE&md5=e4449755928aae15774a850b56064142</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2008.03136.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2008.03136.x%26sid%3Dliteratum%253Aachs%26aulast%3DAlgaier%26aufirst%3DI.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DAsai%26aufirst%3DF.%26aulast%3DVon%2BK%25C3%25BCgelgen%26aufirst%3DI.%26atitle%3DInteraction%2520of%2520the%2520active%2520metabolite%2520of%2520prasugrel%252C%2520R-138727%252C%2520with%2520cysteine%252097%2520and%2520cysteine%2520175%2520of%2520the%2520human%2520P2Y12%2520receptor%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2008%26volume%3D6%26spage%3D1908%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamad, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Fresh from the pipeline. Ticagrelor</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=255-256&author=K.+Huberauthor=B.+Hamadauthor=P.+Kirkpatrick&title=Fresh+from+the+pipeline.+Ticagrelor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DHamad%26aufirst%3DB.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DFresh%2520from%2520the%2520pipeline.%2520Ticagrelor%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D255%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gurbel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kereiakes, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tantry, U. S.</span><span> </span><span class="NLM_article-title">Ticagrelor for the treatment of arterial thrombosis</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2251</span><span class="NLM_x">–</span> <span class="NLM_lpage">2259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1517%2F14656566.2010.511175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20707759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVansbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=2251-2259&author=P.+A.+Gurbelauthor=D.+J.+Kereiakesauthor=U.+S.+Tantry&title=Ticagrelor+for+the+treatment+of+arterial+thrombosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor for the treatment of arterial thrombosis</span></div><div class="casAuthors">Gurbel, Paul A.; Kereiakes, Dean J.; Tantry, Udaya S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2251-2259</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: High platelet reactivity has been linked to recurrent ischemic events in patients treated with conventional dual antiplatelet therapy, in patients with arterial diseases and particularly in patients treated with coronary artery stenting.  The limitations of clopidogrel have served as a major rationale for the development of new P2Y12 blockers that have superior pharmacodynamic profiles uninfluenced by concomitant therapies or specific genotypes.  Ticagrelor is the first direct-acting reversibly binding oral P2Y12 receptor antagonist.  Extensive Phase II investigations have addressed the pharmacokinetic, pharmacodynamic and safety-related properties of ticagrelor compared with clopidogrel.  The recently completed PLATO trial demonstrated promise for ticagrelor as a major treatment strategy for a wide spectrum of patients with acute coronary syndromes.  Ticagrelor is now being reviewed by the FDA as a P2Y12 receptor blocker to treat patients with coronary artery disease and, once accepted, will be in widespread use as an antiplatelet agent.  Thus, it is both appropriate and timely to review available data and provide a comprehensive review of ticagrelor.  Areas covered in this review: We discuss the rationale for the development of ticagrelor, a reversible and potent P2Y12 receptor blocker.  The data regarding ticagrelor based on preclin. and clin. studies are examd.  We researched articles about AZD6140' and ticagrelor' in PubMed from 2006 to 2010 and also reviewed data presented at recent cardiol. meetings.What the reader will gain: This is an updated and comprehensive review of ticagrelor.  The advantages and disadvantages of ticagrelor and available P2Y12 receptor blockers such as clopidogrel and prasugrel are discussed, thus providing a clear picture to readers.Take home message: Ticagrelor has an important role as an antiplatelet agent in the settings of acute coronary syndrome and percutaneous coronary intervention and once accepted will be in widespread use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdRFG4AInIx7Vg90H21EOLACvtfcHk0lj1IQC8bTyGmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVansbbF&md5=a2dba4a166c5b7fe8c1930b3fff6ed6a</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2010.511175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2010.511175%26sid%3Dliteratum%253Aachs%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26aulast%3DKereiakes%26aufirst%3DD.%2BJ.%26aulast%3DTantry%26aufirst%3DU.%2BS.%26atitle%3DTicagrelor%2520for%2520the%2520treatment%2520of%2520arterial%2520thrombosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2010%26volume%3D11%26spage%3D2251%26epage%3D2259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ueno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolillo, D. J.</span><span> </span><span class="NLM_article-title">Elinogrel: Pharmacological principles, preclinical and early phase clinical testing</span> <span class="citation_source-journal">Future Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.2217%2Ffca.10.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20608816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosFClt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=445-453&author=M.+Uenoauthor=S.+V.+Raoauthor=D.+J.+Angiolillo&title=Elinogrel%3A+Pharmacological+principles%2C+preclinical+and+early+phase+clinical+testing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Elinogrel: pharmacological principles, preclinical and early phase clinical testing</span></div><div class="casAuthors">Ueno, Masafumi; Rao, Sunil V.; Angiolillo, Dominick J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Cardiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">445-453</span>CODEN:
                <span class="NLM_cas:coden">FCUAAZ</span>;
        ISSN:<span class="NLM_cas:issn">1479-6678</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Antiplatelet drug therapy represents the cornerstone of treatment for cardiovascular atherothrombotic disease processes.  Dual antiplatelet therapy with aspirin and oral ADP-receptor antagonists such as clopidogrel are currently the std. care for prevention of ischemic events in patients with acute coronary syndrome and who are undergoing percutaneous coronary intervention.  However, despite the clin. benefit assocd. with clopidogrel therapy, this drug has several limitations, including a broad interindividual response variability, drug-drug interactions, slow onset of action and irreversible platelet inhibition, emphasizing the need for novel P2Y12-receptor antagonists.  Elinogrel (PRT060128) is a reversible, potent and competitive inhibitor of the P2Y12 receptor with a fast onset and offset of action that can be administered by both oral and i.v. routes and rapidly achieves near complete platelet inhibition.  Preclin. and early-phase clin. testing have shown promising results with this novel compd., which awaits further testing in outcome-driven clin. trials.  This article provides an overview of the current level of knowledge regarding elinogrel, focusing on its pharmacol. properties and preclin. and early-phase clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRooj0tD1UfbVg90H21EOLACvtfcHk0lj1IQC8bTyGmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosFClt7g%253D&md5=75d68933ec9311f6291e53da4be6f0f1</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.2217%2Ffca.10.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffca.10.67%26sid%3Dliteratum%253Aachs%26aulast%3DUeno%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DS.%2BV.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26atitle%3DElinogrel%253A%2520Pharmacological%2520principles%252C%2520preclinical%2520and%2520early%2520phase%2520clinical%2520testing%26jtitle%3DFuture%2520Cardiol.%26date%3D2010%26volume%3D6%26spage%3D445%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Oestreich, J. H.</span><span> </span><span class="NLM_article-title">Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=340-348&author=J.+H.+Oestreich&title=Elinogrel%2C+a+reversible+P2Y12+receptor+antagonist+for+the+treatment+of+acute+coronary+syndrome+and+prevention+of+secondary+thrombotic+events"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOestreich%26aufirst%3DJ.%2BH.%26atitle%3DElinogrel%252C%2520a%2520reversible%2520P2Y12%2520receptor%2520antagonist%2520for%2520the%2520treatment%2520of%2520acute%2520coronary%2520syndrome%2520and%2520prevention%2520of%2520secondary%2520thrombotic%2520events%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D11%26spage%3D340%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Berger, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilaru, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blankenship, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzger, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretler, D. D</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grines, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeymer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buszman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, P. W.</span><span> </span><span class="NLM_article-title">Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI)</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">998</span><span class="NLM_x">–</span> <span class="NLM_lpage">1004</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=998-1004&author=J.+S.+Bergerauthor=M.+T.+Roeauthor=C.+M.+Gibsonauthor=R.+Kilaruauthor=C.+L.+Greenauthor=L.+Meltonauthor=J.+D.+Blankenshipauthor=D.+C.+Metzgerauthor=C.+B.+Grangerauthor=D.+D+Gretlerauthor=C.+L.+Grinesauthor=K.+Huberauthor=U.+Zeymerauthor=P.+Buszmanauthor=R.+A.+Harringtonauthor=P.+W.+Armstrong&title=Safety+and+feasibility+of+adjunctive+antiplatelet+therapy+with+intravenous+elinogrel%2C+a+direct-acting+and+reversible+P2Y12+ADP-receptor+antagonist%2C+before+primary+percutaneous+intervention+in+patients+with+ST-elevation+myocardial+infarction%3A+The+Early+Rapid+ReversAl+of+Platelet+ThromboSis+with+Intravenous+Elinogrel+before+PCI+to+Optimize+REperfusion+in+Acute+Myocardial+Infarction+%28ERASE+MI%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DJ.%2BS.%26aulast%3DRoe%26aufirst%3DM.%2BT.%26aulast%3DGibson%26aufirst%3DC.%2BM.%26aulast%3DKilaru%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DC.%2BL.%26aulast%3DMelton%26aufirst%3DL.%26aulast%3DBlankenship%26aufirst%3DJ.%2BD.%26aulast%3DMetzger%26aufirst%3DD.%2BC.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DGretler%26aufirst%3DD.%2BD%26aulast%3DGrines%26aufirst%3DC.%2BL.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DZeymer%26aufirst%3DU.%26aulast%3DBuszman%26aufirst%3DP.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26atitle%3DSafety%2520and%2520feasibility%2520of%2520adjunctive%2520antiplatelet%2520therapy%2520with%2520intravenous%2520elinogrel%252C%2520a%2520direct-acting%2520and%2520reversible%2520P2Y12%2520ADP-receptor%2520antagonist%252C%2520before%2520primary%2520percutaneous%2520intervention%2520in%2520patients%2520with%2520ST-elevation%2520myocardial%2520infarction%253A%2520The%2520Early%2520Rapid%2520ReversAl%2520of%2520Platelet%2520ThromboSis%2520with%2520Intravenous%2520Elinogrel%2520before%2520PCI%2520to%2520Optimize%2520REperfusion%2520in%2520Acute%2520Myocardial%2520Infarction%2520%2528ERASE%2520MI%2529%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2009%26volume%3D158%26spage%3D998%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bryant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morser, J.</span><span> </span><span class="NLM_article-title">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1016%2Fj.thromres.2008.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=18495218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=523-532&author=J.+Bryantauthor=J.+M.+Postauthor=S.+Alexanderauthor=Y.+X.+Wangauthor=L.+Kentauthor=S.+Schirmauthor=J.+L.+Tsengauthor=B.+Subramanyamauthor=B.+Buckmanauthor=I.+Islamauthor=S.+Yuanauthor=M.+E.+Sullivanauthor=M.+Sniderauthor=J.+Morser&title=Novel+P2Y12+adenosine+diphosphate+receptor+antagonists+for+inhibition+of+platelet+aggregation+%28I%29%3A+in+vitro+effects+on+platelets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets</span></div><div class="casAuthors">Bryant, Judi; Post, Joseph M.; Alexander, Serene; Wang, Yi-Xin; Kent, Lorraine; Schirm, Sabine; Tseng, Jih-Lie; Subramanyam, Babu; Buckman, Brad; Islam, Imadul; Yuan, Shendong; Sullivan, Mark E.; Snider, Mike; Morser, John</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-532</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ADP plays a key role in platelet aggregation which has led to the development of antiplatelet drugs that target the P2Y12 receptor.  The aim of this study was to characterize the effects of two novel P2Y12 receptor antagonists, BX 667 and its active metabolite BX 048, on platelets.  BX 667 and BX 048 block the binding of 2MeSADP to platelets and antagonize ADP-induced platelet aggregation in human, dog and rat washed platelets.  Both compds. were shown to be reversible inhibitors of platelet aggregation.  BX 048 prevents the decrease in cAMP induced by treatment of platelets with ADP.  The specificity of BX 667 and BX 048 was demonstrated against cell lines expressing P2Y1 and P2Y6 as well as against a panel of receptors and enzymes.  Taken all together these data show that both BX 048 and BX 667 are potent P2Y12 antagonists with high specificity which, in the accompanying paper are demonstrated to behave predictably in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpePdQfPdqtrbVg90H21EOLACvtfcHk0lirJwH2RjpVnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbs%253D&md5=9667b7bdfa878d9cee94486f77c4dd9f</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DKent%26aufirst%3DL.%26aulast%3DSchirm%26aufirst%3DS.%26aulast%3DTseng%26aufirst%3DJ.%2BL.%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DSnider%26aufirst%3DM.%26aulast%3DMorser%26aufirst%3DJ.%26atitle%3DNovel%2520P2Y12%2520adenosine%2520diphosphate%2520receptor%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%2520%2528I%2529%253A%2520in%2520vitro%2520effects%2520on%2520platelets%26jtitle%3DThromb.%2520Res.%26date%3D2008%26volume%3D122%26spage%3D523%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Post, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincelette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergona, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dole, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, B.</span><span> </span><span class="NLM_article-title">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1016%2Fj.thromres.2008.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=18539312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=533-540&author=J.+M.+Postauthor=S.+Alexanderauthor=Y.+X.+Wangauthor=J.+Vinceletteauthor=R.+Vergonaauthor=L.+Kentauthor=J.+Bryantauthor=M.+E.+Sullivanauthor=W.+P.+Doleauthor=J.+Morserauthor=B.+Subramanyam&title=Novel+P2Y12+adenosine+diphosphate+receptor+antagonists+for+inhibition+of+platelet+aggregation+%28II%29%3A+Pharmacodynamic+and+pharmacokinetic+characterization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization</span></div><div class="casAuthors">Post, Joseph M.; Alexander, Serene; Wang, Yi-Xin; Vincelette, Jon; Vergona, Ron; Kent, Lorraine; Bryant, Judi; Sullivan, Mark E.; Dole, William P.; Morser, John; Subramanyam, Babu</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-540</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antiplatelet drugs are used to prevent aberrant platelet activation in pathophysiol. conditions such as myocardial infarction and ischemic stroke.  The key role that ADP plays in this process has led to the development of antiplatelet drugs that target the P2Y12 receptor.  The aim of this study was to characterize the pharmacodynamic (PD) and pharmacokinetic (PK) properties of the novel P2Y12 receptor antagonists, BX 667 and BX 048.  BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50 = 97, 317 and 3000 nM resp.).  BX 667 had nominal effects on collagen-induced aggregation and weakly inhibited arachidonic acid-induced aggregation.  BX 667 has an active metabolite, BX 048, that also potently inhibits ADP-induced aggregation (IC50 = 290 nM) in human blood.  BX 667 was shown to have high oral bioavailability in both dog and rat unlike BX 048.  Administration of BX 667 resulted in a rapid and sustained inhibition of platelet aggregation where the extent and duration of platelet inhibition was directly proportional to circulating plasma levels.  This report describes the PK/PD properties of BX 667 showing that it has the properties required for a potential antiplatelet therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjWxENonqg7bVg90H21EOLACvtfcHk0lirJwH2RjpVnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbg%253D&md5=87826ec634199235a94b2f89553fe806</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DVincelette%26aufirst%3DJ.%26aulast%3DVergona%26aufirst%3DR.%26aulast%3DKent%26aufirst%3DL.%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DDole%26aufirst%3DW.%2BP.%26aulast%3DMorser%26aufirst%3DJ.%26aulast%3DSubramanyam%26aufirst%3DB.%26atitle%3DNovel%2520P2Y12%2520adenosine%2520diphosphate%2520receptor%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%2520%2528II%2529%253A%2520Pharmacodynamic%2520and%2520pharmacokinetic%2520characterization%26jtitle%3DThromb.%2520Res.%26date%3D2008%26volume%3D122%26spage%3D533%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincelette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Cunha, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-McNulty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitch, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckman, B. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergona, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dole, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, J.</span><span> </span><span class="NLM_article-title">A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">855</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=17479197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlvVGrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=847-855&author=Y.+X.+Wangauthor=J.+Vinceletteauthor=V.+da+Cunhaauthor=B.+Martin-McNultyauthor=C.+Mallariauthor=R.+M.+Fitchauthor=S.+Alexanderauthor=I.+Islamauthor=B.+O.+Buckmanauthor=S.+Yuanauthor=J.+M.+Postauthor=B.+Subramanyamauthor=R.+Vergonaauthor=M.+E.+Sullivanauthor=W.+P.+Doleauthor=J.+Morserauthor=J.+Bryant&title=A+novel+P2Y%2812%29+adenosine+diphosphate+receptor+antagonist+that+inhibits+platelet+aggregation+and+thrombus+formation+in+rat+and+dog+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models</span></div><div class="casAuthors">Wang, Yi-Xin; Vincelette, Jon; da Cunha, Valdeci; Martin-McNulty, Baby; Mallari, Cornell; Fitch, Richard M.; Alexander, Serene; Islam, Imadul; Buckman, Brad O.; Yuan, Shendong; Post, Joseph M.; Subramanyam, Babu; Vergona, Ronald; Sullivan, Mark E.; Dole, William P.; Morser, John; Bryant, Judi</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">847-855</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">Irreversible platelet inhibitors, such as aspirin and clopidogrel, have limited antithrombotic efficacy in the clinic due to their bleeding risk.  We have developed an orally active reversible P2Y12 receptor antagonist, BX 667.  The aim of this study was to det. if the reversible antagonist BX 667 had a greater therapeutic index than the irreversible P2Y12 receptor antagonist clopidogrel.  Since BX 667 is rapidly converted to its active metabolite BX 048 in rats, we first injected BX 048 i.v. in a rat arterial venous (A-V) shunt model of thrombosis.  BX 048 dose- and concn.-dependently attenuated thrombosis.  When administered orally, BX 667 and clopidogrel had similar efficacy, but BX 667 caused less bleeding than clopidogrel.  In a rat model of a platelet-rich thrombus induced by vessel injury with FeCl2, both BX 667 and clopidogrel exhibited higher levels of thrombus inhibition after oral administration compared to their potency in the A-V shunt model.  Again, BX 667 caused less bleeding than clopidogrel.  In a dog cyclic flow model, i.v. injection of either BX 667 or clopidogrel dose-dependently reduced thrombus formation with lower bleeding for BX 667 than clopidogrel.  Inhibition of thrombosis was highly correlated with inhibition of ADP-induced platelet aggregation in these animal models.  In dogs pre-treated with aspirin, BX 667 maintained its wider therapeutic index, measured by inhibition of platelet aggregation over bleeding, compared to the aspirin-clopidogrel combination.  These data demonstrate that the reversible P2Y12 receptor antagonist, BX 667, has a wider therapeutic index than clopidogrel in exptl. models of thrombosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA0dlxE8Vj3LVg90H21EOLACvtfcHk0liyoxEWmKmm8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlvVGrtb4%253D&md5=96a72e2264df899f95bbf91ee6a8a0a6</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DVincelette%26aufirst%3DJ.%26aulast%3Dda%2BCunha%26aufirst%3DV.%26aulast%3DMartin-McNulty%26aufirst%3DB.%26aulast%3DMallari%26aufirst%3DC.%26aulast%3DFitch%26aufirst%3DR.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DBuckman%26aufirst%3DB.%2BO.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DVergona%26aufirst%3DR.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DDole%26aufirst%3DW.%2BP.%26aulast%3DMorser%26aufirst%3DJ.%26aulast%3DBryant%26aufirst%3DJ.%26atitle%3DA%2520novel%2520P2Y%252812%2529%2520adenosine%2520diphosphate%2520receptor%2520antagonist%2520that%2520inhibits%2520platelet%2520aggregation%2520and%2520thrombus%2520formation%2520in%2520rat%2520and%2520dog%2520models%26jtitle%3DThromb.%2520Haemostasis%26date%3D2007%26volume%3D97%26spage%3D847%26epage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cattaneo, M.</span><span> </span><span class="NLM_article-title">Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function</span> <span class="citation_source-journal">Semin. Thromb. Hemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1055%2Fs-0029-1220324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=19408189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFaisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=158-167&author=M.+Cattaneo&title=Light+transmission+aggregometry+and+ATP+release+for+the+diagnostic+assessment+of+platelet+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function</span></div><div class="casAuthors">Cattaneo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-167</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Light transmission aggregometry (LTA) is the gold std. for the study of patients with defects of platelet function.  Use of LTA in clin. practice for predicting the risk of thrombosis or monitoring the pharmacol. effects of antiplatelet agents should be discouraged, because not only is the monitoring of treatment with antiplatelet agents (with any lab. test) not indicated at present, but also the lack of standardization of the technique for LTA makes it addnl. unsuitable for this purpose.  The need for standardization of LTA has recently been emphasized by the results of four surveys, which showed that there is a wide variation in the methodol. used worldwide.  A modification of the traditional LTA is the lumiaggregometer, which measures platelet secretion in parallel with platelet aggregation.  This technique is probably preferable to traditional LTA in the diagnostic workup of patients with inherited defects of platelet function, because it is more sensitive to the most common disorders, which are characterized by abnormalities of platelet secretion.  LTA (or lumiaggregometry) is useful as a first screening test of patients with the clin. suspicion of defects of platelet function because it helps to provide an interim diagnostic hypothesis, which can then be confirmed or discounted using appropriate and specific tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCR4jtci4drVg90H21EOLACvtfcHk0liyoxEWmKmm8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFaisrs%253D&md5=c75f4813ef0f90f0f46556bc2bda1912</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1220324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1220324%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DLight%2520transmission%2520aggregometry%2520and%2520ATP%2520release%2520for%2520the%2520diagnostic%2520assessment%2520of%2520platelet%2520function%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2009%26volume%3D35%26spage%3D158%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Breet, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Werkum, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouman, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruven, H. J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bal, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deneer, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmsze, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heyden, J. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rensing, B. J. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suttorp, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackeng, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ten Berg, J. M.</span><span> </span><span class="NLM_article-title">Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">754</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1001%2Fjama.2010.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20179285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFyisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2010&pages=754-762&author=N.+J.+Breetauthor=J.+W.+van+Werkumauthor=H.+J.+Boumanauthor=J.+C.+Kelderauthor=H.+J.+T.+Ruvenauthor=E.+T.+Balauthor=V.+H.+Deneerauthor=A.+M.+Harmszeauthor=J.+A.+S.+van+der+Heydenauthor=B.+J.+W.+M.+Rensingauthor=M.+J.+Suttorpauthor=C.+M.+Hackengauthor=J.+M.+ten+Berg&title=Comparison+of+Platelet+Function+Tests+in+Predicting+Clinical+Outcome+in+Patients+Undergoing+Coronary+Stent+Implantation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation</span></div><div class="casAuthors">Breet, Nicoline J.; van Werkum, Jochem W.; Bouman, Heleen J.; Kelder, Johannes C.; Ruven, Henk J. T.; Bal, Egbert T.; Deneer, Vera H.; Harmsze, Ankie M.; van der Heyden, Jan A. S.; Rensing, Benno J. W. M.; Suttorp, Maarten J.; Hackeng, Christian M.; ten Berg, Jurien M.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">754-762</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context High on-treatment platelet reactivity is assocd. with atherothrombotic events following coronary stent implantation.  Objective To evaluate the capability of multiple platelet function tests to predict clin. outcome.  Design, Setting, and Patients Prospective, observational, single-center cohort study of 1069 consecutive patients taking clopidogrel undergoing elective coronary stent implantation between Dec. 2005 and Dec. 2007.  On-treatment platelet reactivity was measured in parallel by light transmittance aggregometry, VerifyNow P2Y12 and Plateletworks assays, and the IMPACT-R and the platelet function anal. system (PFA-100) (with the Dade PFA collagen/ADP [ADP] cartridge and Innovance PFA P2Y).  Cut-off values for high on-treatment platelet reactivity were established by receiver operating characteristic curve anal.  Main Outcome Measurement The primary end point was defined as a composite of all-cause death, nonfatal acute myocardial infarction, stent thrombosis, and ischemic stroke.  The primary safety end point included TIMI (Thrombolysis In Myocardial Infarction) criteria major and minor bleeding.  Results At 1-yr follow-up, the primary end point occurred more frequently in patients with high on-treatment platelet reactivity when assessed by light transmittance aggregometry (11.7%; 95% confidence interval [CI], 8.9%-15.0% vs 6.0%; 95% CI, 4.2%-8.2%; P < .001), VerifyNow (13.3%; 95% CI, 10.2%-17.0% vs 5.7%; 95% CI, 4.1%-7.8%; P < .001) and Plateletworks (12.6%; 95% CI, 8.8%-17.2% vs 6.1%; 95% CI, 3.8%-9.2%; P = .005), which also had modest ability to discriminate between patients having and not having a primary event: light transmittance aggregometry (area under the curve [AUC], 0.63; 95% CI, 0.58-0.68), VerifyNow (AUC, 0.62; 95% CI, 0.57-0.67), and Plateletworks (AUC, 0.61; 95% CI, 0.53-0.69).  The IMPACT-R, Dade PFA collagen/ADP, and Innovance PFA P2Y were unable to discriminate between patients with and without primary end point at 1-yr follow-up (all AUCs included 0.50 in the CI).  None of the tests identified patients at risk for bleeding.  Conclusions Of the platelet function tests assessed, only light transmittance aggregometry, VerifyNow, and Plateletworks were significantly assocd. with the primary end point.  However, the predictive accuracy of these tests was only modest.  None of the tests provided accurate prognostic information to identify low-risk patients at higher risk of bleeding following stent implantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogpQQJv7aPwrVg90H21EOLACvtfcHk0li-ajgp0n44xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFyisbw%253D&md5=3168abf2b1e74d50a8488a1628a9c52d</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1001%2Fjama.2010.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2010.181%26sid%3Dliteratum%253Aachs%26aulast%3DBreet%26aufirst%3DN.%2BJ.%26aulast%3Dvan%2BWerkum%26aufirst%3DJ.%2BW.%26aulast%3DBouman%26aufirst%3DH.%2BJ.%26aulast%3DKelder%26aufirst%3DJ.%2BC.%26aulast%3DRuven%26aufirst%3DH.%2BJ.%2BT.%26aulast%3DBal%26aufirst%3DE.%2BT.%26aulast%3DDeneer%26aufirst%3DV.%2BH.%26aulast%3DHarmsze%26aufirst%3DA.%2BM.%26aulast%3Dvan%2Bder%2BHeyden%26aufirst%3DJ.%2BA.%2BS.%26aulast%3DRensing%26aufirst%3DB.%2BJ.%2BW.%2BM.%26aulast%3DSuttorp%26aufirst%3DM.%2BJ.%26aulast%3DHackeng%26aufirst%3DC.%2BM.%26aulast%3Dten%2BBerg%26aufirst%3DJ.%2BM.%26atitle%3DComparison%2520of%2520Platelet%2520Function%2520Tests%2520in%2520Predicting%2520Clinical%2520Outcome%2520in%2520Patients%2520Undergoing%2520Coronary%2520Stent%2520Implantation%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2010%26volume%3D303%26spage%3D754%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, K. J.</span><span> </span><span class="NLM_article-title">A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: An integrated analysis</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2010&pages=29-37&author=J.+A.+Jakubowskiauthor=Y.+G.+Liauthor=D.+S.+Smallauthor=C.+D.+Payneauthor=M.+E.+Tomlinauthor=J.+Luoauthor=K.+J.+Winters&title=A+comparison+of+the+VerifyNow+P2Y12+point-of-care+device+and+light+transmission+aggregometry+to+monitor+platelet+function+with+prasugrel+and+clopidogrel%3A+An+integrated+analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DY.%2BG.%26aulast%3DSmall%26aufirst%3DD.%2BS.%26aulast%3DPayne%26aufirst%3DC.%2BD.%26aulast%3DTomlin%26aufirst%3DM.%2BE.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26atitle%3DA%2520comparison%2520of%2520the%2520VerifyNow%2520P2Y12%2520point-of-care%2520device%2520and%2520light%2520transmission%2520aggregometry%2520to%2520monitor%2520platelet%2520function%2520with%2520prasugrel%2520and%2520clopidogrel%253A%2520An%2520integrated%2520analysis%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2010%26volume%3D56%26spage%3D29%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burney, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiebsch, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ennis, M. D.</span><span> </span><span class="NLM_article-title">Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4657</span><span class="NLM_x">–</span> <span class="NLM_lpage">4663</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4657-4663&author=J.+J.+Parlowauthor=M.+W.+Burneyauthor=B.+L.+Caseauthor=T.+J.+Girardauthor=K.+A.+Hallauthor=R.+R.+Hiebschauthor=R.+M.+Huffauthor=R.+M.+Lachanceauthor=D.+A.+Mischkeauthor=S.+R.+Rappauthor=R.+S.+Woerndleauthor=M.+D.+Ennis&title=Piperazinyl-glutamate-pyridines+as+potent+orally+bioavailable+P2Y12+antagonists+for+inhibition+of+platelet+aggregation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DBurney%26aufirst%3DM.%2BW.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DGirard%26aufirst%3DT.%2BJ.%26aulast%3DHall%26aufirst%3DK.%2BA.%26aulast%3DHiebsch%26aufirst%3DR.%2BR.%26aulast%3DHuff%26aufirst%3DR.%2BM.%26aulast%3DLachance%26aufirst%3DR.%2BM.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%2BS.%26aulast%3DEnnis%26aufirst%3DM.%2BD.%26atitle%3DPiperazinyl-glutamate-pyridines%2520as%2520potent%2520orally%2520bioavailable%2520P2Y12%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4657%26epage%3D4663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burney, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiebsch, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ennis, M. D.</span><span> </span><span class="NLM_article-title">Part II: Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1388</span><span class="NLM_x">–</span> <span class="NLM_lpage">1394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1388-1394&author=J.+J.+Parlowauthor=M.+W.+Burneyauthor=B.+L.+Caseauthor=T.+J.+Girardauthor=K.+A.+Hallauthor=P.+K.+Harrisauthor=R.+R.+Hiebschauthor=R.+M.+Huffauthor=R.+M.+Lachanceauthor=D.+A.+Mischkeauthor=S.+R.+Rappauthor=R.+S.+Woerndleauthor=M.+D.+Ennis&title=Part+II%3A+Piperazinyl-glutamate-pyridines+as+potent+orally+bioavailable+P2Y12+antagonists+for+inhibition+of+platelet+aggregation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DBurney%26aufirst%3DM.%2BW.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DGirard%26aufirst%3DT.%2BJ.%26aulast%3DHall%26aufirst%3DK.%2BA.%26aulast%3DHarris%26aufirst%3DP.%2BK.%26aulast%3DHiebsch%26aufirst%3DR.%2BR.%26aulast%3DHuff%26aufirst%3DR.%2BM.%26aulast%3DLachance%26aufirst%3DR.%2BM.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%2BS.%26aulast%3DEnnis%26aufirst%3DM.%2BD.%26atitle%3DPart%2520II%253A%2520Piperazinyl-glutamate-pyridines%2520as%2520potent%2520orally%2520bioavailable%2520P2Y12%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1388%26epage%3D1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burney, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiebsch, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ennis, M. D.</span><span> </span><span class="NLM_article-title">Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2010</span><span class="NLM_x">–</span> <span class="NLM_lpage">2037</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901518t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2010-2037&author=J.+J.+Parlowauthor=M.+W.+Burneyauthor=B.+L.+Caseauthor=T.+J.+Girardauthor=K.+A.+Hallauthor=P.+K.+Harrisauthor=R.+R.+Hiebschauthor=R.+M.+Huffauthor=R.+M.+Lachanceauthor=D.+A.+Mischkeauthor=S.+R.+Rappauthor=R.+S.+Woerndleauthor=M.+D.+Ennis&title=Piperazinyl+glutamate+pyridines+as+potent+orally+bioavailable+P2Y12+antagonists+for+inhibition+of+platelet+aggregation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1021%2Fjm901518t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901518t%26sid%3Dliteratum%253Aachs%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DBurney%26aufirst%3DM.%2BW.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DGirard%26aufirst%3DT.%2BJ.%26aulast%3DHall%26aufirst%3DK.%2BA.%26aulast%3DHarris%26aufirst%3DP.%2BK.%26aulast%3DHiebsch%26aufirst%3DR.%2BR.%26aulast%3DHuff%26aufirst%3DR.%2BM.%26aulast%3DLachance%26aufirst%3DR.%2BM.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%2BS.%26aulast%3DEnnis%26aufirst%3DM.%2BD.%26atitle%3DPiperazinyl%2520glutamate%2520pyridines%2520as%2520potent%2520orally%2520bioavailable%2520P2Y12%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2010%26epage%3D2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="note"><p class="first last">Part of this work has been patented by the authors:</p></div><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nazare, M.; Zech, G.; Goerlitzer, J.; Just, M.; Weiss, T.; Hessler, G.; Czechtizky, W.; Ruf, S.</span><span> </span><span class="NLM_article-title">Pyrazole-carboxamide derivatives as P2Y12 antagonist</span>. WO2009080227,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Nazare&author=G.+Zech&author=J.+Goerlitzer&author=M.+Just&author=T.+Weiss&author=G.+Hessler&author=W.+Czechtizky&author=S.+Ruf&title=Pyrazole-carboxamide+derivatives+as+P2Y12+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNazare%26aufirst%3DM.%26atitle%3DPyrazole-carboxamide%2520derivatives%2520as%2520P2Y12%2520antagonist%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nazare, M.; Zech, G.; Just, M.; Weiss, T.; Hessler, G.; Kohlmann, M.</span><span> </span><span class="NLM_article-title">Heterocyclic pyrazole-carboxamides as P2Y12 antagonists</span>. WO2009080226,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Nazare&author=G.+Zech&author=M.+Just&author=T.+Weiss&author=G.+Hessler&author=M.+Kohlmann&title=Heterocyclic+pyrazole-carboxamides+as+P2Y12+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNazare%26aufirst%3DM.%26atitle%3DHeterocyclic%2520pyrazole-carboxamides%2520as%2520P2Y12%2520antagonists%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Caroff, E.; Hilpert, K.; Meyer, E.</span><span> </span><span class="NLM_article-title">2-Phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists</span>. WO2008050301,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Caroff&author=K.+Hilpert&author=E.+Meyer&title=2-Phenyl-6-aminocarbonyl-pyrimidine+derivatives+and+their+use+as+P2Y12+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26atitle%3D2-Phenyl-6-aminocarbonyl-pyrimidine%2520derivatives%2520and%2520their%2520use%2520as%2520P2Y12%2520receptor%2520antagonists%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Caroff, E.; Hilpert, K.; Meyer, E.</span><span> </span><span class="NLM_article-title">Preparation of N-(2-pyridylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists</span>. WO2008044217,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Caroff&author=K.+Hilpert&author=E.+Meyer&title=Preparation+of+N-%282-pyridylcarbonyl%29+amino+acid+piperazides+and+their+use+as+P2Y12+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26atitle%3DPreparation%2520of%2520N-%25282-pyridylcarbonyl%2529%2520amino%2520acid%2520piperazides%2520and%2520their%2520use%2520as%2520P2Y12%2520receptor%2520antagonists%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Caroff, E.; Fretz, H.; Hilpert, K.; Houille, O.; Hubler, F.; Meyer, E.</span><span> </span><span class="NLM_article-title">Pyrimidine derivatives and their use as P2Y12 receptor antagonists</span>. WO2006114774,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=E.+Caroff&author=H.+Fretz&author=K.+Hilpert&author=O.+Houille&author=F.+Hubler&author=E.+Meyer&title=Pyrimidine+derivatives+and+their+use+as+P2Y12+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26atitle%3DPyrimidine%2520derivatives%2520and%2520their%2520use%2520as%2520P2Y12%2520receptor%2520antagonists%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Deflorian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor</span> <span class="citation_source-journal">J. Comput.-Aided. Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=329-338&author=F.+Deflorianauthor=K.+A.+Jacobson&title=Comparison+of+three+GPCR+structural+templates+for+modeling+of+the+P2Y12+nucleotide+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DComparison%2520of%2520three%2520GPCR%2520structural%2520templates%2520for%2520modeling%2520of%2520the%2520P2Y12%2520nucleotide%2520receptor%26jtitle%3DJ.%2520Comput.-Aided.%2520Mol.%2520Des.%26date%3D2011%26volume%3D25%26spage%3D329%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Wheatley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wootten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conner, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simms, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poyner, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barwell, J.</span><span> </span><span class="NLM_article-title">Lifting the lid on GPCRs: The role of extracellular loops</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1111%2Fj.1476-5381.2011.01629.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=21864311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVKqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=1688-1703&author=M.+Wheatleyauthor=D.+Woottenauthor=M.+T.+Connerauthor=J.+Simmsauthor=R.+Kendrickauthor=R.+T.+Loganauthor=D.+R.+Poynerauthor=J.+Barwell&title=Lifting+the+lid+on+GPCRs%3A+The+role+of+extracellular+loops"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Lifting the lid on GPCRs: the role of extracellular loops</span></div><div class="casAuthors">Wheatley, M.; Wootten, D.; Conner, M. T.; Simms, J.; Kendrick, R.; Logan, R. T.; Poyner, D. R.; Barwell, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1688-1703</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  GPCRs exhibit a common architecture of seven transmembrane helixes (TMs) linked by intracellular loops and extracellular loops (ECLs).  Given their peripheral location to the site of G-protein interaction, it might be assumed that ECL segments merely link the important TMs within the helical bundle of the receptor.  However, compelling evidence has emerged in recent years revealing a crit. role for ECLs in many fundamental aspects of GPCR function, which supported by recent GPCR crystal structures has provided mechanistic insights.  This review will present current understanding of the key roles of ECLs in ligand binding, activation and regulation of both family A and family B GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD7EIc0sohgrVg90H21EOLACvtfcHk0liCohUFQrKFsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVKqur0%253D&md5=32433dbd28c1b128dc019772f5606a59</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01629.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01629.x%26sid%3Dliteratum%253Aachs%26aulast%3DWheatley%26aufirst%3DM.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DConner%26aufirst%3DM.%2BT.%26aulast%3DSimms%26aufirst%3DJ.%26aulast%3DKendrick%26aufirst%3DR.%26aulast%3DLogan%26aufirst%3DR.%2BT.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26aulast%3DBarwell%26aufirst%3DJ.%26atitle%3DLifting%2520the%2520lid%2520on%2520GPCRs%253A%2520The%2520role%2520of%2520extracellular%2520loops%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D1688%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">Combined 3D-QSAR, Molecular Docking, and Molecular Dynamics Study on Piperazinyl-Glutamate-Pyridines/Pyrimidines as Potent P2Y12 Antagonists for Inhibition of Platelet Aggregation</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2560</span><span class="NLM_x">–</span> <span class="NLM_lpage">2572</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci2002878" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2560-2572&author=M.+Haoauthor=Y.+Liauthor=Y.+Wangauthor=Y.+Yanauthor=S.+Zhangauthor=G.+Liauthor=L.+Yang&title=Combined+3D-QSAR%2C+Molecular+Docking%2C+and+Molecular+Dynamics+Study+on+Piperazinyl-Glutamate-Pyridines%2FPyrimidines+as+Potent+P2Y12+Antagonists+for+Inhibition+of+Platelet+Aggregation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Combined 3D-QSAR, Molecular Docking, and Molecular Dynamics Study on Piperazinyl-Glutamate-Pyridines/Pyrimidines as Potent P2Y12 Antagonists for Inhibition of Platelet Aggregation</span></div><div class="casAuthors">Hao, Ming; Li, Yan; Wang, Yonghua; Yan, Yulian; Zhang, Shuwei; Li, Guohui; Yang, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2560-2572</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An unusually large data set of 397 piperazinyl-glutamate-pyridines/pyrimidines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation was studied for the first time based on the combination of three-dimensional quant. structure-activity relationship (3D-QSAR), mol. docking, and mol. dynamics (MD) methods.  The comparative mol. field anal. (CoMFA) and comparative mol. similarity index anal. (CoMSIA) studies have been performed with a training set of 317 compds., estg. three superimposition methods.  The best CoMFA and CoMSIA models, derived from superimposition I, shows leave-one-out cross-validation correlation coeffs. (Q2) of 0.571 and 0.592 as well as the conventional correlation coeffs. (R2ncv) of 0.814 and 0.834, resp.  In addn., the satisfactory results, based on the bootstrapping anal. and 10-fold cross-validation, further indicate the highly statistical significance of the optimal models.  The external predictive abilities of these models were evaluated using a prediction set of 80 compds., producing the predicted correlation coeffs. (R2pred) of 0.664 and 0.668, resp.  The key amino acid residues were identified by mol. docking, and the stability and rationality of the derived mol. conformations were also validated by MD simulation.  The good concordance between the docking results and CoMFA/CoMSIA contour maps provides helpful clues about the rational modification of mols. in order to design more potent P2Y12 antagonists.  We hope the developed models could provide some instructions for further synthesis of highly potent P2Y12 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZNom6OC6JTrVg90H21EOLACvtfcHk0liCohUFQrKFsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7nM&md5=94d60809a0e6b3acd40e04c3200bda7d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fci2002878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2002878%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DL.%26atitle%3DCombined%25203D-QSAR%252C%2520Molecular%2520Docking%252C%2520and%2520Molecular%2520Dynamics%2520Study%2520on%2520Piperazinyl-Glutamate-Pyridines%252FPyrimidines%2520as%2520Potent%2520P2Y12%2520Antagonists%2520for%2520Inhibition%2520of%2520Platelet%2520Aggregation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2560%26epage%3D2572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Takasaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamohara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushime, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, K.</span><span> </span><span class="NLM_article-title">Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">432</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=432-439&author=J.+Takasakiauthor=M.+Kamoharaauthor=T.+Saitoauthor=M.+Matsumotoauthor=S.+Matsumotoauthor=T.+Ohishiauthor=T.+Sogaauthor=H.+Matsushimeauthor=K.+Furuichi&title=Molecular+cloning+of+the+platelet+P2T%28AC%29+ADP+receptor%3A+pharmacological+comparison+with+another+ADP+receptor%2C+the+P2Y%281%29+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakasaki%26aufirst%3DJ.%26aulast%3DKamohara%26aufirst%3DM.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DMatsushime%26aufirst%3DH.%26aulast%3DFuruichi%26aufirst%3DK.%26atitle%3DMolecular%2520cloning%2520of%2520the%2520platelet%2520P2T%2528AC%2529%2520ADP%2520receptor%253A%2520pharmacological%2520comparison%2520with%2520another%2520ADP%2520receptor%252C%2520the%2520P2Y%25281%2529%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D432%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labouret, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delesque, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guette, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J. M.</span><span> </span><span class="NLM_article-title">P2Y(12), a new platelet ADP receptor, target of clopidogrel</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2001&pages=379-383&author=P.+Saviauthor=C.+Labouretauthor=N.+Delesqueauthor=F.+Guetteauthor=J.+Lupkerauthor=J.+M.+Herbert&title=P2Y%2812%29%2C+a+new+platelet+ADP+receptor%2C+target+of+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DLabouret%26aufirst%3DC.%26aulast%3DDelesque%26aufirst%3DN.%26aulast%3DGuette%26aufirst%3DF.%26aulast%3DLupker%26aufirst%3DJ.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26atitle%3DP2Y%252812%2529%252C%2520a%2520new%2520platelet%2520ADP%2520receptor%252C%2520target%2520of%2520clopidogrel%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2001%26volume%3D283%26spage%3D379%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashby, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunapuli, S. P.</span><span> </span><span class="NLM_article-title">Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">644</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1016%2Fj.ejphar.2010.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=20599922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVejs7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=644&publication_year=2010&pages=10-16&author=Y.+Maoauthor=L.+Zhangauthor=J.+Jinauthor=B.+Ashbyauthor=S.+P.+Kunapuli&title=Mutational+analysis+of+residues+important+for+ligand+interaction+with+the+human+P2Y%2812%29+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational analysis of residues important for ligand interaction with the human P2Y12 receptor</span></div><div class="casAuthors">Mao, Yingying; Zhang, Lili; Jin, Jianguo; Ashby, Barrie; Kunapuli, Satya P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">644</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">10-16</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The P2Y12 receptor, a Gi protein-coupled receptor, plays a central role in platelet activation.  In this study, we did a mutational anal. of residues possibly involved in the ligand interactions with the human P2Y12 receptor.  Mutant receptors were stably expressed in CHO-K1 cells with an HA-tag at the N-terminus.  Expression of wild-type and mutant receptors was confirmed by detecting the HA-tag on the cell membrane.  Residues in transmembrane helical domains (TMs) 3, 5, 6, and 7, which are homologous to residues important for P2Y1 receptor activation and ligand recognition, were replaced by site-directed mutagenesis.  ADP-induced inhibition of forskolin-stimulated cAMP levels in the presence or absence of antagonist AR-C69931MX were investigated for each of the mutant receptors.  F104S and S288P significantly increased agonist-induced receptor function without affecting the antagonism by AR-C69931MX.  Arg256 in TM6 and Arg 265 in extracellular loop 3 (EL3) are more important for antagonist recognition than effect on agonist-mediated receptor function.  Compared to wild-type P2Y12 receptor, mutations in Arg 256 or/and Arg 265 significantly increased the sensitivity to antagonist AR-C69931MX.  Our study shows that the cytosolic side of TM3 and the exofacial side of TM5 are crit. for P2Y12 receptor function, which is different from P2Y1.  Arg 256 in TM6 and Arg265 in EL3 appear to play a role in antagonist recognition rather than effects on agonist-induced receptor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoBsxmabYAsbVg90H21EOLACvtfcHk0lgk3JkfFOJAqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVejs7jI&md5=7b5975b7e89a4daf402f8b63c99c1437</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DAshby%26aufirst%3DB.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DMutational%2520analysis%2520of%2520residues%2520important%2520for%2520ligand%2520interaction%2520with%2520the%2520human%2520P2Y%252812%2529%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D644%26spage%3D10%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hoffmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sixel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Pasquale, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Kügelgen, I.</span><span> </span><span class="NLM_article-title">Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1213</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2008&pages=1201-1213&author=K.+Hoffmannauthor=U.+Sixelauthor=F.+Di+Pasqualeauthor=I.+von+K%C3%BCgelgen&title=Involvement+of+basic+amino+acid+residues+in+transmembrane+regions+6+and+7+in+agonist+and+antagonist+recognition+of+the+human+platelet+P2Y%2812%29-receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DSixel%26aufirst%3DU.%26aulast%3DDi%2BPasquale%26aufirst%3DF.%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DI.%26atitle%3DInvolvement%2520of%2520basic%2520amino%2520acid%2520residues%2520in%2520transmembrane%2520regions%25206%2520and%25207%2520in%2520agonist%2520and%2520antagonist%2520recognition%2520of%2520the%2520human%2520platelet%2520P2Y%252812%2529-receptor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D76%26spage%3D1201%26epage%3D1213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Graff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinkhardt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harder, S.</span><span> </span><span class="NLM_article-title">Pharmacodynamic profile of antiplatelet agents: Marked differences between single versus costimulation with platelet activators</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1016%2Fj.thromres.2004.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=15183041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks12qsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=295-302&author=J.+Graffauthor=U.+Klinkhardtauthor=S.+Harder&title=Pharmacodynamic+profile+of+antiplatelet+agents%3A+Marked+differences+between+single+versus+costimulation+with+platelet+activators"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators</span></div><div class="casAuthors">Graff, Jochen; Klinkhardt, Ute; Harder, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: In pharmacodynamic studies with antiplatelet agents, platelets are usually activated in vitro with single agonists (e.g., ADP) solely.  We questioned whether differences occur between single and combined stimulation of platelets [involving the major thrombin-receptors, protease-activated receptors (PAR)1 and PAR4], and whether the pharmacodynamic response to common antiplatelet drugs vary when a combined stimulus is applied instead of a single agonist.  Methods: We investigated the influence of different antiplatelet agents (aspirin [500 mg]) in vivo, the P2Y12-antagonist AR-C 69931MX (4 nM) and the GPII/IIIa-antagonist (abciximab [5 μg/mL] in vitro) on the degranulation response (CD62) and expression of the activated GPIIb/IIIa-receptor (PAC-1) after stimulation with ADP (2 μM), collagen (4 μg/mL), a PAR1-activating peptide (3 μM TRAP) and a PAR4-activating peptide (200 μM AYPGKF) alone or in a combination of each two agonists by flow cytometry in healthy subjects.  Results: (1) Combined activation of TRAP with AYPGKF resulted in synergistic CD62 and PAC-1 expression.  Only AYPGKF but neither TRAP nor ADP acted synergistically with collagen.  (2) AR-C 69931MX inhibited platelet degranulation (CD62) in all inducer combinations with ADP or the combination TRAP with AYPGKF.  The effect was considerably smaller or absent for the combination of collagen with a second inducer. (3) Aspirin intake reduced platelet degranulation and PAC-1 expression only for AYPGKF costimulation with collagen.  Conclusion: Because a variety of different agonists influence platelet activation and its distinct functions at a time, investigations which regard the concert of these agonists might be closer to the in vivo situation and better reflect the pharmacodynamic profile of an antiplatelet agent than using one single inducing agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom-mGmTjy7v7Vg90H21EOLACvtfcHk0lgk3JkfFOJAqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks12qsrs%253D&md5=31f5f53e58e43be4f3a655c376bfb1ba</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2004.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2004.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DGraff%26aufirst%3DJ.%26aulast%3DKlinkhardt%26aufirst%3DU.%26aulast%3DHarder%26aufirst%3DS.%26atitle%3DPharmacodynamic%2520profile%2520of%2520antiplatelet%2520agents%253A%2520Marked%2520differences%2520between%2520single%2520versus%2520costimulation%2520with%2520platelet%2520activators%26jtitle%3DThromb.%2520Res.%26date%3D2004%26volume%3D113%26spage%3D295%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Storey, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newby, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heptinstall, S.</span><span> </span><span class="NLM_article-title">Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood</span> <span class="citation_source-journal">Platelets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=443-447&author=R.+F.+Storeyauthor=L.+J.+Newbyauthor=S.+Heptinstall&title=Effects+of+P2Y%281%29+and+P2Y%2812%29+receptor+antagonists+on+platelet+aggregation+induced+by+different+agonists+in+human+whole+blood"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DNewby%26aufirst%3DL.%2BJ.%26aulast%3DHeptinstall%26aufirst%3DS.%26atitle%3DEffects%2520of%2520P2Y%25281%2529%2520and%2520P2Y%252812%2529%2520receptor%2520antagonists%2520on%2520platelet%2520aggregation%2520induced%2520by%2520different%2520agonists%2520in%2520human%2520whole%2520blood%26jtitle%3DPlatelets%26date%3D2001%26volume%3D12%26spage%3D443%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sugidachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoneda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otsuguro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, H.</span><span> </span><span class="NLM_article-title">Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1038%2Fsj.bjp.0703761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11156560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFCisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2001&pages=47-54&author=A.+Sugidachiauthor=F.+Asaiauthor=K.+Yonedaauthor=R.+Iwamuraauthor=T.+Ogawaauthor=K.+Otsuguroauthor=H.+Koike&title=Antiplatelet+action+of+R-99224%2C+an+active+metabolite+of+a+novel+thienopyridine-type+G%28i%29-linked+P2T+antagonist%2C+CS-747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747</span></div><div class="casAuthors">Sugidachi, Atsuhiro; Asai, Fumitoshi; Yoneda, Kenji; Iwamura, Ryo; Ogawa, Taketoshi; Otsuguro, Ken-Ichi; Koike, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CS-747 is a novel thienopyridine-type platelet ADP inhibitor which lacks in vitro activity.  This study examd. pharmacol. profiles of R-99224, a hepatic metabolite of CS-747.  R-99224 produced a concn.-dependent inhibition of in vitro platelet aggregation in washed human platelets (0.03-1 μg ml-1), which was relatively specific to ADP compared to collagen and thrombin.  R-99224 (0.1-3 μg ml-1) also elicited a similar inhibition of ADP-induced aggregation in rat platelets.  The inhibition by R-99224 (10 μg ml-1) persisted even after platelets were washed three times.  I.v. injection of R-99224 (0.1-3 mg kg-1) to rats resulted in a dose-dependent inhibition of ex vivo ADP-induced platelet aggregation.  R-99224 (0.1-100 μM) decreased binding of [3H]-2-methylthio-ADP ([3H]-2-MeS-ADP), a stable ligand for platelet ADP receptors, to washed human platelets.  The inhibition by R-99224 reached a plateau at a concn. of 3 μM (1.4 μg ml-1), but complete inhibition was not achieved even at the highest concn. used (100 μM).  R-99224 (10 μM) in combination with ARL-66096 (0.3 μM), an ATP analog-type Gi-linked P2T receptor antagonist, produced no addnl. inhibition of [3H]-2-MeS-ADP binding.  In contrast, [3H]-2-MeS-ADP binding was completely abolished by R-99224 (10 μM) in combination with A3P5PS (300 μM), a selective P2Y1 antagonist, suggesting that R-99224 selectively binds to the Gi-linked P2T receptor.  R-99224 (0.01-3 μg ml-1) inhibited ADP-induced [125I]-fibrinogen binding to human platelets in a concn.-dependent manner.  R-99224 (0.1-1 μg ml-1) also inhibited the ADP-induced decrease in cAMP levels in PGE1-stimulated platelets, whereas the agent did not affect ADP (10 μM)-induced Ca2+ mobilization.  These findings suggest that R-99224 is a selective and irreversible antagonist of Gi-linked P2T receptors and that R-99224 is a responsible mol. for in vivo actions of CS-747.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzAkm8uWF_4LVg90H21EOLACvtfcHk0lhBugRegu9Lig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFCisLY%253D&md5=c8c37c95516f245f0c345c910ad7d6ff</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703761%26sid%3Dliteratum%253Aachs%26aulast%3DSugidachi%26aufirst%3DA.%26aulast%3DAsai%26aufirst%3DF.%26aulast%3DYoneda%26aufirst%3DK.%26aulast%3DIwamura%26aufirst%3DR.%26aulast%3DOgawa%26aufirst%3DT.%26aulast%3DOtsuguro%26aufirst%3DK.%26aulast%3DKoike%26aufirst%3DH.%26atitle%3DAntiplatelet%2520action%2520of%2520R-99224%252C%2520an%2520active%2520metabolite%2520of%2520a%2520novel%2520thienopyridine-type%2520G%2528i%2529-linked%2520P2T%2520antagonist%252C%2520CS-747%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D132%26spage%3D47%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucchesi, B. R.</span><span> </span><span class="NLM_article-title">Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">492</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=11046080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsl2ksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=492-499&author=J.+Huangauthor=E.+M.+Driscollauthor=M.+L.+Gonzalesauthor=A.+M.+Parkauthor=B.+R.+Lucchesi&title=Prevention+of+arterial+thrombosis+by+intravenously+administered+platelet+P2T+receptor+antagonist+AR-C69931MX+in+a+canine+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model</span></div><div class="casAuthors">Huang, Jinbao; Driscoll, Edward M.; Gonzales, Michael L.; Park, Andrew M.; Lucchesi, Benedict R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">492-499</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P2Y1, P2X1, and P2T receptors mediate ADP-induced platelet aggregation.  The antithrombotic effects of AR-C69931MX (N6-[2-(methylthio)ethyl]-2-[3,3,3-trifluoropropylthio]-5'-adenylic acid, monoanhydride with dichloromethylenebiphosphonic acid), a selective P2T platelet receptor antagonist, was assessed in a canine model of arterial thrombosis.  Placebo or AR-C69931MX (4.0 μg/kg/min for 6 h) pretreatment was administered as an i.v. infusion beginning 15 min before inducing vessel wall injury.  A 300-μA anodal current was applied to the intima of the carotid artery for 180 min or discontinued 30 min after cessation of blood flow due to thrombus formation.  Each of five control animals developed occlusive thrombi within 3 h after induction of vessel wall injury.  In contrast, carotid artery blood flow in five of six AR-C69931MX-treated animals was maintained for the duration of the protocol.  Ex vivo platelet aggregation in response to ADP was inhibited at the first measurement time point of 75 min after the start of drug infusion and remained inhibited during drug administration.  Bleeding time values were increased in the drug-treated group.  Values for both the ex vivo platelet aggregation and the bleeding times returned to control values shortly after discontinuation of AR-C69931MX.  The results indicate that AR-C69931MX antagonizes the ex vivo and in vivo aggregatory actions of ADP, and displays a rapid onset and offset of action with the ability to prevent occlusive arterial thrombus formation.  AR-C69931MX may be suitable for the management of patients who require short-term modulation of platelet function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi9DvtaJndgbVg90H21EOLACvtfcHk0lhBugRegu9Lig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsl2ksLg%253D&md5=64169692c627b4a8d79535601a0c9f93</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DE.%2BM.%26aulast%3DGonzales%26aufirst%3DM.%2BL.%26aulast%3DPark%26aufirst%3DA.%2BM.%26aulast%3DLucchesi%26aufirst%3DB.%2BR.%26atitle%3DPrevention%2520of%2520arterial%2520thrombosis%2520by%2520intravenously%2520administered%2520platelet%2520P2T%2520receptor%2520antagonist%2520AR-C69931MX%2520in%2520a%2520canine%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D492%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Soloviev, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harasaki, H.</span><span> </span><span class="NLM_article-title">Whole blood platelet aggregation in humans and animals: A comparative study</span> <span class="citation_source-journal">J. Surg. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Fjm300771j&amp;key=10.1006%2Fjsre.1998.5543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Fjm300771j&amp;key=10090827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFKrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=180-187&author=M.+V.+Solovievauthor=Y.+Okazakiauthor=H.+Harasaki&title=Whole+blood+platelet+aggregation+in+humans+and+animals%3A+A+comparative+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Whole Blood Platelet Aggregation in Humans and Animals: A Comparative Study</span></div><div class="casAuthors">Soloviev, Maxim V.; Okazaki, Yukio; Harasaki, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-187</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Many animal species are used to evaluate the performance and blood compatibility of cardiovascular devices, but interspecies differences in platelet activity have not been well characterized.  This study measures platelet response to six agonists in human, dog, and calf blood.  We used whole blood impedance lumi-aggregometry to measure platelet aggregation and ATP release in blood samples from adult humans (n = 19), mongrel dogs (n = 19), and Holstein calves (n = 7).  The agonists were collagen, ristocetin, arachidonic acid, thrombin, and three concns. of both ADP and epinephrine.  Only collagen (1 μg/mL) and ADP (5, 10, and 20 μM) caused aggregation and ATP release in all samples.  Canine platelets responded to all six agonists at all doses.  Human platelets responded to everything except epinephrine at 2 and 100 μM. Bovine platelets responded only to collagen, ADP, and thrombin.  In bovine platelets, aggregation from collagen and ATP release from thrombin were significantly lower than the corresponding responses in human and canine blood.  The aggregation induced by 10 μM ADP was significantly higher in canine than in human platelets.  Human, canine, and bovine platelets have very different responses to agonists.  In these models, collagen (1 μg/mL) and ADP (10 μM) are the agonists of choice for investigating whole blood platelet aggregation because they provide the most consistent results between species.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqK0W4AU8abVg90H21EOLACvtfcHk0lhBugRegu9Lig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFKrsL4%253D&md5=30f69ee4bd2b4d422a0fc151725c346d</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1006%2Fjsre.1998.5543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjsre.1998.5543%26sid%3Dliteratum%253Aachs%26aulast%3DSoloviev%26aufirst%3DM.%2BV.%26aulast%3DOkazaki%26aufirst%3DY.%26aulast%3DHarasaki%26aufirst%3DH.%26atitle%3DWhole%2520blood%2520platelet%2520aggregation%2520in%2520humans%2520and%2520animals%253A%2520A%2520comparative%2520study%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D1999%26volume%3D82%26spage%3D180%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Klabunde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giegerich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, A.</span><span> </span><span class="NLM_article-title">MARS: Computing three-dimensional alignments for multiple ligands using pairwise similarities</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">–</span> <span class="NLM_lpage">2030</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci3000369" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVaktrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=2022-2030&author=T.+Klabundeauthor=C.+Giegerichauthor=A.+Evers&title=MARS%3A+Computing+three-dimensional+alignments+for+multiple+ligands+using+pairwise+similarities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">MARS: Computing Three-Dimensional Alignments for Multiple Ligands Using Pairwise Similarities</span></div><div class="casAuthors">Klabunde, Thomas; Giegerich, Clemens; Evers, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2022-2030</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The three-dimensional (3D) superimposition of mols. of one biol. target reflecting their relative bioactive orientation is key for several ligand-based drug design studies (e.g., QSAR studies, pharmacophore modeling).  However, with the lack of sufficient ligand-protein complex structures, an exptl. alignment is difficult or often impossible to obtain.  Several computational 3D alignment tools have been developed by academic or com. groups to address this challenge.  Here, we present a new approach, MARS (Multiple Alignments by ROCS-based Similarity), that is based on the pairwise alignment of all mols. within the data set using the tool ROCS (Rapid Overlay of Chem. Structures).  Each pairwise alignment is scored, and the results are captured in a score matrix.  The ideal superimposition of the compds. in the set is then identified by the anal. of the score matrix building stepwise a superimposition of all mols.  The algorithm exploits similarities among all mols. in the data set to compute an optimal 3D alignment.  This alignment tool presented here can be used for several applications, including pharmacophore model generation, 3D QSAR modeling, 3D clustering, identification of structural outliers, and addn. of compds. to an already existing alignment.  Case studies are shown, validating the 3D alignments for six different data sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBgAGzrLYIwrVg90H21EOLACvtfcHk0li3f4ZmV53t2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVaktrrO&md5=a5c741f942d8c7e5a091b02043308b34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fci3000369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3000369%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DGiegerich%26aufirst%3DC.%26aulast%3DEvers%26aufirst%3DA.%26atitle%3DMARS%253A%2520Computing%2520three-dimensional%2520alignments%2520for%2520multiple%2520ligands%2520using%2520pairwise%2520similarities%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D2022%26epage%3D2030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, R.</span><span> </span><span class="NLM_article-title">Novel procedure for modeling ligand/receptor induced fit effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+procedure+for+modeling+ligand%2Freceptor+induced+fit+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0li3f4ZmV53t2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520procedure%2520for%2520modeling%2520ligand%252Freceptor%2520induced%2520fit%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Rush, T. S.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosyak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, A.</span><span> </span><span class="NLM_article-title">A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1489</span><span class="NLM_x">–</span> <span class="NLM_lpage">1495</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040163o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm300771j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Ols78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1489-1495&author=T.+S.+Rushauthor=J.+A.+Grantauthor=L.+Mosyakauthor=A.+Nicholls&title=A+shape-based+3-D+scaffold+hopping+method+and+its+application+to+a+bacterial+protein-protein+interaction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Shape-Based 3-D Scaffold Hopping Method and Its Application to a Bacterial Protein-Protein Interaction</span></div><div class="casAuthors">Rush, Thomas S., III; Grant, J. Andrew; Mosyak, Lidia; Nicholls, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1489-1495</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, the authors describe the first prospective application of the shape-comparison program ROCS (Rapid Overlay of Chem. Structures) to find new scaffolds for small mol. inhibitors of the ZipA-FtsZ protein-protein interaction, a proposed antibacterial target.  The shape comparisons are made relative to the crystallog. detd., bioactive conformation of a high-throughput screening (HTS) hit.  The use of ROCS led to the identification of a set of novel, weakly binding inhibitors with scaffolds presenting synthetic opportunities to further optimize biol. affinity and lacking development issues assocd. with the HTS lead.  These ROCS-identified scaffolds would have been missed using other structural similarity approaches such as ISIS 2D fingerprints.  X-ray crystallog. anal. of one of the new inhibitors bound to ZipA reveals that the shape comparison approach very accurately predicted the binding mode.  These exptl. results validate this use of ROCS for chemotype switching or "lead hopping" and suggest that it is of general interest for lead identification in drug discovery endeavors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4EX9jFtct37Vg90H21EOLACvtfcHk0li3f4ZmV53t2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Ols78%253D&md5=05b6e54a657a3b8c768e63852d871ef6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm040163o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040163o%26sid%3Dliteratum%253Aachs%26aulast%3DRush%26aufirst%3DT.%2BS.%26aulast%3DGrant%26aufirst%3DJ.%2BA.%26aulast%3DMosyak%26aufirst%3DL.%26aulast%3DNicholls%26aufirst%3DA.%26atitle%3DA%2520shape-based%25203-D%2520scaffold%2520hopping%2520method%2520and%2520its%2520application%2520to%2520a%2520bacterial%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1489%26epage%3D1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span> <span class="citation_source-book">SYBYL Molecular Modelling Package</span>, Version 8.0; <span class="NLM_publisher-name">Tripos</span>: <span class="NLM_publisher-loc">St. Louis, MO</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SYBYL+Molecular+Modelling+Package%2C+Version+8.0%3B+Tripos%3A+St.+Louis%2C+MO%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DSYBYL%2520Molecular%2520Modelling%2520Package%26pub%3DTripos%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1odu" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1odu','PDB','1odu'); return false;">PDB: 1odu</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i54"><a href="/doi/suppl/10.1021/jm300771j">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_11872"></div></div></div></div></div><hr /></hr><p class="last">Experimental data for selected compounds <b>17</b>–<b>20</b> and additional biological characterization data. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300771j/suppl_file/jm300771j_si_001.pdf">jm300771j_si_001.pdf (190.51 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300771j&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm300771j%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-20%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300771j" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679abf00acff3ce2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
